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ABSTRACT 
The role of basal ganglia circuitry in motivation 
Fernanda Carvalho Poyraz 
 
The basal ganglia are a set of subcortical nuclei in the forebrain of vertebrates that are 
highly conserved among mammals. Classically, dysfunction in the basal ganglia has been linked 
to motor abnormalities. However, it is now widely recognized that in addition to their role in 
motor behavior, these set of nuclei play a role in reinforcement learning and motivated behavior 
as well as in many diseases that present with abnormal motivation. In this dissertation, I first 
provide a review of the literature that describes the current state of research on the basal ganglia 
and the background for the original studies I later present. I describe the anatomy and physiology 
of the basal ganglia, including how structures are interconnected to form two parallel pathways, 
the direct and the indirect pathways. I further review published studies that have investigated 
how the basal ganglia regulate motor behavior and motivation. And finally, I also summarize 
findings on how disruption in basal ganglia circuitry function has been linked to a number of 
neuropsychiatric diseases, with special focus on the symptoms of schizophrenia. I then present 
original data and discuss the results of three studies investigating basal ganglia function and 
behavior. 
In the first study, I investigated the bridging collaterals, axon collaterals of direct-
pathway medium spiny neurons (dMSNs) in the striatum that target the external segment of the 
globus (GPe), the canonical target of indirect-pathway medium spiny neurons (iMSNs). Previous 
work in the Kellendonk laboratory has linked these collaterals to increased dopamine D2 
receptor (D2R) function and increased striatal excitability, as well as to abnormal locomotor 
response to stimulation of the direct pathway. I expanded on these findings by first 
demonstrating that bridging collaterals form synaptic contacts with GPe cells. I was also able to 
generate a viral vector to selectively increase excitability in specific populations of MSNs. I used 
this virus to show that chronically increasing excitability of the indirect pathway, but not the 
direct pathway, leads to a circuit-level change in connectivity by inducing the growth of bridging 
collaterals from dMSNs in the GPe. I also confirmed that increased density of bridging 
collaterals are associated with an abnormal locomotor response to stimulation of striatal dMSNs 
and further demonstrated that chronic pharmacologic blockade of D2Rs can rescue this abnormal 
locomotor phenotype. Furthermore, I found that motor training reverses the enhanced density of 
bridging collaterals and partially rescue the abnormal locomotor phenotype associated with 
increased collaterals, thereby establishing a new link between connectivity in the basal ganglia 
and motor learning. 
In the second study, I conducted a series of experiments in which I selectively increased 
excitability of the direct or indirect pathway in specific striatal sub-regions that have been 
implicated in goal-directed behavior, namely the DMS and NA core. I found that this 
manipulation was not sufficient to induce significant effects in different behavioral assays of 
locomotion and motivation, including the progressive ratio and concurrent choice tasks. These 
findings also suggest that increased bridging collateral density does not have a one-to-one 
relationship with the motivational deficit of D2R-OEdev mice, as previously hypothesized. 
In the third and final study, my original aim was to determine whether the motivational 
deficit of D2R-OEdev mice, induced by upregulation of D2Rs in the striatum, could be reversed 
by acutely activating Gαi-coupled signaling in the indirect pathway in these animals. I found that 
this manipulation increased motivation in D2R-OEdev mice but also in control littermates. This 
effect was due to energized behavioral performance, which, however, came at the cost of goal-
directed efficiency. Moreover, selective manipulation of MSNs in either the DMS or NA core 
showed that both striatal regions contribute to this effect on motivation. Further investigation 
aimed at understanding how Gαi-coupled signaling affects striatal circuit function revealed that 
activating a Gαi-coupled receptor did not lead to a significant change in somatic MSN activity in 
vivo or to a change in neuronal excitability in vitro. In contrast, the GPe, which receives 
monosynaptic inhibition from the indirect pathway, showed disinhibited activity when Gαi 
signaling was activated in striatal iMSNs. In addition, as drug therapies for psychiatric diseases 
are not usually given acutely but involve long-term, continuous administrations, I also studied 
how chronically decreasing function of iMSNs would affect behavior. I showed that chronically 
activating a Gαi-coupled receptor in iMSNs does not lead to a measurable effect on locomotion or 
motivation, a behavioral desensitization response that can be recovered within 48 h and may be 
due to receptor desensitization to the drug or circuit-level compensation to a chronic decrease in 
iMSN function. 
Finally, I conclude this dissertation with a general discussion addressing how the findings 
from each study can be related to each other to provide a more complete understanding of how 
basal ganglia function regulate behavior, how disruption in the basal ganglia can underlie 
neuropsychiatric disease, and how strategies to target basal ganglia function should be employed 
to treat disorders of motivation. I conclude this dissertation by proposing new avenues of 
research for further exploring my findings. 
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The basal ganglia are a set of subcortical nuclei in the forebrain of vertebrates that are 
highly conserved among mammals. These nuclei are interconnected with various brain regions, 
including cortex, thalamus, and brain stem, forming complex circuits that have been implicated 
in a number of behavioral processes. The gross connectivity between the basal ganglia and other 
regions of the brain have been described since the seventeenth century (Willis, 1664), with early 
anatomical studies characterizing the gross interconnectivity among these nuclei (Percheron et 
al., 1994). As new research tools became available, neuroscientists have been able to more 
carefully dissect circuits, and the anatomy of the basal ganglia has been further linked to 
physiology and behavior. Historically, the basal ganglia were first implicated in motor behavior 
through early observations in patients with Parkinson’s disease, Huntington’s disease, and brain 
lesions (Albin et al., 1989). However, basal ganglia dysfunction has also been observed in 
patients with neuropsychiatric disease, such as drug addiction and schizophrenia. This set of 
nuclei is now widely recognized for their involvement in reinforcement learning and motivated 
behavior, as well as in a number of diseases that present with abnormal motivation. 
Involvement of the basal ganglia in disorders of motivation provided the impetus for the 
work presented here. In the following sections, I will first review the literature relevant to the 
original studies I conducted, including the anatomy and physiology of the basal ganglia and what 
is known about their function in normal behavior and diseased states. For consistency, as the 
original research findings I present in this dissertation were conducted in mice, most of my 
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review of the literature will include studies done in rodents. But at appropriate points, I will also 
discuss how these findings relate to work done in primates and humans. After reviewing the 
literature, I will describe in detail the three studies I conducted. In the first study, I contributed to 
the anatomical and functional characterization of the “bridging collaterals”, axon collaterals that 
interconnect the direct and indirect pathways of the basal ganglia and may be important in 
schizophrenia. In the second study, I tested whether chronic manipulations increasing excitability 
of specific pathways in the basal ganglia could affect motivation. And finally, in the last study I 
investigated how decreasing function of the indirect pathway of the basal ganglia, both acutely 
and chronically, affects motivation and neuronal activity, providing mechanistic and behavioral 
insight for development for new therapies for disorders of abnormal motivation. I conclude this 
dissertation with a general discussion that brings together findings from all three studies and 
proposes future directions for my work. 
 
BASAL GANGLIA ANATOMY AND PHYSIOLOGY 
 
CONNECTIVITY AND PATHWAYS 
The basal ganglia are composed of a bilateral set of evolutionarily conserved nuclei in the 
vertebrate forebrain. Anatomically, the striatum, comprising the dorsal striatum and nucleus 
accumbens (NA) – also referred to as the ventral striatum – is the largest of these nuclei and is 
considered the main input nucleus of the basal ganglia. In primates, the striatum is composed of 
the caudate nucleus and putamen, which are separated by the internal capsule. In rodents, 
however, there are no physical barriers separating striatal sub-regions. The striatum receives 
glutamatergic inputs from both cortex and thalamus. Cortical inputs to the striatum comes from a 
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broad range of cortical regions, including sensory, motor, and associational cortex, in a highly 
topographical manner (Alexander et al., 1986). The thalamic inputs to the striatum come 
predominantly from midline and intralaminar nuclei (Berendse and Groenewegen, 1990, Erro et 
al., 2001, Van der Werf et al., 2002, Vercelli et al., 2003, Yasukawa et al., 2004, Doig et al., 
2010). Most of these synaptic inputs are axo-dendritic, targeting the dendritic spines of medium 
spiny neurons (MSNs) – also known as spiny projection neurons – which express both NMDA 
and AMPA glutamate receptors (Carter et al., 2007). MSNs make up 95% of all neurons in the 
striatum and connect the striatum to other nuclei of the basal ganglia through GABAergic 
projections (Kemp and Powell, 1971). The other 5% of neurons in the striatum are interneurons 
that release acetylcholine or GABA. These interneurons are known to also receive cortico-
thalamic excitatory inputs, and they can synapse on other interneurons or on MSNs (Calabresi et 
al., 2000, Tepper et al., 2010).  
The other structures in the basal ganglia include the pallidum, substantia nigra, and 
subthalamic nucleus. The pallidum consists of the globus pallidus and its ventral extension, the 
ventral pallidum (VP). The globus pallidus consists of two functionally distinct parts, the internal 
segment of the globus pallidus (GPi) and the external segment of the globus pallidus (GPe). 
Pallidal neurons are GABAergic and tonically active, providing inhibitory tone to neurons in the 
nuclei to which they project (Surmeier et al., 2005). The substantia nigra is another structure of 
the basal ganglia, and it is located in the midbrain. Functionally, it can be divided into the 
substantia nigra pars compacta (SNc) and the substantia nigra pars reticulata (SNr). The SNc 
contains dopaminergic neurons, while neurons in the SNr are more similar to pallidal neurons in 
that they are GABAergic and tonically inhibit the nuclei to which they project (Surmeier et al., 
2005). Together, the GPi and SNr are considered output nuclei because, unlike other nuclei of 
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the basal ganglia, they project to structures outside the basal ganglia, predominantly the 
thalamus. Finally, the subthalamic nucleus (STN) is also part of the basal ganglia and is 
composed of tonically-active glutamatergic projection neurons (Surmeier et al., 2005). 
Interconnectivity among all these nuclei can be complex, and it is useful to describe it by 
considering the basal ganglia as an integral component of the cortico-basal ganglia-thalamo-
cortical loop. 
Information received by the striatum, the main input nucleus of the basal ganglia, flows 
to other nuclei through two parallel pathways, the direct and indirect pathways, arising from 
distinct populations of MSNs distributed uniformly throughout the striatum and approximately 
equal in number (Valjent et al., 2009). The direct pathway is formed by MSNs that express the 
dopamine D1 receptor (D1R), as well as the peptide neurotransmitters substance P and 
dynorphin. The indirect pathway, in turn, arises from MSNs that express the dopamine D2 
receptor (D2R) in addition to the adenosine A2A receptor and the neuropeptide enkephalin. The 
gene and protein expression profiles of these two neuronal populations have been characterized 
by immunohistochemistry, in situ hybridization, as well as single-cell RT-PCR studies (Gerfen 
and Young, 1988, Surmeier et al., 1996, Matamales et al., 2009). The segregation of these two 
populations of striatal MSNs has been further confirmed in transgenic mice using bacterial 
artificial chromosomes (BAC) expressing fluorescent proteins under the control of the promoters 
for the D1R and D2R genes, Drd1 and Drd2, respectively (Gong et al., 2003, Ade et al., 2011). 
Using these BAC transgenic mice, researchers have demonstrated that D1Rs and D2Rs are co-
expressed in fewer than 5% of MSNs in the adult striatum (Bertran-Gonzalez et al., 2008, Shuen 
et al., 2008). Thus, at the somatic level, two populations of MSNs can be readily distinguished 
based on their gene expression profiles. 
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As suggested by their name, MSNs of the direct pathway (dMSNs) project directly to the 
output nuclei of the basal ganglia, the GPi and SNr. The latter two nuclei project mainly to the 
thalamus, including the ventral anterior, ventral lateral, and mediodorsal nuclei, as well as to the 
superior colliculus and pedunculopontine nucleus in both rodents and primates (Moriizumi and 
Hattori, 1992, Shink et al., 1997, McFarland and Haber, 2002, Bodor et al., 2008, Kaneda et al., 
2008). Some researchers have proposed that GPi and SNr function as basal ganglia output nuclei 
in segregated loops, with the GPi predominantly targeting the motor cortex via the ventrolateral 
thalamus, while the SNr preferentially targets association cortical areas via the ventroanterior 
and mediodorsal thalamus (Romanelli et al., 2005). Regardless of the specific thalamic nuclei to 
which they project, the majority of neurons in the SNr and GPi inhibit the thalamus by providing 
GABAergic tone to its targets. As a result, increased dMSN activity, or activation of the direct 
pathway of the basal ganglia, inhibits the basal ganglia output nuclei, thereby providing a net 
disinhibition of the thalamus.  
MSNs of the indirect pathway (iMSNs), in turn, can have the opposite effect on the 
output of the basal ganglia. These striatal neurons only project to the GPe or to the VP. Neurons 
in the GPe are known to provide inhibitory tone to the output nuclei of the basal ganglia by 
synapsing on neurons in the STN, which in turn send excitatory projections to the GPi and SNr 
(Kita and Kitai, 1987). Since pallidal neurons are GABAergic and neurons in the STN are 
glutamatergic, through a polysynaptic circuit, the net effect of iMSNs on basal ganglia output is 
to decrease disinhibition to the thalamus. Figure 1 outlines the connectivity of the direct and 
indirect pathways described above, illustrating how the distinct neuroanatomical organization of 
these pathways can lead to opposing effects on basal ganglia output. 
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Despite the conceptual appeal of having two dichotomous circuits that provide opposing 
influences on basal ganglia output, a number of functionally-relevant anatomical complexities 
exist within this circuitry. For instance, while iMSNs project exclusively to the GPe or VP, not 
all dMSNs project only to the SNr or GPi. In the dorsal striatum, dMSNs that project to the 
output nuclei of the basal ganglia are known to also extend axonal collaterals to the GPe, 
classically known to be the targets of iMSNs (Wu et al., 2000, Fujiyama et al., 2011), and axon 
terminals of dMSNs arising from the NA can also be found in the pallidum (Lu et al., 1998). 
Moreover, the GPe has been shown to project back to the striatum (Staines and Fibiger, 1984). 
Another exception to the direct/indirect pathway dichotomy is the fact that, in contrast to the 
GPe, the VP can function as an output nucleus of the basal ganglia, much like the GPi and SNr, 
as some cells in the VP have been shown to project to the mediodorsal thalamus (Tripathi et al., 
2013). Finally, the STN is also part of a third pathway that can influence basal ganglia output, 
Figure 1: Connectivity and pathways in the basal ganglia. A. The striatum is the main input nucleus of 
the basal ganglia and receives excitatory inputs from the cortex and thalamus (blue arrows). The internal 
segment of the globus pallidus (GPi) and the substantia nigra pars reticulata (SNr) are the main output 
nuclei of the basal ganglia; they project to regions outside the basal ganglia, predominantly the thalamus 
(red arrows). B. Within the basal ganglia two parallel pathways interconnect input and output nuclei. The 
direct pathway is formed by striatal medium spiny neurons (MSNs) that project monosynaptically to the 
GPi or SNr, output nuclei of the basal ganglia (solid red arrows). Many of the direct-pathway MSNs 
(dMSNs) also have axon collaterals that project to the external segment of the globus pallidus (GPe) 
(dotted red arrow). In contrast, the indirect pathway arising from striatal MSNs (iMSNs) interconnect 
with the output nuclei of the basal ganglia, the GPi and SNr, through a polysynaptic circuit via the GPe or 




the so-called hyperdirect pathway. Excitatory projections, predominantly from motor cortex but 
also prefrontal regions, have been shown to directly target the STN, allowing cortical 
information to enter the basal ganglia bypassing the striatum (Haynes and Haber, 2013). 
Despite these exceptions, the circuit connectivity described above and illustrated in 
Figure 1 explains how the basal ganglia are integrated in a loop with the cortex and thalamus. 
The striatum receives corticothalamic inputs and relays neural information to the output nuclei of 
the basal ganglia either directly via the dMSNs or indirectly via iMSNs. Influence from both the 
direct and indirect pathways determines whether neurons in the SNr and GPe will inhibit or 
disinhibit their thalamic targets. Thalamic nuclei, in turn, send excitatory projections to the 
cortex and can project directly back to the striatum, thereby closing the cortico-basal ganglia-
thalamo-cortical loop. Anatomical tracing studies in both rodents and primates have 
demonstrated that functional regions in the cortex that send inputs to the basal ganglia are 
connected with specific areas of each nucleus of the basal ganglia and the thalamus, revealing a 
topographical pattern of connectivity through cortex, basal ganglia, and thalamus composed of a 
series of parallel, segregated loops (Haber and Calzavara, 2009). Data in primates have also 
demonstrated that terminals from different functional regions converge at nodes within the 
corticostriatal pathway (Haber et al., 2006, Calzavara et al., 2007). From a circuitry point of 
view, this organization allows for specific loops to be activated or inhibited independently. 
Therefore, it is conceptually feasible that opposing influence of the direct and indirect pathways 
on basal ganglia output can occur simultaneously on different loops when animals engage in 
complex behaviors: while the direct pathway promotes thalamic disinhibition to drive specific 
behaviors via a particular loop, the indirect pathway maintains thalamic inhibition via competing 
loops to suppress unwanted actions. 
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In addition to being integrated in a series of loops with the cortex and thalamus, the basal 
ganglia are modulated by dopaminergic neurons in the midbrain located both in the SNc and 
ventral tegmental area (VTA). Dopaminergic terminals densely innervate dMSNs and iMSNs 
throughout the entire striatum (Moss and Bolam, 2008). One functionally-relevant feature of 
dopaminergic terminals in the striatum is that they exhibit presynaptic D2R expression thought 
to function as autoreceptors in a negative feedback mechanism, whereby their activation leads to 
decreased release of dopamine (Sesack et al., 1994, Ford, 2014). Moreover, presynaptic D2R 
expression in the striatum does not only occur in the terminals of dopaminergic neurons, as 
cortical afferent presynaptic terminals to the striatum have also been shown to express D2Rs 
(Wang and Pickel, 2002). The presynaptic expression of D2Rs in the striatum has posed a 
challenge to the study of D2R function in iMSNs since pharmacological agents targeting this 
receptor in the striatum can bind to both presynaptic and postsynaptic receptors, and it can be 
difficult to experimentally isolate the effects elicited by targeting D2Rs in each of these neuronal 
compartments. 
Histologically, the striatum displays another level of heterogeneity in its organization into 
patch (striosome) and matrix compartments that have specialized gene expression as well as 
different inputs and outputs. The patch compartment has enriched immunoreactivity for 
enkephalin, substance P, as well as cholinergic muscarinic receptors and mu opioid receptors 
(Graybiel et al., 1981, Moriwaki et al., 1996, Bernard et al., 1999). In contrast, the matrix 
compartment has high acetylcholinesterase activity, somatostatin-immunoreactive fibers, and 
GABAergic neurons that co-express calbindin (Graybiel and Ragsdale, 1978, Herkenham and 
Pert, 1981, Gerfen, 1984, Gerfen et al., 1985). Patches receive inputs from the prelimbic cortex 
and project to the SNc, while the matrix receives inputs from sensory and motor cortical regions 
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and projects to the SNr (Gerfen, 1984). The connectivity of striatal patch and matrix 
compartments has been proposed to represent a second level of functional organization in the 
basal ganglia in addition to the parallel circuits formed by the direct and indirect pathways 
(Gerfen, 1992). 
Moreover, different types of striatal neurons form synaptic contacts locally within the 
striatum. MSN-to-MSN lateral inhibition represents one type of such synaptic contact. In 
addition to projecting outside of the striatum, both dMSNs and iMSNs are known to extend 
richly-branching axon collateral arbors around their cell bodies (Kawaguchi et al., 1989). 
GABAergic synapses between these collaterals and GABAA receptors on neighboring MSNs 
represent a lateral inhibition mechanism via which striatal output may be further regulated 
(Czubayko and Plenz, 2002). Using BAC transgenic mice, researchers have characterized MSN-
to-MSN lateral connectivity by demonstrating that, while iMSNs project both to other iMSNs 
and to dMSNs, dMSNs locally synapse only onto other dMSNs (Taverna et al., 2008).  
Synapses involving striatal interneurons represent a second type of local connectivity 
within the striatum. Among striatal interneurons, it is known that the GABAergic interneurons 
form feed-forward inhibitory synaptic connections with both MSNs and neighboring 
interneurons (Koos and Tepper, 1999). In addition, cholinergic interneurons release 
acetylcholine in the striatum, and changes in their activity have been linked to motor and 
reinforcement learning in primates (Kimura et al., 1984, Aosaki et al., 1994). However, the 
mechanisms by which acetylcholine affects basal ganglia output are not well characterized. 
Although MSNs lack nicotinic receptors (Luo et al., 2013), they express muscarinic receptors 
that are thought to mediate increased MSN excitation when acetylcholine is released from 
cholinergic interneurons, even in the absence of synaptic input (Hsu et al., 1996, Hsu et al., 1997, 
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Galarraga et al., 1999). Studies using optogenetics have also demonstrated that activation of 
cholinergic interneurons triggers dopamine release from presynaptic terminals in the striatum 
(Cachope et al., 2012, Threlfell et al., 2012).  In addition, cholinergic interneurons express D2Rs 
and their activity can be modulated by dopamine (Yan et al., 1997). Thus, even though they 
represent a small minority of neurons in the basal ganglia, striatal interneurons can influence 
basal ganglia output by modulating dopamine release and activity of MSNs. 
With an understanding of the parallel circuits that integrate basal ganglia input and 
output, it is important to also acknowledge specific differences in the anatomical connectivity 
involving the dorsal striatum and the NA. These differences exist at the level of afferents and 
efferents and further reinforce the concept that the basal ganglia are integrated in parallel loops 
with the cortex and thalamus. Afferent dopaminergic modulation from the midbrain to the 
striatum target striatal sub-regions selectively. The vast majority of dopaminergic neurons 
projecting to the dorsal striatum come from the SNc, while those projecting to the NA come 
from the VTA (Ungerstedt, 1971, Fallon and Moore, 1978, Gerfen et al., 1987). In respect to 
cortical inputs, the dorsal striatum receives inputs from associative and sensorimotor cortical 
areas, while the NA receives inputs from the orbitofrontal cortex and other limbic cortical areas 
(Gerfen, 1984, Nakano et al., 2000). There are also differences in the efferent targets of striatal 
MSNs arising from the dorsal striatum and NA. Consistent with their dorsal-ventral orientation, 
iMSNs in the dorsal striatum project to the GPe, while iMSNs in the NA project to the VP. 
Similarly, among the dMSNs that project to the pallidum, those arising from the dorsal striatum 
target the GPe, while those arising from the NA target the VP. Moreover, it is known that in the 
dorsal striatum, projections from dMSNs to the GPe are predominantly axon collaterals from 
neurons that also project to output nuclei of the basal ganglia (Kawaguchi et al., 1990, Wu et al., 
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2000, Fujiyama et al., 2011). Although axon terminals of dMSNs arising from the NA can also 
be found in the VP (Lu et al., 1998), it is not known if these terminals represent axon collaterals. 
Moreover, functional differences related to anatomical connectivity have been reported between 
dMSN “non-canonical” projections from the dorsal striatum to the GPe and those from the NA to 
the VP. One recent study estimated that 18% of the neurons in the GPe receive input from 
dMSNs in the dorsal striatum, while as many as 50% of the neurons in the VP receive inputs 
from dMSNs in the NA (Kupchik et al., 2015). 
The dorsal striatum and NA can be further divided into sub-compartments. The medial 
and lateral regions of the dorsal striatum receive inputs from distinct cortical regions. While 
sensorimotor cortex projects to the dorsolateral striatum (DLS), associative cortical structures, 
including medial prefrontal cortex and anterior cingulate, project to the dorsomedial striatum 
(DMS) (Pan et al., 2010). The NA, in turn, can be anatomically subdivided into core and shell. 
The core of the NA receives inputs from associative and limbic cortex (Brog et al., 1993), much 
like the DMS. In contrast, the shell of the NA has very distinct morphological and anatomical 
properties when compared to the rest of the striatum and is considered by some to be part of the 
extended amygdala (Alheid and Heimer, 1988, Heimer et al., 1991, Heimer et al., 1997). 
Compared to the NA core, neurons in the NA shell have lower density of dendritic spines and 
less branching (Meredith et al., 1992). The NA shell also receives afferent innervation from 
different cortical and subcortical structures compared to those of the core, including lateral 
hypothalamus and brainstem (Brog et al., 1993). In addition to innervating the VP and GPi, the 
NA shell also project to the VTA, as well as to the lateral hypothalamus and other structures in 
the extended amygdala (Heimer et al., 1991). Despite this traditional sub-compartmentalization, 
it has also been proposed that functional sub-regions within the striatum follow a gradient along 
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the dorsolateral-to-ventromedial axis, especially when considering the source of corticostriatal 
inputs (Moriwaki et al., 1996). 
In summary, although a number of exceptions have been described, the basal ganglia can 
be conceptually framed as integrated in serial loops with the cortex and thalamus, with the direct 
and indirect parallel pathways providing opposing influence on basal ganglia output. Activity in 
this circuit is modulated internally by striatal interneurons and externally by dopaminergic 
neurons that project to the striatum.  
 
NEUROPHYSIOLOGY OF MEDIUM SPINY NEURONS 
Much of the intrinsic neurophysiological properties of dMSNs and iMSNs, as well as 
their influence of basal ganglia output, have been characterized both in vitro and in vivo. Both 
dMSNs and iMSNs have a low resting membrane potential in the absence of corticothalamic 
input. At rest, inward rectifying Kir2 potassium channels, expressed in abundance by all striatal 
MSNs hold the membrane potential near the equilibrium potential of potassium (Wilson, 1993). 
In response to glutamatergic synaptic inputs from the cortex and thalamus, MSNs can depolarize 
if inputs have enough temporal and spatial convergence to overwhelm Kir2 channels and cause 
them to close, allowing the membrane potential to reach spike threshold (Wilson and 
Kawaguchi, 1996). Slice electrophysiological recordings from genetically-identified iMSNs and 
dMSNs have demonstrated that both types of MSNs share similar passive membrane properties, 
including resting membrane potential, action potential properties, input resistance, and 
afterhyperpolarization amplitude (Cepeda et al., 2008). Using optogenetic tools to identify 
dMSNs and iMSNs, findings from in vivo electrophysiology experiments are in line with in vitro 
data and provide further insight on how MSN activity is related to behavior. Both types of MSNs 
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show similarly low baseline activity when animals are not engaging in motor actions and are 
concomitantly active during initiation of action sequences (Jin et al., 2014b), presumably driven 
by strong corticothalamic inputs that reverse hyperpolarization in MSNs to allow initiation of 
behavioral programs. 
Even though dMSNs and iMSNs exhibit similar passive membrane properties and 
general levels of activity in vivo, there are many known functional differences between these two 
neuronal populations that can lead to different responses to synaptic input. Some of these 
functional differences arise from differences in the morphology of dMSNs and iMSNs. In 
rodents, the total dendritic length of iMSNs is smaller than that of dMSNs (Gertler et al., 2008). 
From this difference in dendritic surface area, with no evident dissimilarity in the density of 
synaptic inputs to dMSNs and iMSNs, some have inferred that dMSNs receive more 
glutamatergic inputs than iMSNs (Gerfen and Surmeier, 2011). In addition, smaller dendritic 
length leads to lower membrane capacitance, which can account for the higher intrinsic 
excitability of iMSNs compared to dMSNs that has been demonstrated in a number of studies 
using slice physiology (Kreitzer and Malenka, 2007, Cepeda et al., 2008, Gertler et al., 2008, 
Lobo et al., 2010).  
However, most of the physiological differences between dMSNs and iMSNs can be 
attributed to the different dopamine receptors they express that are thought to mediate diverging 
modulatory effects of dopamine on these two populations of striatal neurons. It is thought that 
activation of D1Rs leads to somatic depolarization and facilitates spiking in dMSNs, while 
activation of D2Rs on iMSNs has the opposing effect, causing cells to become less likely to 
depolarize and fire action potentials. However, although researchers have some insight on how 
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membrane conductances can be changed upon activation of D1Rs and D2Rs on the cell surface 
of MSNs, much of the intracellular mechanisms underlying these effects remain unknown. 
The D1R is a Gαs/olf-protein-coupled receptor that activates adenylate cyclase and 
consequently increases production of cyclic AMP (cAMP). High levels of cAMP in MSNs lead 
to the activation of protein kinase A (PKA), which induces phosphorylation of various 
substrates, as well as activation of immediate early gene expression and modulation of ion 
channels. Some specific physiological effects of D1R activation on MSNs have been described. 
For instance, intracellular signaling activated by D1Rs has been shown to increase Cav1 L-type 
channel currents (Surmeier et al., 1995, Galarraga et al., 1997) and to decrease somatic A-type 
potassium currents (Kitai and Surmeier, 1993). D1R activation in MSNs can also reduce N- and 
P-type calcium currents (Surmeier et al., 1995) that control activation of calcium-dependent 
potassium currents (Vilchis et al., 2000). In addition, bypassing G protein signaling, the second 
intracellular loop of the D1R has been shown to interact directly with the C-terminal region of N-
type Cav2.2 channels and mediate inhibition or internalization of these channels both in 
transfected cells and in native tissue (Kisilevsky et al., 2008, Kisilevsky and Zamponi, 2008). 
Moreover, in both transfected cells and cultured neurons, the D1R has been shown to interact 
with the NR1 and NR2A subunits of the glutamatergic NMDA receptor (Lee et al., 2002, 
Fiorentini et al., 2003).  
In contrast, D2Rs are Gαi/o-protein-coupled receptors that when activated leads to 
inhibition of adenylate cyclase and decreased cAMP production. Decreased production of cAMP 
decreases PKA activity, which can have a modulatory effect on ions channel conductances. 
Assuming that dMSNs and iMSNs express similar intracellular signaling proteins, it is expected 
that activation of D2Rs in iMSNs would have opposite physiological effects compared to 
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activation of D1Rs in dMSNs. Studies using slice electrophysiology have indeed shown this 
dichotomy for some conductances regulated by G protein signaling. For instance, in contrast to 
the effect of activating D1Rs, activation of D2Rs reduces Cav1 L-type channel currents 
(Hernandez-Lopez et al., 1997, Hernandez-Lopez et al., 2000). In heterologous cell culture 
systems, it has been demonstrated that D2Rs can also activate G-protein coupled inwardly 
rectifying potassium (GIRK) channels via the Gβγ subunit (Kuzhikandathil et al., 1998, Lavine et 
al., 2002). The activation of GIRKs induced by activation of D2Rs and other G-protein coupled 
receptors (GPCRs) has an inhibitory effect on neurons and could potentially mediate several 
functions of dopamine in vivo (Luscher and Slesinger, 2010). However, the striatum expresses 
low levels of GIRK channels (Karschin et al., 1996), and D2R-dependent outward currents that 
are characteristic of GIRKs cannot be readily measured in MSNs unless GIRK channels are 
artificially overexpressed (Marcott et al., 2014). Thus, the well-characterized GIRK-mediated 
decrease in excitability promoted by Gαi signaling is likely not relevant for D2Rs expressed in 
MSNs. Moreover, the D2R can also interact directly with the NR2B subunit of the NMDA 
receptor in response to high extracellular dopamine in the postsynaptic density microdomain of 
excitatory synapses in striatal neurons (Liu et al., 2006). Thus, most studies investigating the 
physiological effects of dopamine on D1Rs and D2Rs suggest that activation of each receptor 
leads to opposing downstream effects, reinforcing a dichotomy between these two neuronal 
populations. 
It is also important to note that two splice variants of the D2R exist, the D2R long and 
short isoforms (D2L and D2S, respectively), which are identical except for an insert of 29 amino 
acids in the third extracellular loop of the D2L isoform (Dal Toso et al., 1989). Some differences 
in subcellular distributions and coupling to G proteins have been reported for these two D2R 
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isoforms (Montmayeur et al., 1991, Usiello et al., 2000, Morris et al., 2007, De Mei et al., 2009). 
However, D2Rs expressed postsynaptically by iMSNs are predominantly of the D2L type 
(Usiello et al., 2000), and therefore it can be inferred that the physiological effects described 
above measured in striatal MSNs are likely mediated by the D2L isoform. 
The 32-kDa dopamine- and cAMP-regulated phosphoprotein (DARPP-32) is a substrate 
of PKA that plays a role in dopamine signaling in striatal MSNs, mediating some of the opposite 
physiological effects of D1R and D2R activation. Phosphorylation of DARPP-32 at threonine 34 
by PKA activates the protein phosphatase 1 (PP1) inhibitory function of DARPP-32 (Hemmings 
et al., 1984). Studies in BAC transgenic mice overexpressing DARPP-32 tagged for 
immunoprecipitation have shown that enhanced D1R stimulation results in increased 
phosphorylation of DARPP-32 in response to PKA activation in dMSNs, whereas stimulation of 
D2Rs in iMSNs reduces phosphorylation of DARPP-32 at threonine 34, presumably as a 
consequence of reduced PKA activation (Bateup et al., 2008) and/or the dephosphorylation of 
threonine 34 by the calmodulin-dependent protein calcineurin that is also activated by increased 
intracellular Ca2+ after activation of D2Rs (Nishi et al., 1997). In MSNs, the phosphorylation 
state of multiple PKA targets, such as ionotropic glutamate and GABA receptors, is the result of 
an equilibrium between PKA and PP1 activity (Greengard et al., 1999, Greengard, 2001). 
Therefore, DARPP-32 is a regulator protein that acts to amplify PKA signaling and can mediate 
the opposing functions of D1Rs and D2Rs in the striatum. 
In addition, several MAP kinases have been shown to mediate signaling involved in the 
physiological effects of dopamine. Observations in heterologous cell culture systems suggest that 
both D1Rs and D2Rs can regulate the MAP kinases extracellular signal regulated kinases 1 and 2 
(ERK1 and ERK2) (Chen et al., 2004, Wang et al., 2005). Pharmacological studies in vivo have 
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shown that psychostimulants that lead to high extracellular dopamine, such as amphetamine or 
cocaine (Valjent et al., 2006), and the D2R antagonist haloperidol (Pozzi et al., 2003) enhances 
phosphorylation of ERK1 and ERK2 in the striatum. These findings were confirmed with BAC 
transgenic mice, further revealing that psychostimulants activate ERK selectively in dMSNs, 
while haloperidol activates ERK selectively in iMSNs (Bertran-Gonzalez et al., 2008). 
Furthermore, it has also been shown that ERK phosphorylation mediated by D1Rs in the striatum 
involves an interaction with the NMDA glutamate receptor and requires the presence of 
endogenous glutamate (Valjent et al., 2000, Valjent et al., 2005, Pascoli et al., 2011). In cell 
culture, D2R-mediated ERK signaling has been shown to be dependent on Gαi protein coupling 
(Ghahremani et al., 2000, Beom et al., 2004). Thus, evidence suggests that some of the 
dichotomous physiological effects of activating D1Rs and D2Rs in striatal MSNs may be 
mediated by ERK signaling. 
Another important distinction between dMSNs and iMSNs and how they can be 
modulated by dopamine via D1Rs and D2Rs, respectively, relates to the different affinities of 
dopamine for each type of receptor. The affinity of D2Rs for dopamine is reported to be 10- to 
100-fold greater than that of D1Rs (Missale et al., 1998). However, most measures of affinity for 
dopamine have been made using displacement of radiolabeled antagonists from receptors 
expressed in heterologous systems, and these methods do not take into account the coupling 
efficacy to downstream signaling cascades. Even though it is problematic to infer that these 
measurements reflect what happens in vivo, many researchers have proposed that D2Rs are 
preferentially activated by basal (tonic) extracellular levels of dopamine, while burst (phasic) 
firing of dopaminergic neurons mainly activates the low-affinity D1Rs (Grace et al., 2007, 
Surmeier et al., 2011). Researchers have also proposed that both D1Rs and D2Rs can exist in 
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both high- and low- affinity states with similar affinities to dopamine in their high-affinity states 
(Cumming, 2011). These observations have led to different conceptual models of how dopamine 
may affect activity in the basal ganglia during reinforcement learning (Goto and Grace, 2005, 
Grace et al., 2007), but the actual relevance of tonic and phasic dopamine and dopamine receptor 
affinity states to basal ganglia output and behavior still needs to be fully tested with selective 
manipulations in vivo. 
Table 1 summarizes the main biochemical and physiological effects that have been 
shown to result from activation of D1Rs or D2Rs on striatal MSNs. It is important to note, 
however, that most studies reporting electrophysiological changes induced by activation of D1Rs 
and D2Rs in striatal MSNs were done with whole-cell patch clamp in acute slices, a technique 
that allows researchers to measure changes in conductances in the soma but not in other cellular 
compartments, including dendrites and axon terminals. A few studies have used two-photon 
microscopy and calcium sensors to determine how excitability of MSNs are specifically affected 
at proximal and distal dendrites, confirming that dendrites of iMSNs are more excitable than 
those of dMSNs and demonstrating that activation of D2Rs can suppress dendritic excitability of 
iMSNs (Carter and Sabatini, 2004, Carter et al., 2007, Day et al., 2008). Moreover, it is known 
that D2Rs are also expressed in the presynaptic terminals of iMSNs targeting the GPe (Levey et 
al., 1993, Yung et al., 1995), and some findings have shown that dopamine can modulate GABA 
release from iMSN terminals targeting pallidal neurons via presynaptic D2Rs (Floran et al., 
1997, Wei et al., 2013, Mamad et al., 2015). A role for D2Rs acting on presynaptic terminals of 
iMSNs to suppress GABA release has also been demonstrated for axon collaterals that target 




Table 1: Biochemical and physiological effects of activating D1Rs and D2Rs in MSNs 
 Target Effect References 
Activation of 
D1Rs 
Gαs, Gαolf Stimulates cAMP production  
Cav1 L-type channel Increases currents 
(Surmeier et al., 1995, 
Galarraga et al., 1997) 
A-type K+ channels Decreases currents (Kitai and Surmeier, 1993). 
N- and P -type Ca2+ 
channels 
Decreases currents (Surmeier et al., 1995) 
Ca2+- dependent K+ 
channels 
Activates currents (Vilchis et al., 2000) 
N-type l Cav2.2 
channel 
Inhibition and internalization 
(Kisilevsky et al., 2008, 
Kisilevsky and Zamponi, 
2008) 
NR1 and NR2A 
NMDA subunits 
Interacts 
(Lee et al., 2002, Fiorentini 
et al., 2003) 
DARPP-32 Increases phosphorylation (Bateup et al., 2008) 
ERK1 and ERK2 Increases phosphorylation (Valjent et al., 2006) 
Activation of 
D2Rs 
Gαi, Gα0 Inhibits cAMP production  
Cav1 L-type channel Decreases currents 




Interacts (Liu et al., 2006) 
DARPP-32 Decreases phosphorylation (Bateup et al., 2008) 
ERK1 and ERK2 Decreases phosphorylation (Pozzi et al., 2003) 
 
 
STRIATAL PATHWAY AND BEHAVIOR 
 
MOTOR BEHAVIOR 
Despite the complexities in anatomy and function, a number of studies suggest that the 
opposing influence on output to the thalamus exerted by the two main pathways of the basal 
ganglia mediate opposing influences on behavior, with the direct pathway being permissive for 
behavior initiation and the indirect pathway being inhibitory. This opposition has been most 
clearly demonstrated in the domain of motor behavior, and as a result, the two pathways have 
been classically referred to as the “go” (direct) and “no-go” (indirect) pathways. 
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Combining knowledge of basal ganglia connectivity and dopamine receptor function, 
dopamine depletion studies and observed effects of psychostimulants provided some initial 
evidence in support of this classical model. The neurotoxin 6-hydroxydopamine (6-OHDA) can 
selectively destroy dopaminergic neurons and has been used to model parkinsonism in different 
species (Ungerstedt, 1968). When locally delivered into the striatum, 6-OHDA is taken up by 
dopaminergic terminals and induces cell death (Blum et al., 2001). The loss of dopaminergic 
modulation to the striatum that ensues leads to robust motor impairments in both rodents and 
primates (Blesa and Przedborski, 2014). In contrast, psychostimulants such as cocaine and 
amphetamine, which increase extracellular dopamine by blocking dopamine reuptake through 
the dopamine transporter (DAT), induces hyperactive motor behavior in rodents (Jaber et al., 
1997).  
Pharmacological studies measuring the effect of selective dopamine receptor agonists and 
antagonists on motor behavior have further elucidated the role of dMSNs and iMSNs on motor 
control. D1R agonists have a stimulatory effect on locomotor activity in rodents, while treatment 
with D2R agonists leads to a biphasic locomotor response, characterized by decreased activity at 
low doses and behavioral activation at high doses (Eilam et al., 1992). This biphasic effect can 
be explained by the fact that D1Rs are only expressed postsynaptically, while D2Rs are 
expressed both presynaptically and postsynaptically (Sesack et al., 1994). While selective D1R 
stimulation in striatal dMSNs increases locomotor activity by activating the direct pathway, D2R 
agonists in the striatum can lead to activation of postsynaptic receptors on iMSNs and 
presynaptic autoreceptors in dopaminergic terminals. Presynaptic D2Rs have been shown to 
provide negative feedback to dopamine neurons, decreasing dopamine release into the striatum 
(Starke et al., 1989) and likely mediating the initial decreased activity of the biphasic motor 
21 
 
response to D2R agonists. In addition, presynaptic D2Rs are predominantly of the D2S isoform, 
while postsynaptic D2Rs are predominantly of the D2L isoform (Usiello et al., 2000, De Mei et 
al., 2009). As a result, different contributions of D2S and D2L isoforms are thought to also 
mediate the biphasic response of D2R agonists on motor behavior. 
The most direct evidence for a dichotomy between direct and indirect pathways on motor 
output comes from optogenetics studies. Using Cre-dependent expression of the excitatory opsin 
channelrhodopsin-2 (ChR2) in the dorsal striatum of Drd1-Cre and Drd2-Cre mice, researchers 
have shown that activating dMSNs leads to increased movement initiation in freely-behaving 
animals, while activating iMSNs increases freezing and bradykinesia, and decreases initiation of 
movements (Kravitz et al., 2010). Similar optogenetic manipulations in the NA, however, do not 
elicit similar changes in locomotor activity (Lobo et al., 2010). In agreement with this negative 
finding, studies using optogenetics to activate dopaminergic terminals projecting from the VTA 
to the NA also did not show difference in locomotor activity induced by either phasic or tonic 
stimulation (Chaudhury et al., 2013). These studies suggest that the control of locomotor activity 
by the direct and indirect pathways and their modulation by dopamine may be mediated 
primarily by the dorsal striatum. 
Other strategies have also been used to demonstrate the opposing effects on motor output 
by the direct and indirect pathways. For instance, in one study, researchers selectively ablated 
iMSNs in the entire striatum by locally delivering diphtheria toxin to animals that selectively 
expressed the diphtheria toxin receptor in iMSNs (Durieux et al., 2009). Consistent with a role of 
the indirect pathway in inhibiting locomotion, they found that ablating iMSNs induced 
hyperlocomotion in mice (Durieux et al., 2009). In another study, selective deletion of DARPP-
32 in iMSNs or dMSNs was performed to probe the roles of direct and indirect pathways in 
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controlling motor behavior (Bateup et al., 2010). This study showed that DARPP-32 deletion in 
dMSNs decreased basal and psychostimulant-induced locomotion, while DARPP-32 deletion in 
iMSNs led to increased locomotor activity in mice (Bateup et al., 2010), thereby directly 
implicating DARPP-32 in supporting the opposing functions of direct and indirect pathways on 
motor behavior. 
Despite evidence emphasizing the opposing functions of direct and indirect pathways, it 
is known that complex, coordinated activity of both pathways are necessary for the precise 
regulation of motor output. In vivo calcium imaging has shown that both dMSNs and iMSNs 
show increased activity when animals engage in motor actions, yet are inactive when animals are 
not moving (Cui et al., 2013). To expand on these observations, another study used in vivo 
electrophysiology to investigate how activity of dMSNs and iMSNs change while animals 
engage in action sequences. They confirmed that these two types of neurons are concomitantly 
active during initiation of action sequences, but their activities can differ while the action 
sequence is ongoing (Jin et al., 2014a). As previously suggested, based on the anatomical 
organization of the basal ganglia in segregated, parallel loops, these findings are consistent with 
a model in which both pathways are active in different loops when animals initiate movements: 
while the direct pathway functions to activate wanted motor programs, the indirect pathway may 
be activated to suppress unwanted motor programs. These studies further suggest the importance 
of balanced direct- and indirect-pathway output for appropriate control of motor behaviors.  
 
MOTIVATION 
The basal ganglia are also thought to regulate motivated behaviors, and this regulation 
has been largely studied in the context of dopaminergic modulation of striatal function. 
Motivation can be defined as the activation of goal-directed behavior. Animals have the adaptive 
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ability to approach life-sustaining aspects of their environment, which can be considered 
rewards, and to withdraw from what may be life-threatening. Motivation pertains to animals’ 
goal-directed approach behavior to learned rewards, and potential rewards, including exploration 
of their environment and engagement in actions that have been previously reinforced by rewards. 
Furthermore, in addition to what is external and can produce and reinforce motivated behavior, 
the induced internal state that produces and reinforces such behaviors can also be considered 
rewarding (Ikemoto, 2010). This conceptual framework will be helpful in interpreting the body 
of data concerning how dopamine and the basal ganglia regulate motivation. 
It is important to explicitly describe specific aspects of motivation and explain how 
researchers can probe different phases of reinforcement learning and the different components of 
motivation that are at play when subjects engage in reward-seeking behavior. In order to 
effectively engage in motivated behavior, subjects must first learn that certain actions lead to 
rewarding outcomes. In this initial phase, subjects can learn several features of an action-
outcome association, which include the value of the reward, the amount of expended effort 
required to obtain the reward, and the specific action contingencies for achieving that outcome. 
Once subjects learn an action-outcome association, several components of motivation are 
simultaneously at play during reward-seeking behavior. For instance, animals must determine 
how to direct their behavior to specific actions based on how much they bias their decision on 
associations related to reward value, required effort, and contingency. These biases characterize 
motivational states that can be assessed experimentally with instrumental tasks by measuring 
both action selection and action vigor, which represent the “directional”, goal-directed 
component and the “activational”, arousal component of motivation, respectively (Salamone and 
Correa, 2012). Most of the behavioral studies described in this section attempt to understand how 
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the basal ganglia mediate motivated behavior by manipulating a specific aspect of basal ganglia 
function and assaying behavior. In reviewing these studies, I use the framework described above 
to identify reproducible findings that can guide understanding of how different striatal sub-region 
may selectively regulate motivated behavior through dopaminergic modulation of the direct and 
indirect pathways.  
In the 1980s, Wolfram Schultz and colleagues conducted single-cell recordings of 
dopaminergic neurons in the midbrain in primates performing an instrumental task involving 
reaching movements for a food reward in response to auditory and visual cues (Aebischer and 
Schultz, 1984, Schultz, 1986). These researchers found that phasic activity of midbrain dopamine 
neurons that project to the striatum was associated with the presentation of the visual or auditory 
stimuli that would be followed by the food reward. Despite an established link between 
dopamine and motor function, execution of reaching movements was less significantly 
associated with dopaminergic activity, indicating that activity of midbrain dopaminergic neurons 
does not encode specific movement parameters. These observations gave rise to a model of 
reinforcement learning now known as the reward prediction error hypothesis that predicts that 
phasic dopamine release from midbrain neurons to the striatum signals a discrepancy between 
the predicted and expected rewarding properties of an outcome (Schultz, 1998). 
The role of dopaminergic modulation of basal ganglia function on motivated behavior has 
been further supported by research with psychostimulant drugs, including cocaine and 
amphetamine, both of which strongly increases extracellular dopamine concentrations in the 
striatum (Di Chiara and Imperato, 1988). Researchers have applied the reward prediction error 
hypothesis to psychostimulant drug addiction, proposing that recurring drug-induced positive 
prediction errors produce a potentiated increase in the rewarding value of states or actions 
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associated with drug use, prompting compulsive drug-seeking behavior (Redish, 2004). 
However, the predictive value of this model of drug addiction has been challenged (Panlilio et 
al., 2007). Nevertheless, regardless of how drug-seeking behavior can be modeled using the 
reward prediction error hypothesis, studies investigating the reinforcing properties of 
psychostimulants have provided insight on how dopamine regulates goal-directed behavior by 
affecting basal ganglia function. Several lesion studies and intracranial self-administration 
studies have specifically implicated NA dopamine in the effects of psychostimulants on 
behavior. It has been demonstrated that psychostimulants preferentially increase dopamine 
concentrations in the NA compared to the dorsal striatum (Di Chiara and Imperato, 1988). In 
agreement with this observation, local depletion of dopamine with 6-OHDA or local infusion of 
dopamine receptor antagonists in self-administration studies suggest that psychostimulants act 
preferentially in the NA (Lyness et al., 1979, Roberts et al., 1980, Maldonado et al., 1993, 
McGregor and Roberts, 1993). 
Although both psychostimulants and natural rewards lead to increased extracellular 
dopamine in the striatum, it has been estimated that drugs like cocaine and amphetamine increase 
concentrations of dopamine by an additional order of magnitude when compared to natural 
rewards, such as food and sexual stimuli (Damsma et al., 1992, McCullough and Salamone, 
1992, Wise et al., 1995, Fiorino et al., 1997, Bassareo and Di Chiara, 1999, Ranaldi et al., 1999, 
Ikemoto et al., 2015). Despite inducing lower extracellular dopamine in the striatum and 
relatively smaller effects on motivated behavior compared to psychostimulants, a significant 
body of research has investigated the role of striatal dopamine in regulating motivation for 
natural rewards. And, as discussed below, similar to studies on the rewarding effects of 
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psychostimulant drugs, many studies of motivation for natural reward have also focused on the 
effects of dopamine in the NA.  
A large body of literature has characterized how NA dopamine regulates motivation for 
food. In this field, researchers have been able to dissociate motivation from feeding behavior, as 
dopamine depletion or local infusions of D1R and D2R antagonists in the NA does not 
substantially impair food intake (Ungerstedt, 1971, Koob et al., 1978, Salamone et al., 1993, 
Baldo et al., 2002). Evidence also suggest that NA dopamine is not involved in the hedonic 
reactivity to food, as dopamine depletion in the NA does not decrease appetitive taste reactivity 
for food (Berridge and Robinson, 1998). Instead, researchers have demonstrated specific roles 
for NA dopamine on the goal-directed aspects of motivated behavior. For instance, in 
instrumental tasks in which animals are given the choice to either expend little or no effort to 
obtain a small reward or expend a greater effort to obtain a larger reward, dopamine depletion or 
pharmacological blockade of dopamine receptors in the NA reduce selection of the more 
effortful behaviors associated with higher reinforcement (Salamone et al., 1994). In line with a 
role of NA dopamine on reward-related action selection, one study using local infusions of 
dopamine antagonists into the NA showed that both D1R and D2R blockers impair operant 
responding specifically in situations in which animals had to select a new set of approach actions 
for reward-seeking, a behavior they call “flexible approach” (Nicola, 2010). Moreover, 
Pavlovian-to-instrumental transfer (PIT), defined as the ability of a reward-paired cue to initiate 
or invigorate reward-seeking actions, has also been shown to depend on NA dopamine 
(Parkinson et al., 2002). With the advent of optogenetics and cell-specific mouse lines, 
researchers have confirmed that dopamine release from the VTA to the NA is in itself rewarding, 
as measured by conditioned place preference and self-administration of light stimulation (Tsai et 
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al., 2009, Ilango et al., 2014a, Steinberg et al., 2014). In addition, an optogenetics study using a 
food-seeking operant task showed that activation of dopaminergic neurons in the VTA facilitates 
the development of reinforcement during reward seeking (Adamantidis et al., 2011). Overall, 
therefore, studies using experimental methods as diverse as dopamine depletion, pharmacology, 
and optogenetic have established that dopamine modulation in the NA regulates many aspects of 
goal-directed behavior for natural rewards. 
Despite a large body of evidence implicating dopaminergic projections from the VTA to 
the NA in motivation, even before the era of optogenetics, electrical stimulation studies had 
suggested that dopaminergic neurons in the SNc that project to the dorsal striatum are also 
involved in motivation (Routtenberg and Malsbury, 1969, Ritter and Stein, 1974, Corbett and 
Wise, 1980). And more recently, 
optogenetics studies have further 
confirmed that stimulation of 
dopaminergic neurons in the SNc can 
be as rewarding as stimulation of 
dopaminergic neurons in the VTA 
(Rossi et al., 2013, Ilango et al., 
2014b).  
Given that dopamine 
modulation of both dorsal and ventral 
regions of the striatum have been 
linked to motivation, many lesion and 
pharmacological studies have also 
Figure 2: Striatal sub-regions and motivation. The 
striatum can be divided into dorsal and ventral regions. The 
dorsal striatum can be further subdivided into dorsomedial 
striatum (DMS) and dorsolateral striatum (DLS). The ventral 
part of the striatum is the nucleus accumbens (NA), which is 
composed of both core and shell compartments. Lesion and 
pharmacological studies have implicated each of these striatal 
sub-regions in specific aspects of motivated behavior. 
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sought to identify how sub-regions of the striatum may be selectively important for different 
aspects of motivation. In the remainder of this section, I describe in detail a number of findings 
pertaining to the involvement of different striatal sub-regions on specific aspects of motivation. 
The general conclusions that can be drawn from these studies are summarized in Figure 2. 
Similar and distinct roles for the NA core and shell in different aspects of motivated 
behavior have been demonstrated. In a pharmacological study, infusion of D1R or D2R 
antagonists selectively into the NA core or shell showed that dopamine antagonism into either 
region could reduce instrumental responding for high-effort rewards (Nowend et al., 2001). A 
role for effort-based decision making was further confirmed for the NA core, as dopamine 
depletion of this region similarly impaired behavioral response to high-effort rewards in a cost-
benefit T-maze task (Mai et al., 2012). Using a different approach to decrease NA function, a 
study using infusions of muscimol and baclofen into the shell or core compartments of the NA 
demonstrated that the NA core, but not the shell, appears to be part of the neural circuit that 
biases choices towards larger rewards associated with a greater effort cost (Ghods-Sharifi and 
Floresco, 2010). Other specific dissociations between NA sub-compartments have been 
identified. For instance, post-training excitotoxic lesions of the NA core, but not the shell, 
selectively affected outcome devaluation (Corbit et al., 2001), implicating the NA core in 
encoding the value of rewards. In the same study, animals with lesions in the NA shell had intact 
sensitivity to reward value, but instead failed to show positive transfer in a PIT test (Corbit et al., 
2001). Researchers have attempted to distinguish how NA core and shell regulate two different 
types of PIT, general PIT (G-PIT) and outcome-specific PIT (S-PIT). While G-PIT is usually 
demonstrated using a single response procedure, which is typically interpreted in terms of the 
general arousing properties of the conditioned stimulus, in S-PIT animals are usually given 
29 
 
Pavlovian conditioning with two conditioned stimuli each paired with different outcomes and 
tested on how each stimulus can influence specific instrumental responding. A dissociation 
between NA sub-regions was found in a study showing that muscimol inactivation of the NA 
core abolished G-PIT and spared S-PIT, while inactivation of the NA shell abolished S-PIT and 
spared G-PIT (Corbit and Balleine, 2011). This finding is in line with previous studies showing 
that excitotoxic lesion or infusion of dopamine antagonists selectively into the NA core also 
abolished G-PIT (Hall et al., 2001, Lex and Hauber, 2008). These studies, therefore, point to a 
role of the NA shell in processing the sensory specificity of outcomes. Consistent with this idea, 
researchers have shown that the NA shell, but not other striatal sub-regions, can mediate 
animals’ hedonic experience of rewards via the opioid system in the striatum (Pecina and 
Berridge, 2005, Castro and Berridge, 2014). Thus, while the NA core have been implicated in 
goal-directed behavior by modulating reward-seeking behavior based on reward value and effort, 
the NA shell seems to be more involved in processing the sensory specificity of outcomes, 
including hedonic reactivity to rewards through processes that appear to be independent of 
dopamine. 
Functional and anatomical studies of the dorsal striatum predict a stronger link between 
the DMS and motivation than between the DLS and motivation because the DMS receives inputs 
from prefrontal cortex and anterior cingulate, regions that have been implicated in affective 
functions, while the DLS receives inputs predominantly from sensorimotor cortex (Pan et al., 
2010). Behavioral experiments have indeed confirmed this dissociation. For instance, excitotoxic 
lesions to the DLS, but not the DMS, disrupt habit formation of operant responding and does not 
affect sensitivity to the reward value (Yin et al., 2004, Hilario et al., 2012). In contrast, lesions to 
the DMS done either before or after instrumental training revealed that the DMS plays a role in 
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the acquisition of action-outcome associations as well as in the expression of these associations 
by encoding outcome value and contingency (Yin et al., 2005). The DMS has also been linked to 
action vigor, as one study showed that excitotoxic lesion to this striatal sub-region impaired 
state-dependent modulation of vigor in an instrumental task in rodents (Wang et al., 2013). Thus, 
while the DLS has been more clearly linked to motor function and appears to mediate habit 
formation in instrumental tasks of incentive motivation, the DMS has been consistently 
implicated in goal-directed behavior and in modulating performance vigor. 
Although a number of studies have identified or proposed specific mechanisms by which 
dopamine may modulate motivated behavior and have provided insight on which striatal sub-
regions may be important for specific aspects of motivation, few studies have rigorously probed 
how the direct and indirect pathways of the basal ganglia control specific aspects of motivation. 
And most studies that have manipulated these two pathways selectively have studied motivation 
for drugs of abuse (Durieux et al., 2009, Lobo et al., 2010, Bock et al., 2013, Hikida et al., 2013). 
The few studies investigating pathway-specific functions in motivation for natural rewards 
support an opposing influence of direct and indirect pathways on reward-seeking behavior, 
similar to that proposed for motor behavior. For instance, one study using optogenetics to bypass 
dopamine signaling and selectively activate dMSNs and iMSNs in the DMS in mice showed that 
activation of the direct pathway appeared to be rewarding and led to persistent self-stimulation, 
while indirect pathway stimulation appeared to be aversive on a more transient timescale 
(Kravitz et al., 2012). Another study using optogenetics to selectively stimulate dMSNs or 
iMSNs in the DMS demonstrated that selective activation of each pathway can introduce 
opposite biases in the distribution of choices in an operant task of goal-directed action selection 
(Tai et al., 2012). Although these studies help understand how the parallel pathways of the basal 
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ganglia arising from different striatal sub-regions regulate motivated behavior for natural 
rewards, more research is needed in this field. 
In conclusion, incentive motivation, defined as the activation of goal-directed behavior, 
requires learning of action-outcome associations and can be dissected into separate components, 
such as action selection and action vigor, that can often be studied experimentally. Dopaminergic 
modulation of specific striatal sub-regions has been selectively implicated in different aspects of 
motivated behavior for natural rewards. And basal ganglia output regulated by activity of the 
direct and indirect pathways has also been linked to motivation. However, although genetic tools 
have become available for selectively targeting neuronal populations in the rodent striatum, 
comprehensive studies using these tools to probe how dMSNs and iMSNs in different striatal 
sub-regions regulate motivation for natural rewards are still lacking. 
 
STRIATAL PATHWAYS AND DISEASE 
Dysfunction of the basal ganglia has been implicated in many neuropsychiatric diseases, 
many of which involve abnormalities in motor functions or motivation. These diseases include 
Parkinson’s disease, Huntington’s disease, drug addiction, obsessive-compulsive disorder 
(OCD), Tourette’s syndrome, attention deficit hyperactivity disorder (ADHD), and 
schizophrenia. In this section, I will first provide an overview of how basal ganglia dysfunction 
has been shown to underlie symptoms in each of these disorders, with particular emphasis on 
dopaminergic modulation of the direct and indirect pathways. Then I will describe in more detail 
research on schizophrenia that implicates D2R hyperfunction in certain symptoms of this 
disease. Large emphasis will be placed on one particular mouse model of schizophrenia 
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endophenotypes, as insight obtained from this model provided the groundwork for most of the 
studies I present in this dissertation. 
Dysfunction of the basal ganglia underlies many motor neurological disorders, including 
Parkinson’s disease and Huntington’s disease. In Parkinson’s disease, muscular rigidity, 
bradykinesia postural instability, and tremor are thought to be caused by depletion of dopamine 
in the midbrain (Albin et al., 1989). Lack of dopaminergic modulation of both direct and indirect 
pathways can explain impaired motor output when considering that dopamine normally acts to 
disinhibit basal ganglia output to the thalamus via these two parallel pathways. Interestingly, 
even though Parkinson’s disease is more notably characterized by motor abnormalities, lack of 
motivation is also highly prevalent in patients with this disease (Pedersen et al., 2009). And 
although largely correlational, imaging studies have demonstrated differences in dopamine 
binding to D2Rs between patients with Parkinson’s diseases with lack of motivation and those 
without this symptom (Thobois et al., 2010). The motor symptoms observed in Huntington’s 
disease can also be explained using the classic model of basal ganglia circuitry. This disease is 
characterized by abnormal involuntary writhing movements, known as chorea, that result from a 
polyglutamine expansion in the ubiquitously-expressed huntingtin protein, which for unknown 
reasons leads to the degeneration of certain types of neurons, including striatal MSNs. The 
classical model of basal ganglia circuitry has been employed to explain symptoms in 
Huntington’s disease, with researchers proposing that hyperkinetic, choreic movements in the 
early stages of disease result from initial dysfunction of iMSNs, which are preferentially lost in 
this disorder, while hypokinesia during the late disease stages is a consequence of further injury 
to dMSNs (Reiner et al., 1988, Spektor et al., 2002).  
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The basal ganglia have been also implicated in symptoms in a number of psychiatric 
disorders, including drug addition, OCD, Tourette’s syndrome, and ADHD. Drug addiction can 
be classified as a disorder of abnormally high motivation that leads patients to lose control over 
drug intake. Given that drugs of abuse increase extracellular dopamine in the striatum and can 
theoretically promote reward-seeking behavior via effects on both direct and indirect pathways, 
the basal ganglia have been hypothesized to be a site where the neuroplastic events that underlie 
addictive behaviors take place (Lobo and Nestler, 2011, Luscher and Malenka, 2011, Nestler, 
2013, van Huijstee and Mansvelder, 2014). Among patients with OCD, structural abnormalities 
in cortico-basal ganglia-thalamo-cortical loops have been demonstrated (Rodman et al., 2012, de 
Wit et al., 2014). And one of the current hypotheses for the etiology of OCD is that abnormal 
activity in the orbitofrontal cortex and NA underlie symptoms. This hypothesis is supported by 
findings in rodent models that stimulation of this specific cortico-striatal loop can both produce 
and ameliorate compulsive-like behaviors (Ahmari et al., 2013, Burguiere et al., 2013, Ahmari, 
2015). Among neurodevelopmental disorders, Tourette’s syndrome is characterized by simple 
and complex motor tics, and local pharmacological inactivation of dorsal striatal neurons has 
been able to reproduce some of these repetitive behaviors in primates (Worbe et al., 2009). 
Finally, ADHD is a neurodevelopmental disorder that leads to hyperactivity, impulsiveness, and 
cognitive impairments. Psychostimulants that increase extracellular levels of dopamine are 
paradoxically efficacious in treating this disorder, and the theories that have been proposed to 
explain this phenomenon have posited that patients with ADHD have either abnormal cortico-
basal ganglia-thalamo-cortical activity (Vaidya et al., 1998, Max et al., 2002, Sullivan and Brake, 
2003, Shafritz et al., 2004) or abnormal dopaminergic modulation in the basal ganglia 
(Gainetdinov and Caron, 2001, Heiser et al., 2004, Larisch et al., 2006). 
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Schizophrenia is a highly heterogeneous disorder that is characterized by so-called 
positive, negative and cognitive symptoms. The positive symptoms – also known as psychotic 
symptoms – include hallucinations, delusions and disordered thought processes. However, most 
patients also exhibit impairments in a number of social, emotional and cognitive behaviors. Such 
deficits are categorized as either negative symptoms (e.g. social withdrawal, anhedonia and 
deficits in incentive motivation) or cognitive symptoms (e.g. impairments in working memory, 
behavioral flexibility, verbal memory, reference memory and cognitive processing speed). 
Although negative and cognitive symptoms are not required for diagnosis, they are present in a 
high proportion of patients and can be particularly insidious for patient outcomes (Fenton and 
McGlashan, 1991, Green et al., 2000). At the global functional level, the basal ganglia have been 
implicated in both positive and negative symptoms of schizophrenia. Neuroimaging studies have 
demonstrated abnormal basal ganglia activity while patients engage in tasks of reinforcement 
learning that characterize the negative symptoms (Esslinger et al., 2012, Nielsen et al., 2012). In 
addition, it has been shown that intrinsic activity in the striatum is increased in patients during 
psychosis and correlates with severity of positive symptoms (Ettinger et al., 2013). Therefore, it 
has been proposed that altered basal ganglia function is part of the etiology of the disorder 
(Simpson et al., 2010). 
The dopaminergic system is the neurotransmitter system most robustly implicated in 
schizophrenia pathology, with disruptions in subcortical dopamine systems linked to the positive 
symptoms and disruptions in cortical dopamine transmission linked to cognitive impairment. The 
former idea refers to the long-standing dopamine hypothesis originally formulated by van 
Rossum in the 1960s, which posits that dopamine hyperactivity is central to psychosis in 
schizophrenia (Baumeister and Francis, 2002). In the 1950s, the dopamine 
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antagonist chlorpromazine was accidently discovered as an antipsychotic medication. Later in 
the 1970s Philipp Seeman, Solomon Snyder and colleagues found that the therapeutic dose of 
antipsychotic medication is inversely proportional to their binding affinity for dopamine 
receptors (Creese et al., 1976, Seeman et al., 1976). Despite many efforts by the pharmaceutical 
industry, all antipsychotic medications used to treat patients with schizophrenia still target D2Rs 
– the main site of action of chlorpromazine. 
Using post-mortem analyses, direct evidence for alterations in the dopamine system were 
uncovered in the 1980s. These studies consistently showed increased levels of D2Rs in the brains 
of patients with schizophrenia (Mita et al., 1986, Hess et al., 1987), particularly in the striatum 
(Joyce et al., 1988, Marzella and Copolov, 1997). Numerous imaging studies have also pointed 
to increased density of D2Rs in the striatum of patients with schizophrenia, with Laruelle 
calculating a 12% increase in striatal D2R density in drug-naïve or drug-free patients after 
comparing 13 imaging studies (Laruelle, 1998). However, a more recent meta-analysis suggests 
it is still unclear whether the increase in D2R density is truly present early in the disorder or if it 
is due to subsequent antipsychotic treatment (Howes et al., 2012). Dopamine depletion 
experiments have additionally reported increased basal occupancy of striatal D2Rs in drug-free 
patients that not only correlates with positive symptoms but predicts their response 
to antipsychotics, thus suggesting a tight relationship between D2R hyperfunction in the striatum 
and psychosis (Abi-Dargham et al., 2000). 
Impairments in the striatal dopamine system have also been observed at the presynaptic 
level. Increased striatal uptake of 18F-fluorodopa (or L-β-11C-DOPA) and increased 
amphetamine-induced dopamine release have been repeatedly measured in patients as an 
indication of presynaptic dopamine hyperfunction (Howes et al., 2012). These alterations appear 
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to occur early on in the disease process as they are observed in prodromal subjects that are at 
high risk for conversion to schizophrenia(Howes et al., 2009), and newer imaging tools with 
higher spatial resolution have revealed that the largest effect size of these abnormalities is not in 
the limbic striatum, as has been postulated for many years, but rather in the associative striatum – 
a striatal area that receives dense input from several prefrontal cortical areas, including the 
dorsolateral prefrontal cortex (Kegeles et al., 2010, Howes et al., 2012). 
Based on the above-described observations of increased D2R occupancy and density in 
the striatum of patients, a mouse model that overexpresses D2Rs throughout development 
selectively in the striatum was developed to reproduce this pathophysiological aspect of 
schizophrenia. This approach allows for an assessment of the causal consequences on brain 
function and on behaviors relevant to the cognitive or negative symptoms that are downstream of 
striatal D2R hyperfunction. Specifically, the bi-transgenic tetracycline-sensitive expression 
system was used to selectively overexpress D2Rs in the striatum in a temporally controlled, 
reversible manner to generate the D2R-OEdev mice (Kellendonk et al., 2006). D2R-OEdev mice 
have 15% higher D2R binding capacity than wild-type mice, which is in the range of what has 
been calculated by a meta-analysis of imaging studies in patients with schizophrenia (Kellendonk 
et al., 2006). D2R-OEdev mice display cognitive deficits in working memory, a well-established 
cognitive deficit of the disorder (Bach et al., 2008), as well as deficits in incentive motivation, 
with  rigorous behavioral testing of D2R-OEdev mice revealing that this motivational deficit 
cannot be explained by anhedonia, motor dysfunction or decreased appetite (Drew et al., 2007, 
Ward et al., 2009, Simpson et al., 2011, Simpson et al., 2012). Instead, this deficit is associated 
with an inability to adapt behavior to reward and reflects a deficit in incentive motivation similar 
to what has been observed in patients with schizophrenia (Fervaha et al., 2013, Gold et al., 2013, 
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Wolf et al., 2014). The deficit in motivation observed in D2R-OEdev mice can be rescued when 
the overexpression of D2Rs is reversed to normal levels by switching off transgene expression, 
suggesting that concurrent up-regulation of D2Rs in the striatum is contributing to this deficit 
(Drew et al., 2007). 
In an attempt to more precisely and mechanistically understand how this pathophysiology 
may contribute to the motivational deficit, the Kellendonk laboratory examined how 
upregulation of D2Rs in striatal MSNs affects the physiological function and anatomical 
connectivity of these neurons. Published work from the Kellendonk laboratory showed that D2R-
OEdev mice have increased neuronal excitability and decreased dendritic arborization of MSNs in 
both the direct and indirect pathways that result from decreased function and expression of the 
inward rectifier potassium channel 2 family (Kir2.1/2.3) (Cazorla et al., 2012). These 
physiological and morphological changes are reversed by switching off transgene expression in 
adult animals and restoring D2R expression to normal levels (Cazorla et al., 2012). Moreover, 
evidence from this mouse model suggests that D2R overexpression not only increases MSN 
excitability but also alters the anatomical and functional balance of the dorsal striatal output 
pathways (Cazorla et al., 2014). Axon collaterals of dMSNs that target the GPe have the 
potential to bridge direct and indirect pathways and alter the balance of basal ganglia output; 
therefore, they have been referred to as “bridging collaterals”. Studies in the Kellendonk 
laboratory has shown that the bridging collaterals are extremely plastic in the adult animal and 
their density appears to be regulated by D2R expression (Cazorla et al., 2014). Genetic up-
regulation of striatal D2Rs enhances the density of bridging collaterals, whereas genetic down-
regulation leads to a gene dosage-dependent decrease (Cazorla et al., 2014). Moreover, increased 
bridging collaterals of D2R-OEdev mice can be reversed by reinstating lower excitability by re-
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expressing wild-type Kir2 channels in the striatum (Cazorla et al., 2014). The functional 
importance of these bridging collaterals has been confirmed with in vivo direct pathway 
stimulation during anesthetized recordings of GPe activity and also using in vivo direct pathway 
stimulation in behaving animals. In vivo recordings during direct pathway stimulation in D2R-
OEdev mice revealed enhanced inhibition of GPe activity, and in vivo direct pathway stimulation 
in D2R-OEdev mice impaired the behavioral activation that is normally observed after stimulation 
of the direct pathway (Kravitz et al., 2010, Cazorla et al., 2014). Together, these results strongly 
suggest that the reversible anatomical changes observed in the bridging collaterals of the dorsal 
striatum in D2R-OEdev mice are a consequence of the alteration in neuronal excitability that 
result from decreased Kir2 expression in MSNs. The reversibility of motivational deficits, MSN 
excitability, and bridging collateral density when switching off D2R up-regulation offers an 








In the classical model of basal ganglia circuitry, the direct and indirect pathways arising 
from striatal MSNs are often described as segregated both functionally and anatomically. 
However, a number of studies have challenged this view. Tracing studies in rodents have 
demonstrated that MSNs that project to the GPi and SNr have axon collaterals that target the GPe 
(Kawaguchi et al., 1990, Wu et al., 2000, Fujiyama et al., 2011). Similar findings were also 
confirmed in primates (Levesque and Parent, 2005). In fact, these studies suggest that only a 
small minority of striatal MSNs (3% of all labeled neurons in the rat) project only to the output 
structures of the basal ganglia, while closer to half (60% of all labeled neurons) project to the 
GPi and SNr and possess axon collateral terminal fields in the GPe (Kawaguchi et al., 1990, Wu 
et al., 2000, Fujiyama et al., 2011). Anatomically, these collaterals have the potential to bridge 
the direct and indirect pathways, and they are referred to here as “bridging collaterals”. The 
functional relevance of the bridging collaterals in regulating the output of the basal ganglia and 
behaviors that depend on the balance of direct and indirect pathways is still largely unknown. 
A mouse model of chronic upregulation of D2Rs in the striatum provides some insight on 
the potential regulatory mechanisms and functional relevance of the bridging collaterals. 
Transgenic D2Rs are overexpressed throughout development in striatal MSNs of D2R-OEdev 
mice, and this mouse has been shown to model endophenotypes of schizophrenia (Kellendonk et 
al., 2006, Drew et al., 2007). D2R-OEdev mice display more excitable MSNs, a phenotype that 
can be reversed by turning off transgenic overexpression of D2Rs in adulthood (Cazorla et al., 
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2012) (Figure 3A). Similarly, these animals display increased density of bridging collaterals 
when D2Rs are overexpressed (Figure 3B). In addition, the density of collaterals can be reduced 
to control levels when D2R overexpression is genetically turned off in the adult and reversed 
back to high levels when the striatal D2R transgene is subsequently allowed to be expressed 
(Figure 3C). These findings suggest that bridging collaterals are highly plastic in adult animals. 
The observations that MSN excitability and density of bridging collaterals can be modulated by 
Figure 3: Physiological and anatomical changes can be induced by dopamine D2 receptor (D2R) 
upregulation in the striatum. A. Input-output curves for MSNs recorded from 3-month-old D2R-OEdev 
mice are significantly right-shifted compared to those for MSNs of control mice; this difference is 
reversed when transgenic D2R overexpression is turned off (Cazorla et al., 2012). B. Bridging terminals 
of dMSNs in the GPe are increased in D2R-OEdev mice (Cazorla et al., 2014). C. Kinetics of bridging 
collateral retraction in the GPe of D2R-OEdev mice treated with doxycycline for increasing time periods 
and regrowth after re-expressing the transgene for 60 days (14 on + 60 off) (Cazorla et al., 2014). 
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D2R expression in the striatum raise the question of whether some of the behavioral phenotypes 
of D2R-OEdev mice may be mediated by the bridging collaterals. 
Moreover, direct evidence that terminal fields of dMSN in the GPe form functional 
synapses with pallidal neurons is lacking. In an attempt to address this question, previous work 
in the Kellendonk laboratory used in vivo electrophysiology to show that optogenetic stimulation 
of dMSNs leads to greater inhibition of GPe activity in D2R-OEdev mice compared to control 
littermates, presumably because of increased bridging collaterals (Cazorla et al., 2014) (Figure 
4). Inhibition of the pallidum after activation of the dMSNs was compared to inhibition induced 
by activation of iMSNs, an established monosynaptic pathway. Since the time course of 
inhibition following stimulation of dMSNs or iMSNs were comparable, these electrophysiology 
data are consistent with a functional monosynaptic pathway emerging also from dMSNs via the 
bridging collaterals. To further confirm this interpretation, I attempted to use a different 
Figure 4: Increased bridging collaterals are associated with enhanced GPe inhibition. Optogenetic 
activation of the direct pathway reveals inhibition in the GPe that is enhanced in D2R-OEdev mice. A. 
Graphs of relative firing frequency in GPe neurons for direct comparison of four groups before, during, 
and after 5-s laser illumination. B. Change in firing rate during laser-induced stimulation of direct or 
indirect pathway expressed as a z score of the pre-stimulation firing rate distribution. C. Proportion of 




approach to positively establish that dMSNs form synaptic contacts in the GPe. I selectively 
transfected dMSNs with a virus vector designed to label synaptic sites in order to determine 
whether dMSNs form synapses in the GPe that would correspond to the terminal fields of the 
bridging collaterals. 
In many circuits in the brain, neuronal activity has been shown to regulate axonal 
projections and shape connectivity between brain structures (Catalano and Shatz, 1998, Hua et 
al., 2005, De Marco Garcia et al., 2011). Given that D2R-OEdev mice exhibit more excitable 
striatal MSNs, the Kellendonk laboratory has investigated whether increased activity in these 
neurons can mediate plasticity involving the growth of bridging collaterals. Previous work has 
demonstrated that decreased function of Kir2 channels could account for increased MSN 
excitability in D2R-OEdev mice (Cazorla et al., 2012) (Figure 5A-B). Moreover, rescuing 
excitability of MSNs in D2R-OEdev mice by overexpressing the wild-type Kir2.1 channel in the 
striatum or by treating animals chronically with the D2R antagonist haloperidol was sufficient to 
retract bridging collaterals in the adult animal (Cazorla et al., 2014) (Figures 5C-D). These 
findings led to the question of whether activity-dependent plasticity involving bridging 
collaterals was only relevant in the D2R-OEdev mouse model or whether excitability could also 
be involved in regulating bridging collaterals in developmentally normal animals.  
The endogenous Kir2.1 channel is a tetrameric ion channel that is abundantly expressed in 
striatal MSNs and is responsible for rapid inward rectification of potassium from the 
extracellular space, preventing high extracellular potassium from depolarizing neurons. The 
Kir2.1
AAA gene codes for a mutant monomer – the GYG motif of the pore region is replaced by 
three alanine residues (AAA) – that renders the channel inactive when incorporated into its 
tetrameric structure, resulting in a dominant-negative effect that effectively increases excitability 
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of neurons expressing this transgene (Preisig-Muller et al., 2002, Cazorla et al., 2012). The 
Kellendonk laboratory has expressed Kir2.1
AAA in the striatum to show that increasing MSN 
excitability by decreasing function of this channel in the striatum can induce growth of bridging 
collaterals in wild-type animals (Cazorla et al., 2014) (Figure 5E). Based on these observations, I 
further studied regulation of bridging collaterals by selectively increasing excitability in iMSNs 
and dMSNs to determine whether activity-dependent plasticity mediating growth of the bridging 
Figure 5: D2R overexpression decreases striatal inward rectifying currents through 
downregulation of Kir2 channels. A. Representative inward rectifying currents obtained for negative 
membrane potentials (-60 to -150 mV in 10-mV steps) in control and D2R-OEdev mice (Cazorla et al., 
2012). Kir channel currents (IKir) are isolated by subtracting remaining currents in presence of cesium 
(CsCl) to total currents (ACSF). B. Striatal expression of the dominant-negative Kir2.1 AAA channel is 
sufficient to induce MSN hyperexcitability measured by comparing input-output curves (Cazorla et al., 
2012). C. Increased bridging terminal density is restored in D2R-OEdev mice after striatal transfection 
with AAV-Kir2.1WT-IRES-hrGFP (Cazorla et al., 2014). D. Bridging collaterals show reduced density in 
D2R-OEdev mice and control littermates after treatment with haloperidol for 14 days (Cazorla et al., 
2014). E. Increasing MSN excitability promotes the growth of bridging collaterals terminal fields in the 
GPe of adult mice (Cazorla et al., 2014). 
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collaterals may be specifically controlled by the direct or indirect pathways of the basal ganglia. I 
therefore generated an adeno-associated virus (AAV) to manipulate excitability of specific 
neuronal populations in the striatum via Cre-dependent expression of the trans-dominant 
negative mutant Kir2.1
AAA channel. 
In addition, I also investigated how bridging collaterals may be relevant for behavior. 
Optogenetic stimulation of the direct pathway has been shown to induce increased locomotor 
activity in mice (Kravitz et al., 2010). Using a similar paradigm, the Kellendonk laboratory 
expressed ChR2 in the direct pathway of D2R-OEdev mice and control littermates to test for a 
behavioral phenotype that could be linked to the bridging collaterals. This experiment confirmed 
that stimulation of dMSNs increases locomotion in control mice, while in D2R-OEdev mice, 
stimulation of dMSNs led to a paradoxical decrease in locomotion. In addition, when Kir2.1
AAA 
was expressed in the indirect pathway in the dorsal striatum of developmentally normal animals, 
a manipulation that leads to increased density of bridging collaterals, stimulation of dMSNs also 
led to decreased locomotor activity (Cazorla et al., 2014) (Figure 6). Based on these findings, I 
attempted to further confirm the link between the bridging collaterals and this behavioral 
phenotype by investigating whether treating D2R-OEdev mice chronically with haloperidol, a 
manipulation previously shown to retract bridging collaterals, could rescue the abnormal 
locomotor response to activation of dMSNs in D2R-OEdev mice. 
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Furthermore, evidence that growth and retraction of the bridging collaterals can be 
affected by D2Rs via their effects on neuronal excitability suggested that regulating the density 
of bridging collaterals could be a mechanism by which chronic changes in the dopamine system 
modulate basal ganglia output. Due to the importance of the basal ganglia in motor coordination, 
I tested D2R-OEdev mice in the rotarod test of motor performance and found that D2R-OEdev 
mice show a deficit in motor coordination. However, D2R-OEdev mice improve their 
performance in the rotarod test with ongoing training and, after three weeks, reach the level of 
performance of control littermates. Given the evidence for exercise-dependent functional 
plasticity in cortico-striatal input (Costa et al., 2004), I asked whether retraction of collaterals 
was associated with improved motor performance in D2R-OEdev mice. In addition, I also 
investigated whether rotarod training could reverse the functional imbalance of the direct and 
indirect pathways in D2R-OEdev mice.  
Figure 6: Increased bridging collaterals are associated with disrupted behavioral activation of 
direct pathway. Behavioral activation after direct-pathway stimulation is disrupted in mice expressing 
Kir2.1AAA in the striatum. A. Traces showing mean locomotor activity of mice co-expressing Cre-
dependent ChR2 and non-conditional Kir2.1AAA or a control gene in the striatum during open field 
performance. B. Mean locomotor activity of 5 30-s sessions before laser stimulation (pre), during laser 
stimulation (laser), and after laser stimulation (post) for mice in both groups (Cazorla et al., 2014). 
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 Thus, based on previous work done in the Kellendonk laboratory establishing a link 
between D2R function in the striatum and the bridging collaterals, I conducted a series of 
experiments to expand on these findings. First, I confirm that dMSNs form synaptic contacts in 
the GPe. Second, I provide anatomical and behavioral evidence that further supports a link 
between indirect-pathway function and plasticity involving the bridging collaterals. And finally, 
I describe a novel phenomenon whereby behavioral intervention can modify anatomical 
connectivity in the brain and affect the balance of direct and indirect pathways. 
 
MATERIALS AND METHODS 
Viral construct 
The AAV1/2-Syn-DIO-Synaptophysin-GFP virus was obtained from Dr. Thomas Jessell, 
and the AAV5-EF1α-DIO-ChR2(H134R)-eYFP and AAV2-EF1α-DIO-mCherry viruses were 
purchased from the University of North Carolina Vector Core. The AAV2/1-Syn-DIO-
Kir2.1AAA-IRES-mCherry virus was made from a DNA construct generated by molecular 
cloning. To generate the Syn-DIO-Kir2.1AAA-IRES-mCherry viral construct, the IRES-
mCherry sequence, excised using the restriction enzyme NotI from IRES-mCherry3Myc-
pCAGEN (obtained from Dr. Jonathan Javitch), was ligated into pcDNA3.1-IRKAAA-HA 
(obtained from Dr. Paul Slesinger) immediately following the IRKAAA-HA sequence after 
linearizing the latter plasmid with BamHI. The IRKAAA-HA-IRES-mCherry sequence from the 
resulting plasmid was amplified by PCR with designer primers to introduce NheI and AscI 
restriction sites flanking the amplified sequence. The PCR product was then digested with NheI 
and AscI, and the digested fragment was ligated to the backbone fragment of pAAV-Syn-DIO-
SF-D2RL-Venus (obtained from Dr. Jonathan Javitch), also digested with NheI and AscI. This 
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procedure led to replacement of the SF-D2RL-Venus sequence with the IRKAAA-HA-IRES-
mCherry sequence. The DIO-Kir2.1AAA-IRES-mCherry DNA construct was submitted to 
Vector Biolabs for packaging into AAV2/1. 
Animals 
All animal protocols used in the present study were approved by the Institutional Animal 
Care and Use Committees of Columbia University and New York State Psychiatric Institute. 
Drd1-GFP (X60Gsat/Mmmh), Drd1-Cre (FK150Gsat/Mmcd), and Drd2-Cre (ER44Gsat/Mmcd) 
mice on a C57BL/6J background were purchased from the Mutant Mouse Resource & Research 
Centers (National Institutes of Health). Drd1-GFP mice were crossed to either Drd1-Cre or 
Drd2-Cre mice to obtain Drd1-GFP/Drd1-Cre or Drd1-GFP/Drd2-Cre double transgenic mice, 
respectively. The generation of D2R-OEdev mice has been described previously (Kellendonk et 
al., 2006). TetO-D2R mice have been backcrossed onto the C57BL/6J background and 
CaMKIIα-tTA mice backcrossed onto the 129SveVTac background. To generate D2R-OEdev 
mice, tetO-D2R/C57BL6 mice were crossed with CaMKIIα-tTA/129SveVTac mice. Double 
transgenic mice express the transgenic D2R, and these animals were crossed to Drd1-GFP or 
Drd1-Cre mice to obtain the triple transgenic D2R-OEdev/Drd1-GFP or D2R-OE/Drd1-Cre mice, 
respectively. For all experiments that included D2R-OEdev animals, controls were littermates that 
were positive for the Cre or GFP transgenes but negative for the TetO or tTa transgenes. Both 
male and female adult mice at least 8-weeks old were used in this study. Mice were housed under 
a 12:12-hour light:dark cycle in a temperature-controlled environment, and all behavioral testing 




Construction of fiberoptics 
Fiberoptics implanted into the brain for optical stimulation experiments were constructed 
in house by interfacing a 200-mm, 0.37-numerical-aperture optical fiber (Fiber Instrument Sales) 
with a 1.25-mm stick zirconium ferrule. The fiber extended 4 mm beyond the end of the ferrule. 
Fibers were attached with epoxy resin into the ferrules, and subsequently cut with a diamond pen 
and polished. All fibers were calibrated to have a least 80% efficiency of light transmission. 
Fiberoptic patch cords with a 200-mm core diameter were also constructed in house using an 
FC/PC connectorization kit (Thor Labs). 
Stereotaxic injections and fiberoptic implantations 
For all viral injection surgeries mice were anesthetized with a mixture of ketamine and 
xylazine (100 mg/kg and 10 mg/kg) injected by intraperitoneal injection. Animals were then 
placed in a stereotaxic apparatus and body temperature was maintained at 37 ˚C with a heating 
pad. Small cranial windows (< 0.5 mm) were drilled at the appropriate sites and viruses were 
delivered at an average rate of 100 nL/min using glass pipettes (tip opening 10-15 µm). All 
stereotactic coordinates were measured relative to bregma. A total of 0.4-0.5 µL volume was 
delivered into each site for all injections. The DMS was targeted bilaterally with viral injections 
(anterior-posterior (AP) +1.0 mm, medial-lateral (ML) ±1.8 mm, dorsal-ventral (DV) -3.4 mm). 
For surgeries that also involved fiberoptic implantation, implants were done immediately 
following glass pipette used for viral injection were removed. Fiberoptic implants were placed 
bilaterally into the DMS, above the site targeted with the AAV5-ef1a-DIO-ChR2(H134R)-eYFP 
virus (AP: +1.0 mm, ML: ±1.8 mm, DV: -3.3 mm). The implant was secured to the skull using 
dental cement (Dentsply). All behavioral experiments or histological analysis were done at least 




Chronic treatment with haloperidol (1 mg/kg/day) was performed using osmotic 
minipumps (Alzet) designed to deliver the drug at a steady rate of 0.5 µL/h over 14 days. 
Haloperidol was dissolved in 8.5% lactic acid (6 parts by volume) and neutralized with 1 N 
NaOH (4 parts by volume). Vehicle solution consisted of a mixture of 8.5% lactic acid and 1 N 
NaOH at a 6:4 ratio by volume. Drug and vehicle solutions were prepared on the same day of 
implantation. Minipumps were filled with either drug or vehicle and implanted into mice 
subcutaneously in the interscapular region under isoflurane anesthesia.  
Behavioral assays 
Rotarod training 
A rotarod apparatus (Ugo Basile) was used to measure motor coordination and motor 
learning. On each day of training, each mouse was placed on the rotating rotarod system in three 
individual trials. In each trial mice were allowed to stay on the rotarod for up to 10 min, and the 
latency to fall was recorded if animals fell before the 10 min elapsed. Mice were immediately 
placed back in their homecage after falling from the rotarod or after the 10 min elapsed for each 
trial. The rotarod was set to accelerating mode (0 rpm to full speed in 5 min) on the first three 
days of training, and acceleration was started after mice were placed on the rotarod. On each of 
the first three days, mice were subjected to three identical trials, with acceleration from 0 to 20 
rpm on the first day, 0 to 30 rpm on the second day, and 0 to 40 rpm on the third day. On all 
subsequent days of training mice were subjected to three trials per day with the rotarod set to 
constant mode with different speeds: 20 rpm in the first trial, 30 rpm in the second trial, and 40 
rpm in the third trial on each day of training. In all trials with constant speed, animals were 
individually placed on the rotarod while the rotarod was already rotating at the specified speed. 
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In vivo optical stimulation 
Assessment of locomotor activity with stimulation of dMSNs was done in acrylic activity 
chambers (42 cm long × 42 cm wide × 38 cm high) equipped with infrared photobeams for 
motion detection (Kinder Scientific). Mice with fiberoptic implants were first briefly 
immobilized for attachment of fiberoptic patch cords connected to a laser (473 nM) adjusted to 
give an output of 2 mW light intensity. The laser was controlled by a stimulator through which 
the laser could be manually switched to on and off modes. Turning the laser on led to constant 
light output. Once the patchcords were connected, mice were placed in the activity chamber 
where they were allowed to move freely and habituate for 5 min. After the first 5 min, the laser 
was switched on and off in a series of 5 stimulation trials. Each stimulation trial lasted 90 s; the 
laser was off during the first 30 s, it was then switched on for the duration of the subsequent 30 s, 
and it was finally turned off during the last 30 s. Animals were video recorded during the entire 
session to allow for post-hoc hand scoring of motor activity. 
Histology and immunohistochemistry 
For all histological analysis of brain tissue following behavioral experiments, mice were 
anesthetized with a mixture of ketamine and xylazine (100 mg/kg and 10mg/kg, respectively), 
delivered by intraperitoneal injection, and transcardially perfused, first with phosphate buffered 
saline (PBS) and then with 4% paraformaldehyde. Following perfusion, brains were post-fixed in 
4% paraformaldehyde for 24 hours and then transferred to PBS. Brains were sliced into 50-μm 
sagittal sections using a vibratome and every section was collected. 
For co-localization analysis and confirmation of virally targeted region and fiberoptic 
placement, immunohistochemistry using fluorescence was performed on free-floating sections by 
treating sections first with blocking buffer (0.5% bovine serum albumin, 5% horse serum, 0.2% 
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Triton X-100), followed by the primary rabbit dsRed polyclonal antibody (1:250, Clontech, cat. 
632496) and chicken anti-GFP polyclonal antibody (1:1000, Abcam, cat. ab13970) and the 
appropriate fluorescent-labeled secondary antibodies. Sections were washed with 0.2% Triton X-
100 after incubation with antibodies and with 50 mM Tris-Cl pH 7.4 before mounting. Sections 
were mounted on glass slides and subsequently coverslipped for imaging with VectaShield 
containing DAPI (Vector Labs). For confirmation of spread of viral infection in targeted 
structures, images were acquired at 2.5x magnification using a Hamamatsu camera attached to a 
Carl Zeiss epifluorescence microscope. For analysis of co-expression of immune-labelled 
proteins, images were acquired at 40x using a Nikon Ti Eclipse inverted microscope for scanning 
confocal microscopy. Micrographs were processed using ImageJ software (National Institutes of 
Health). 
For quantification of bridging collaterals, immunohistochemistry using 3,3′-
diaminobenzidine (DAB) was performed on free-floating sections by treating sections first with 
blocking buffer (0.5% bovine serum albumin, 5% horse serum, 0.2% Triton X-100). Every 
fourth section covering the GPe and SNr from one hemisphere in their entirety (6 sections per 
mouse) was stained using a rabbit polyclonal antibody against aequorea GFP (1:2000; Molecular 
Probes). The signal was revealed using a biotinylated anti-rabbit antibody (1:1000; Jackson 
ImmunoResearch), together with the Vectastain ABC and DAB peroxidase substrate kits (Vector 
Labs, cat. PK-4000 and SK-4100, respectively). Contrast was intensified using 0.025% nickel 
cobalt and 0.02% nickel ammonium sulfate. Sections were dehydrated, cleared, and mounted on 
slides with Permount (Fisher Scientific). Brightfield and darkfield photomicrographs were taken 
using an AxioImager 2 microscope (Zeiss) connected to an AxioCam video camera. Terminal 
density was evaluated using GFP staining. Quantification was performed using ImageJ using two 
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random counting frames per structure and per slice with background subtraction. Optical density 
was measured for striatum, GPe, and SNr, and all values reported are in percentage of striatal 
optical density.  
Data analysis and statistics 
All data collected in the current study were processed with Excel (Microsoft). Statistical 
analyses were done with either Excel or Prism 5 (GraphPad). For normally-distributed data sets, 
including optical density of terminal fields, locomotor activity, and ambulatory distance, two-
way analyses of variance (ANOVAs) were conducted. Bonferroni post hoc tests were conducted 
when appropriate. Because of the nature of the rotarod task, data was not normally distributed 





To confirm that the bridging collaterals form 
synaptic contacts in the GPe, I obtained a virus 
vector that allowed Cre-dependent selective 
labeling of synaptic vesicles. This virus vector 
(AAV1/2-Syn-DIO-Synaptophysin-GFP) was 
designed to express the synaptic vesicle protein 
synaptophysin fused to GFP in transfected 
cells, thereby labeling all synaptic contacts of 
transfected neurons. I injected this virus into the 
Figure 7: dMSNs form synaptic contacts in the 
GPe. A Cre-dependent virus for expression of 
synaptophysin fused to GFP was injected into the 
DMS of Drd1-Cre mice (tract marks of injection 
pipette highlighted in yellow) for restricted 
expression in dMSNs. GFP signal, indicating 
regions where dMSNs form synaptic contacts was 
observed in the striatum around the injection site, 
in the output nuclei of the basal ganglia (GPi and 
SNr), as well as in the GPe. 
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DMS of Drd1-Cre mice and subsequently located regions in the basal ganglia that showed GFP 
fluorescence. As showed in Figure 7, transfection of striatal dMSNs with this virus led to 
labeling of both GPi and SNr, the output nuclei of the basal ganglia. In addition, labeling was 
also observed within the striatum itself around the injected site, confirming that MSNs form local 
synaptic contacts, presumably with neighboring MSNs. Most importantly, however, robust 
labeling was observed in the GPe, confirming that dMSNs projecting from the DMS form 
synaptic contacts with cells in the GPe. These synaptic contacts likely correspond to axon 
terminal fields of the bridging collaterals. 
 
REGULATION BY INDIRECT PATHWAY 
In order to study how the bridging collaterals may be selectively regulated by activity of 
the direct or indirect pathways, I constructed a Cre-dependent viral vector to restrict expression 
of the trans-dominant negative Kir2.1
AAA channel to either the direct or indirect pathway to 
determine which population of MSNs mediates the growth of collaterals. The DNA construct for 
the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry was generated by sub-cloning the sequences 
for Kir2.1
AAA and IRES-mCherry from pcDNA3.1-IRKAAA-HA and IRES-mCherry3Myc-
pCAGEN, respectively, into the backbone of pAAV-SyI-DIO-SF-D2RL-Venus. Figure 4 shows 
scheme of the viral vector construct as well as micrographs from sections immune-stained for 
mCherry, confirming expression restricted to dMSNs or iMSNs. To confirm specificity, the virus 
was injected into the DMS of Drd1-GFP+ mice that were also Drd1-Cre+, Drd1-Cre-, Drd2-Cre+, 
or Drd2-Cre+. Since GFP is expressed in dMSNs in Drd1-GFP+ mice (Figure 8B), injection of 
AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry into Drd1-GFP+/Drd1-Cre+ led to co-expression 
of GFP and mCherry in dMSNs in the striatum (Figure 8C), and no mCherry expression was 
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detected when the virus was injected into Drd1-GFP+/Drd1-Cre- animals (Figure 8D). In 
contrast, when Drd1-GFP+/Drd2-Cre+ animals were injected with the viral vector, expression of 
both GFP and mCherry were detected in the striatum, but no cells co-expressed both fluorescent 
markers (Figure 8E). The specificity of viral expression to Cre-positive cells was further 
confirmed by the lack of mCherry expression in the striatum of Drd1-GFP+/Drd2-Cre- mice also 
injected with the virus (Figure 8F).  
Figure 8: Kir2.1AAA can be expressed selectively in dMSNs or iMSNs. A. Schematic of viral DNA 
construct used to generate the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry virus that was used to 
selectively express Kir2.1AAA in Cre-positive neurons. B. GFP signal in sagittal section of Drd1-GFP 
BAC transgenic mouse used in C-F. Striatal expression of Kir2.1AAA/mCherry (red) and GFP (green) in 
Drd1-GFP+/Drd1-Cre+ (C), Drd1-GFP+/Drd1-Cre- (D), Drd1-GFP+/Drd2-Cre+ (E), Drd1-GFP+/Drd2-
Cre- (F) Scale bar, 1 mm.  
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Previous work from the Kellendonk laboratory has demonstrated that nonselective 
expression of Kir2.1
AAA in the dorsomedial striatum leads to increased neuronal excitability and 
can induce growth of bridging collaterals in mice (Cazorla et al., 2012, Cazorla et al., 2014). 
Having confirmed the generation of a new virus to selectively express Kir2.1
AAA in Cre-positive 
cells, the virus was injected into the DMS of Drd1-GFP+/Drd1-Cre+ and Drd1-GFP+/Drd2-Cre+ 
adult mice to determine how increased excitability in specific populations of striatal MSNs, 
dMSNs or iMSNs, contributes to the growth of bridging collaterals. As a control, the AAV2-
EF1α-DIO-mCherry virus was also injected in littermates of the same genotype. After waiting 
four weeks following viral injection to allow stable expression of transfected Kir2.1
AAA in 
dMSNs or iMSNs, mice were sacrificed and the density of GFP-positive terminal fields in the 
GPe, representing bridging collaterals from striatal dMSNs, were quantified. Compared to 
Figure 9: Bridging collaterals are regulated by excitability of the indirect pathway. A. 
Expression of Kir2.1
AAA in dMSNs did not significantly change the density of dMSN terminal 
fields in the GPe but led to a significant increase in the density of terminal fields in the SNr (p = 
0.0012; Bonferroni post hoc test: GPe: p > 0.05; SNr: p < 0.001). B. Expression of Kir2.1
AAA in 
iMSNs significantly increased the density of GFP-positive terminal fields of dMSNs in the GPe, 
but did not significantly change the density of terminal fields in the SNr (p = 0.0049; Bonferroni 
post hoc test: GPe: p < 0.01; SNr: p > 0.05). A total of 4 Drd2-Cre and 3 Drd2-Cre mice injected 
with each virus were used for this analysis.  
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expression of a control gene, expression of Kir2.1
AAA in dMSNs did not lead to a significant 
change in the density of bridging collaterals, while a significant increase in the density of 
terminal fields in the SNr, the main projection target of dMSNs, was observed (F(1,12) = 17.76; p 
= 0.0012 Bonferroni post hoc test: GPe: p > 0.05; SNr: p < 0.001; n = 4 mice per group) (Figure 
9A). In contrast, expression of Kir2.1
AAA in the indirect pathway led to a significant increase in 
the density of bridging collaterals, and no change was observed in the density of terminal fields 
in the SNr (F(1,12) = 14.81; p = 0.0049 Bonferroni post hoc test: GPe: p < 0.01; SNr: p > 0.05; n = 
3 mice per group) (Figure 9B). These findings show that chronically increasing excitability of 
iMSNs in adult mice is sufficient to promote the growth of bridging collaterals (axon collaterals 
originating from striatal dMSNs), whereas chronically increasing excitability of dMSNs did not 
promote the growth of these collaterals. Chronically increasing excitability of dMSNs, however, 
was sufficient to increase the density of terminal fields to the SNr, one of the main target nuclei 
of the direct pathway.  
 
ASSOCIATION WITH BEHAVIORAL ACTIVATION OF DIRECT PATHWAY 
Having shown that activity in the indirect pathway can induce a circuit-level connectivity 
change in the basal ganglia, I proceeded to investigate whether this change in connectivity could 
be relevant for behavior. Two previous findings from the Kellendonk laboratory led to the 
question of whether the D2R antagonist haloperidol could affect basal ganglia output at the 
behavioral level by changing the density of bridging collaterals. First, it was previously shown 
that increased bridging collateral density in D2R-OEdev mice, induced by D2R upregulation, 
could be reversed in adult animals by chronic treatment with the D2R antagonist haloperidol 
(Cazorla et al., 2014). And second, increased density of bridging collaterals was shown to be 
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associated with abnormal locomotor activation upon optogenetic stimulation of the direct 
pathway (Cazorla et al., 2014). Thus, to further investigate whether pharmacologically targeting 
the indirect pathway could have behavioral effects associated with the bridging collaterals, Cre-
dependent ChR2 was expressed in dMSNs in the DMS of D2R-OEdev/Drd1-Cre mice and control 
Drd1-Cre littermates. Fiberoptic implants were also placed in the DMS of these mice to allow for 
temporally-controlled light-stimulation of dMSNs while animals were allowed to move freely. 
Before behavioral testing, animals were treated for 14 days with the D2R antagonist haloperidol 
or vehicle.  
Figure 10 shows how stimulation of dMSNs affected movement initiation in D2R-OEdev 
and control littermates after chronic treatment with haloperidol or vehicle. As previously 
reported (Kravitz et al., 2010), control animals treated with vehicle moved more when the laser 
was turned on compared to when the laser was turned off (F(2,14) = 21.11, p = 0.0006; 
Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.001; LASER vs. POST: p < 0.01, 
PRE vs. POST:  p > 0.05; n = 5 mice) (Figure 10). Moreover, as had been previously 
demonstrated in the Kellendonk laboratory, D2R-OEdev mice paradoxically moved less when the 
laser was turned on compared to when the laser was turned off (F(2,14) = 58.71, p < 0.0001; 
Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.001; LASER vs. POST: p < 0.001, 
PRE vs. POST: p > 0.05; n = 5 mice) (Figure 10). Compared to animals treated with vehicle, 
animals treated with haloperidol, including both D2R-OEdev mice and control littermates, showed 
decreased movements at baseline when the laser was turned off (F(1,20) = 31.40, p < 0.0001; 
Bonferroni post hoc tests, D2R-OEdev: p < 0.001, 5-6 mice per treatment, Control: p < 0.05, n = 
5-8 mice per treatment) (Figure 10). Nevertheless, after chronic treatment with haloperidol, 
control mice still responded with increased locomotion to laser stimulation (F(2,17) = 39.44, p < 
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0.0001; Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.001; LASER vs. POST: p < 
0.001, PRE vs. POST: p > 0.05; n = 8 mice) (Figure 10). Most remarkably, however, after 
chronic treatment with haloperidol, D2R-OEdev mice no longer exhibited decreased movements 
Figure 10: Retraction of bridging collaterals can rescue behavioral activation of direct pathway. 
Mean locomotor activity of 5 30-s sessions before laser stimulation (PRE), during laser stimulation 
(LASER), and after laser stimulation (POST) for D2R-OEdev mice and control littermates treated with 
haloperidol or vehicle for 14 days. Control animals treated with vehicle moved more when the laser was 
turned on compared to when the laser was turned off (p = 0.0006; Bonferroni’s multiple comparisons: 
PRE vs. LASER: p < 0.001; LASER vs. POST: p < 0.01, PRE vs. POST:  p > 0.05). D2R-OEdev mice 
moved less when the laser was turned on compared to when the laser was turned off (p < 0.0001; 
Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.001; LASER vs. POST: p < 0.001, PRE vs. 
POST: p > 0.05). Control mice still responded with increased locomotion to laser stimulation after 
treatment with haloperidol (p < 0.0001; Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.001; 
LASER vs. POST: p < 0.001, PRE vs. POST: p > 0.05). After chronic treatment with haloperidol, D2R-
OEdev mice responded to laser stimulation of dMSNs with increased movement (p < 0.0001; Bonferroni’s 
multiple comparisons: PRE vs. LASER: p < 0.001; LASER vs. POST: p < 0.001, PRE vs. POST: p > 
0.05). A total of 5 control mice treated with vehicle, 5 D2R-OEdev mice animals treated with haloperidol, 




when the laser was turned on but instead responded to laser stimulation of dMSNs with 
increased movement similarly to control animals (F(2,17) = 114.3, p < 0.0001; Bonferroni’s 
multiple comparisons: PRE vs. LASER: p < 0.001; LASER vs. POST: p < 0.001, PRE vs. POST: 
p > 0.05; n = 6) (Figure 10). Therefore, chronic haloperidol treatment was sufficient to fully 
rescue a behavioral phenotype associated with increased bridging collaterals. 
 
REGULATION BY MOTOR TRAINING 
Thus far, I have provided evidence demonstrating that the bridging collaterals (axon 
collaterals of dMSNs that target the GPe) can increase in density when chronic excitability of 
iMSNs is increased and are associated with disrupted behavioral activation upon stimulation of 
dMSNs. Since D2R-OEdev mice show increased density of bridging collaterals and their growth 
and retraction are plastic even in the adult animal, I hypothesized that other behavioral 
phenotypes of D2R-OEdev mice may also be associated with these collaterals. In addition to the 
anatomical and physiological phenotypes of D2R-OEdev described so far, these animals also 
display a deficit in motor coordination compared to control littermates, as measured by impaired 
performance on the rotarod task. As shown in Figure 11, while control mice are able to remain 
on a horizontal rod rotating at constant 20 rpm or 30 rpm speeds for 10 min without extensive 
training, D2R-OEdev mice exhibit impaired performance in comparison during the first week of 
training (Log-rank tests: 20 rpm: χ² = 7.429, p = 0.0064; 30 rpm: χ² = 4.531, p = 0.0333; n = 5 
mice per genotype). However, while this impairment is most pronounced in the first week, the 
difference decreased with ongoing motor training, and at the end of three weeks, D2R-OEdev 
mice can perform at a similar level to their control littermates (Log-rank tests: 20 rpm: χ² = 
1.000, p = 0.3173; 30 rpm: χ² = 2.242, p = 0.1343; n = 5 mice per genotype) (Figure 11). 
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Given that the time course of this effect was comparable to the time course of growth and 
retraction of bridging collaterals, together with evidence for exercise-dependent functional 
plasticity in cortico-striatal input (Costa et al., 2004), I questioned whether plasticity involving 
the bridging collaterals could be associated with improved performance of D2R-OEdev in the 
rotarod task after repeated motor training. To this end, I trained D2R-OEdev/Drd1-GFP and 
Drd1-GFP control mice daily on the rotarod task for three weeks and measured density of 
bridging collaterals after training. Statistical analysis revealed a significant effect of rotarod 
training (F(1,15) = 13.96, p = 0.0467, n = 3-6 mice per group) (Figure 12) Specifically, after daily 
motor training in the rotarod task, D2R-OEdev mice had decreased density of bridging collaterals 
compared to D2R-OEdev mice that were never trained in this motor task (Bonferroni post hoc 
test: p < 0.01, n = 3-6 mice per training condition) (Figure 12). Among control littermates not 
expressing the D2R transgene, rotarod training did not appear to affect the density of bridging 
collaterals (Bonferroni post hoc test: p > 0.05, n = 4-6 mice per training condition) (Figure 12).  
Figure 11: D2R-OEdev mice have a motor impairment that improves with training. Performance in 
the rotarod, measured as latency to fall from a rod rotating at (A) 20 rpm and (B) 30 rpm is shown for 
D2R-OEdev mice and control littermates. During the first week of training in the rotarod task, D2R-OEdev 
mice exhibit impaired performance in comparison to control littermates (20 rpm: p = 0.0064, 30 rpm: p = 
0.0333). At the end of three weeks of training, D2R-OEdev mice can perform at a similar level to their 




Given the potential implications of this experience-induced plasticity for disease-
modifying therapies in schizophrenia, I decided to further explore this phenomenon. I 
hypothesized that rotarod training might be sufficient to reverse the functional imbalance of the 
direct and indirect pathways in D2R-OEdev mice, as measured by motor output following 
stimulation of dMSNs. Therefore, I expressed ChR2 selectively in dMSNs in the DMS of D2R-
OEdev/Drd1-Cre mice and control Drd1-Cre littermates. Fiberoptic implants were also placed 
into the DMS of these mice to allow for temporally-controlled light-stimulation of dMSNs while 
animals moved freely. After undergoing surgery, D2R-OEdev mice and control littermates were 
divided into subgroups; a subset of animals of each genotype underwent daily rotarod training 
for at least three weeks while the other half remained rotarod-naïve. Following training, I used 
the same behavioral paradigm used to demonstrate the behavioral effect of chronic haloperidol in 
D2R-OEdev mice to measure motor activity induced by light-stimulation of dMSNs in D2R-OEdev 
Figure 12: Rotarod training induces retraction of bridging collaterals in D2R-OEdev mice. Quantification of 
bridging collaterals in D2R-OEdev and control littermates that were rotarod-naïve or trained in the rotarod for three 
weeks showed a significant effect of rotarod training (p = 0.0467). Among control mice, rotarod training did not 
affect density of bridging collaterals (Bonferroni post hoc test: p > 0.05). Rotarod-trained D2R-OEdev mice had 
decreased density of bridging collaterals compared to rotarod-naïve D2R-OEdev (Bonferroni post hoc test: p < 0.01). 
A total of 3 rotarod-naïve control mice, 6 rotarod-trained control mice, 4 rotarod-naïve D2R-OEdev mice, and 6 
rotarod-trained D2R-OEdev mice were used for this analysis. 
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and control mice that were rotarod-trained or rotarod-naive. Figure 13 shows motor performance 
for animals trained in the rotarod, as well as measures of locomotor response to stimulation of 
the direct pathway after rotarod training. Similar to performance of the previous cohort (see 
Figure 13), among animals that received rotarod training, D2R-OEdev showed an initial 
impairment in motor performance compared to control mice (Log-rank tests: 20 rpm: χ² = 4.521, 
p = 0.0335; 30 rpm: χ² = 10.43, p = 0.0012) that was no longer present after three weeks of 
rotarod training (Log-rank tests: 20 rpm: χ² = 2.560, p = 0.1096; 30 rpm: χ² = 1.421, p = 0.2333) 
(Figure 13A-B). Since I have previously demonstrated that three weeks of rotarod training is 
sufficient to induce retraction of bridging collaterals in D2R-OEdev mice, I tested whether motor 
training could also rescue the disrupted behavioral phenotype of D2R-OEdev upon optogenetic 
stimulation of dMSNs. Figure 13C shows measures of locomotor activity when rotarod-trained 
and rotarod-naïve D2R-OEdev and control mice were tested in the optogenetic open field 
paradigm. I was able to reproduce the impaired behavioral activation of D2R-OEdev mice with 
stimulation of striatal dMSNs, as rotarod-naïve D2R-OEdev mice showed reduced locomotor 
activity when the laser was turned on compared to when the laser was turned off (F(2,11) = 8.721, 
p = 0.0168; Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.05; LASER vs. POST: p 
< 0.05, PRE vs. POST:  p > 0.05; n = 4) (Figure 13C). Among control animals, rotarod training 
did not affect increased locomotion induced by stimulation of dMSNs, and both rotarod-naïve 
(F(2,20) = 6.607, p = 0.0116; Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.05; 
LASER vs. POST: p < 0.05, PRE vs. POST:  p > 0.05; n = 7) and rotarod-trained (F(2,32) = 6.986, 
p = 0.0050; Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.001; LASER vs. POST: 
p < 0.05, PRE vs. POST:  p > 0.05; n = 11) mice responded to laser stimulation with increased 




Figure 13: Rotarod training partially rescues abnormal behavioral activation of direct pathway. A-B. 
Performance in the rotarod, measured as latency to fall from a rod rotating at (A) 20 rpm and (B) 30 rpm 
is shown for D2R-OEdev mice and control littermates that underwent rotarod training. During the first week 
of training, D2R-OEdev mice exhibited impaired performance in comparison to control littermates (20 rpm: p = 
0.0064; 30 rpm: p = 0.0333). At the end of three weeks of training, D2R-OEdev mice performed at a similar level to 
their control littermates (20 rpm: p = 0.1096; 30 rpm: p = 0.2333). C. Mean locomotor activity of 5 30-s sessions 
before laser stimulation (PRE), during laser stimulation (LASER), and after laser stimulation (POST) for D2R-OEdev 
mice and control littermates that were either rotarod-naïve or trained in the rotarod for at least three weeks. Rotarod-
naïve control animals moved more when the laser was turned on compared to when the laser was turned off (p = 
0.0116; Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.05; LASER vs. POST: p < 0.05, PRE vs. POST:  
p > 0.05); rotarod-naïve D2R-OEdev mice moved less when the laser was turned on compared to when the laser was 
turned off (p = 0.0168; Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.05; LASER vs. POST: p < 0.05, 
PRE vs. POST:  p > 0.05). Control mice still responded with increased locomotion to laser stimulation after rotarod 
training (p = 0.0050; Bonferroni’s multiple comparisons: PRE vs. LASER: p < 0.001; LASER vs. POST: p < 0.05, 
PRE vs. POST:  p > 0.05). But rotarod-trained D2R-OEdev mice no longer responded to laser stimulation of dMSNs 
with decreased movement (F(2,38) = 0.4662, p = 0.6335). A total of 7 rotarod-naïve control mice, 4 rotarod-trained 
control mice, 11 rotarod-naïve D2R-OEdev mice, and 12 rotarod-trained D2R-OEdev mice were used for this analysis. 
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no longer responded to stimulation of dMSNs with decreased locomotion during laser 
stimulation (F(2,38) = 0.4662, p = 0.6335; n = 12) (Figure 13C). Therefore, behavioral intervention 
through motor training was sufficient to partially rescue an abnormal behavioral phenotype of 
D2R-OEdev associated with the balance of direct and indirect pathways. 
 
DISCUSSION 
In summary, in the current study I provide mechanistic insight on plasticity involving the 
bridging collaterals, as well as evidence related to how the bridging collaterals may regulate 
behavior and how behavior may regulate the bridging collaterals. First, I demonstrated that 
bridging collaterals form synaptic contacts with GPe cells. I was also able to generate a viral 
vector to selectively increase excitability in specific populations of MSNs. I used this virus to 
demonstrate that chronically increasing excitability of the indirect pathway, but not the direct 
pathway, leads to a circuit-level change in connectivity by inducing the growth of bridging 
collaterals from dMSNs in the GPe. I also confirmed that increased density of bridging 
collaterals are associated with an abnormal locomotor response to stimulation of striatal dMSNs 
and demonstrated that chronic pharmacologic blockade of D2Rs can rescue this abnormal 
locomotor phenotype. Furthermore, I demonstrated that motor training can lead to changes in the 
density of bridging collaterals and partially rescue the abnormal locomotor phenotype associated 
with increased collaterals, thereby establishing a new link between connectivity in the basal 
ganglia and motor learning. 
Many studies have established a role for neuronal activity in the regulation of axonal 
growth and in shaping proper connectivity within neural circuits (Catalano and Shatz, 1998, Hua 
et al., 2005, De Marco Garcia et al., 2011). Neuronal excitability via changes in the function of 
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Kir channels have been shown to regulate plasticity in a variety of neurons and brain circuits 
(Burrone et al., 2002, Hartman et al., 2006). In the current study, I contributed to the 
characterization of a new form of plasticity in the basal ganglia using a genetic tool that knocks 
down Kir2 channel function. By generating and characterizing the AAV2/1-Syn-DIO-
Kir2.1AAAIRES-mCherry virus, I provide a useful tool for research on the effects of neuronal 
excitability on brain circuit plasticity and behavior. Numerous mouse lines are available in which 
Cre recombinase is expressed in selective neuronal populations. I expect, therefore, that this viral 
construct will be used to study how chronically increasing excitability in restricted neuronal 
populations can affect neuronal circuits and behavior in a variety of brain regions and animal 
models. 
However, one limitation to the use of the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry 
virus is that I did not perform an extensive characterization of how transfecting Kir2.1
AAA into 
MSNs affects neuronal excitability. The original experiments done in the Kellendonk laboratory 
that showed that non-conditional expression of Kir2.1
AAA in the DMS leads to increased MSN 
excitability were done using a virus (AAV2-CMV-Kir2.1AAA-IRES-hrGFP) that had the 
cytomegalovirus (CMV) promoter instead of the synapsin (Syn) promoter to drive Kir2.1
AAA 
expression. The CMV promoter is known to lead to higher but more transient expression of 
virally-transfected genes in neurons compared to the Syn promoter using AAV vectors in rodents 
(McCown et al., 1996, Paterna et al., 2000, Kugler et al., 2003). In addition, these two promoters 
have been shown to preferentially drive transgene expression in different cells types (Gholizadeh 
et al., 2013). Thus, although robust viral transfection was observed for both viruses, as measured 
by fluorophore signal in striatal MSNs, it cannot be immediately assumed that transfection with 
both viruses resulted in equal expression of Kir2.1
AAA in MSNs. The internal ribosomal entry site 
66 
 
(IRES) in both constructs allowed expression of fluorophores (hrGFP or mCherry) as separate 
proteins, and their pattern of expression do not represent the pattern of expression of Kir2.1
AAA in 
the cell. Since an HA tag is included in the Kir2.1
AAA sequence in both constructs, 
immunohistochemically probing for the HA tag would be a reasonable strategy to directly 
compared Kir2.1
AAA expression using each virus. Or, alternatively, slice physiology 
characterization of intrinsic excitability in genetically-identified dMSNs and iMSNs after 
transfection with the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry construct could be directly 
compared to previously collected slice physiology data using the AAV2-CMV-Kir2.1AAA-
IRES-hrGFP construct (Cazorla et al., 2012). 
Another limitation of the study is the fact that all manipulations of excitability targeted 
the DMS even though increased excitability in MSNs throughout the striatum has been measured 
in D2R-OEdev mice (Cazorla et al., 2012). It would be informative, for example, to characterize 
how increasing excitability of MSNs in the DLS may affect density of bridging collaterals. 
Given that the DLS is known to be part of the motor cortico-basal ganglia-thalamic loop and in 
this study I also implicate the bridging collaterals in motor learning, it is plausible the collaterals 
are regulated by MSN excitability in this striatal sub-region. Moreover, it is not known if 
structures analogous to the bridging collaterals are also formed by dMSNs in the NA projecting 
to the VP. The tools used in this study to measure density of collaterals in Drd1-GFP mice could 
also be employed to measure terminal field density in the VP. Given recent evidence that as 
much as 50% of GPe neurons receive inputs from dMSNs (Kupchik et al., 2015), it is plausible 




The fact that the D2R-OEdev mouse recapitulates increased striatal D2R function, as seen 
in patients with schizophrenia, and also exhibits phenotypes reminiscent of this disease 
(Kellendonk et al., 2006, Drew et al., 2007) raises the question of whether density and function 
of bridging collaterals may also be increased in schizophrenia. Furthermore, the robust effect of 
the D2R antagonist and antipsychotic haloperidol on retracting the bridging collaterals and 
rescuing an abnormal behavioral phenotype of D2R-OEdev mice suggests that a similar 
phenomenon may underlie the mechanism via which haloperidol alleviates symptoms in patients. 
In fact, all antipsychotics currently used to treat schizophrenia are either antagonists or weak 
partial agonists for D2Rs. These medications take weeks to reach their full efficacy in patients, 
suggesting that neural plasticity results from chronic downregulation of D2R function. This 
evidence supports a possible link between the collaterals and schizophrenia. Testing these 
hypotheses in patients could lead to important insight on the pathophysiology of schizophrenia 
and potentially new tools for therapies that target specific circuit elements in the basal ganglia. 
One first step to determine the strength of the association between the bridging collaterals and 
pharmacological treatment would be to test whether other antipsychotic medications, including 
atypical antipsychotics that also antagonize D2Rs, can retract bridging collaterals in D2R-OEdev 
mice. 
Furthermore, the findings presented here demonstrating that bridging collaterals are also 
associated with motor learning may have implications for schizophrenia beyond motor control. 
Patients with schizophrenia have increased striatal D2R availability, which predicts treatment 
response to antipsychotic medication (Abi-Dargham et al., 2000). I propose that not only 
antipsychotics but also behavioral intervention may be efficacious in patients by retracting 
bridging collaterals, possibly correcting an anatomical imbalance in the cortico-basal ganglia-
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thalamo-cortical loops involved in psychosis. In line with this idea, a recent study has 
demonstrated that behavioral therapy can be effective in treating psychosis (Leff et al., 2013). 
Since bridging collaterals are regulated by neuronal activity and given previous evidence for 
behavioral-induced functional plasticity in cortico-striatal inputs (Costa et al., 2004), my 
demonstration that behavioral training can lead to changes in connectivity in the basal ganglia is 
consistent with the idea that, by engaging activity in cortico-striatal circuits, behavioral 
intervention may alter the anatomy of the same striatal output pathways that are sensitive to 
antipsychotic medication. This idea is attractive, as cognitive behavioral therapy is widely 
discussed as adjunct therapy for schizophrenia. Elucidating the circuits and mechanisms by 
which these therapies exert their effects may be important for developing safer, effective 
therapies for patients with schizophrenia. 
One way to strengthen the link between behavioral intervention through motor training 
and retraction of bridging collaterals would be to obtain parallel measures of collateral density, 
rotarod performance, and locomotor response to stimulation of the direct pathway. In order to 
obtain such data set, mice expressing four different transgenes would be required, D2R-OEdev 
mice (CaMKIIa-tTa+/TetO-D2R+) that are also positive for Drd1-GFP, and Drd1-Cre. Thus, a 
large breeding colony would be necessary, and the data collected would be merely correlational. 
In addition, large cohorts may be necessary to establish strong associations between behavioral 
measures and density of bridging collaterals. In the current study, regression analyses were 
underpowered for establishing correlations between measures of rotarod performance and 
density of collaterals, or measures of behavioral response to direct-pathway stimulation and 
density of collaterals. 
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 Given the well-accepted theory that the basal ganglia are integrated with the thalamus 
and cortex in parallel loops that regulate different types of behaviors, it may be possible that 
plasticity involving the bridging collaterals is topographically-specified by the loops that are 
preferentially activated. The finding from the Kellendonk laboratory that D2R-OEdev mice have a 
larger increase in the density of bridging collaterals in the more medial aspect of the GPe 
compared to controls supports this hypothesis (Cazorla et al., 2014). It is plausible that motor 
training in the rotarod task leads to selective retraction of collaterals in specific medial-lateral or 
dorsal-ventral aspects of the GPe. If such selective retraction occurs, it is also possible that 
expression of ChR2 in the DMS may not have been optimal to activate basal ganglia loops that 
undergo bridging collateral plasticity with rotarod training. In fact, the DLS, rather than the 
DMS, is a striatal sub-region that has been more strongly established as be part of sensorimotor 
cortico-basal ganglia-thalamo-cortical loop (Pan et al., 2010). Thus, it may be possible that the 
rescue of locomotor response to stimulation of the direct pathway after rotarod training would 
have been more robust if ChR2 was expressed in the DLS. 
Finally, in order to move from correlational analyses and establish a causal link between 
behavioral intervention and altered connectivity in the basal ganglia, it would be necessary to 
directly and specifically target the bridging collaterals. Optogenetics would be one strategy to 
establish causality, as ChR2 or the inhibitory opsin Archaerhodposin-3 (Arch3.0) could be Cre-
dependently expressed in dMSNs and the bridging collaterals selectively targeted with 
fiberoptics placed in the GPe. This approach would answer whether stimulating or inhibiting the 
bridging collaterals during motor learning tasks can affect performance, causally linking the 
collaterals to behavior. However, opsins such as ChR2 and Arch3.0 are expressed throughout 
axonal projections, and laser illumination of the GPe would also stimulate dMSN projections to 
70 
 
the SNr and GPi, potentially confounding the results. Therefore, some technical limitations still 







EXCITABILITY OF STRIATAL PATHWAYS AND MOTIVATION 
 
INTRODUCTION 
By studying the phenotypes induced by altered MSN excitability and connectivity in 
D2R-OEdev mice, I showed in Chapter 2 how the balance of the direct and indirect pathways can 
be important for regulating behaviors mediated by the basal ganglia. Using optogenetics, I 
contributed to establishing that increased bridging collaterals are associated with enhanced 
pallidal inhibition and disrupted locomotor response to stimulation of the direct pathway. 
Moreover, the D2R antagonist and antipsychotic haloperidol reverses both the morphological 
changes and the disruption in locomotor activation of D2R-OEdev mice. These findings suggest 
that an increase in bridging collaterals, as observed in D2R-OEdev mice, may also be involved in 
the generation of symptoms of schizophrenia. Positive symptoms, such as hallucinations and 
delusions, cannot currently be modeled in the mouse. As a model of schizophrenia 
endophenotypes, D2R-OEdev mice exhibit phenotypes that resemble both the cognitive deficits 
and the impaired motivation seen in patients with this disorder (Kellendonk et al., 2006, Drew et 
al., 2007). Similar to what is observed in patients with schizophrenia, the motivational deficit of 
D2R-OEdev mice is consistent with an impairment in assessing effort in anticipation of a reward 
as these mice will expend less effort to obtain a reward despite having intact hedonic reactivity to 
rewards (Drew et al., 2007, Gard et al., 2009). However, while the deficits in working memory 
observed in D2R-OEdev mice appear to result from developmental processes and are not reversed 
when D2R overexpression is turned off in adulthood, the motivational deficit of D2R-OEdev mice 
appears to be more directly linked to striatal overexpression of D2Rs because this deficit is 
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rescued when levels of striatal D2R expression is reverted to baseline in the adult animal 
(Kellendonk et al., 2006, Drew et al., 2007). Since the bridging collaterals are regulated by 
chronic changes in excitability of MSNs via changes in Kir2 channel function, as demonstrated 
and discussed in Chapter 2, I hypothesized that increased density of bridging collaterals and/or 
increased excitability might underlie impaired incentive motivation in D2R-OEdev mice.  
To test this hypothesis, I attempted to phenocopy the motivation deficit of D2R-OEdev 
mice by downregulating Kir2.1 channel function in selective populations of striatal MSNs. For 
this purpose, I used cell-type restricted expression of the trans-dominant negative mutant 
Kir2.1
AAA channel in the mouse striatum, in either dMSNs or iMSNs and in specific striatal sub-
regions, to chronically increase excitability of these neurons. Increased excitability in D2R-OEdev 
mice is observed in both dMSNs and iMSNs and in both dorsal and ventral regions of the 
striatum (Cazorla et al., 2012). However, the DMS and NA core have been more consistently 
implicated in the activation of goal-directed behavior (Corbit et al., 2001, Yin et al., 2005). 
Therefore, I chose to target the DMS or the NA core to manipulate excitability in a pathway-
specific manner. I assessed motivation using instrumental tasks, including a progressive ratio 
schedule of reinforcement and a concurrent choice task. Both of these tasks have been validated 
in rodents and can provide reliable measures of how much effort an animal is willing to expend 
to obtain a food reward (Salamone et al., 2003, Bradshaw and Killeen, 2012). In addition, I also 
tested whether chronically increasing excitability of dMSNs or dMSNs in specific striatal sub-
regions alters locomotor activity in mice. Thus, in addition to investigating how excitability in 
different circuits and brain regions may contribute to the motivation phenotype of D2R-OEdev 
mice, I also aimed to understand how the basal ganglia regulate motivated behavior for natural 




MATERIALS AND METHODS 
Animals 
All animal protocols used in the present study were approved by the Institutional Animal 
Care and Use Committees of Columbia University and New York State Psychiatric Institute. 
Drd1-Cre (FK150Gsat/Mmcd) and Drd2-Cre (ER44Gsat/Mmcd) on a C57BL/6J background 
were purchased from the Mutant Mouse Resource & Research Centers (National Institutes of 
Health). Both male and female adult mice at least eight weeks old were used in this study. Mice 
were housed under a 12:12-hour light:dark cycle in a temperature-controlled environment, and 
all behavioral testing was done during the light cycle. Food and water were available ad libitum, 
except when they were being trained or tested in operant behavioral tasks, during which time 
mice were only given 2 h per day of unrestricted feeding time, which occurred immediately after 
testing session. Mice were also food deprived on days when they underwent testing for food 
preference, during which time they were given an additional hour of unrestricted feeding with 
laboratory chow immediately after each test session.  
Stereotaxic injections 
For all viral injection surgeries mice were anesthetized with a mixture of ketamine and 
xylazine (100 mg/kg and 10 mg/kg) administered by intraperitoneal injection. Animals were then 
placed in a stereotaxic apparatus and body temperature was maintained at 37 ˚C with a heating 
pad. Small cranial windows (< 0.5 mm) were drilled at the appropriate sites and viruses were 
delivered at an average rate of 100 nL/min using glass pipettes (tip opening 10-15 µm). All 
stereotactic coordinates were measured relative to bregma. A total of 0.4-0.5 µL volume was 
delivered into each site for all injections. Two bilateral sites of injection were used for targeting 
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the DMS to allow diffusion of the virus to the entire region (site A: AP: +1.3 mm, ML: ±1.4 mm, 
DV: -3.3; site B: AP +0.9 mm, ML ±2.0 mm, DV -3.4 mm). The NA core was targeted 
bilaterally with one set of coordinates (AP: +1.7 mm, ML: ±1.2 mm, DV: 4.0 mm). All 
behavioral experiments were started least four weeks after surgery to allow for stable viral 
transfection. 
Drug treatments 
D-Amphetamine (Sigma A5880) was dissolved in sterile saline (0.9% NaCl) at 0.2 
mg/mL and administered via intraperitoneal injection at a dose of 2 mg/kg. Amphetamine 
solution was prepared on the same day of experiment. 
Behavioral assays 
Open field locomotion 
 Locomotor activity in an open field was assessed in acrylic activity chambers (42 cm 
long × 42 cm wide × 38 cm high) equipped with infrared photobeams for motion detection 
(Kinder Scientific). To measure baseline locomotion, mice were placed in the open field, and 
activity was automatically recorded for 60 min. To measure amphetamine-induced locomotion, 
mice were similarly placed in the open field after the system had been programmed to interrupt 
recording 90 min after starting a session, at which point mice were administered amphetamine 
and placed back in the open field. Recording of locomotor activity resumed for another 90 min 




Operant training and progressive ratio 
Operant training and testing were done in experimental chambers equipped with liquid 
dippers, retractable levers, head entry detector in the feeder trough, a house light, and an exhaust 
fan. Unless otherwise indicated, for every session the dipper was submerged into a tray 
containing evaporated milk, so that raising the dipper provided a reward of one drop of 
evaporated milk into the feeder trough. Throughout the study, each animal was subjected to only 
one operant session per day. 
Mice were first trained to consume the liquid reward from the dipper located inside the 
feeder trough. In the first session, they were placed inside the chambers with the dipper in the 
raised position, providing access to a drop of evaporated milk. The dipper was retracted 10 
seconds after the first head entry into the feeder trough. A variable inter-trial interval (ITI) 
ensued, followed by a new trial identical to the first. The session ended after 30 minutes or 20 
dipper presentations. On the following day, mice underwent another session similar to the first, 
except that the dipper retraction was response-independent. During each trial, the dipper was 
raised for 8 seconds and then lowered independently of whether mice had made a head entry. 
The session ended after 30 minutes or 30 dipper presentations. All mice underwent dipper 
training for 2 days before moving on to Pavlovian training. All mice underwent one hour-long 
Pavlovian training session, in which the mechanical dipper was raised approximately once per 
minute for 5 seconds. Immediately before the dipper was raised, the lever was extended into the 
chamber for 6 seconds to allow mice to associate the lever extension to the milk reward. Whether 
the mouse pressed the lever or not, the dipper was raised when the lever was retracted, providing 
access to the reward. In the subsequent phase of training, mice were required to press a lever to 
earn the milk reward. At the beginning of a session, the lever was extended into the chamber, and 
lever presses were reinforced on a continuous reinforcement (CRF) schedule. In CRF and in all 
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subsequent sessions, the reward consisted of raising the dipper with a drop of evaporated milk in 
it for 5 seconds. The lever was retracted after every two times the mouse earned a reward, and 
then was re-extended after a variable ITI (averaging 30 seconds). The session ended when the 
mouse earned 60 reinforcements, or one hour elapsed. Mice continued undergoing daily CRF 
sessions until they earned 60 rewards in two consecutive sessions. When all mice reached 
criterion, they were moved to training fixed interval (FI) schedules. 
In FI schedule training, lever presses were not reinforced until after a fixed interval 
(timed relative to the lever extension) had elapsed. Mice began on FI 4 s schedule, meaning that 
the first lever press occurring 4 s after lever extension was reinforced. Each reinforcement was 
followed by a variable ITI (mean of 30 seconds; range of 110 seconds), during which the lever 
remained retracted. The start of a new trial was signaled by the extension of the lever. Each 
session consisted of a maximum of 36 trials or 1 hour. Mice were subjected to sessions with 
increasing intervals on each day; the FI durations were 4, 8, 16, and 24 s. All animals were 
required to complete all 36 trails in the FI 24 s schedule before being tested in the progressive 
ratio schedule. 
The progressive ratio task directly assesses operant motivation by quantifying the amount 
of effort a subject is willing to expend to earn a reward. The progressive ratio schedule used was 
one in which the amount of presses required to obtain each successive reward increased 
exponentially by a power of two. Motivation was measured by recording the total number of 
lever presses made and number of rewards earned during a session, as well as how long a subject 
continued to respond before giving up. Each session could last up to 2 hours but ended early if 
the mouse did not press the lever for 3 minutes. Mice underwent 5-7 consecutive days of testing 




All mice were first tested in the progressive ratio schedule before being trained for the 
concurrent choice task. A random ratio (RR) schedule, consisting of a constant probability of 
reinforcement for each lever press, was used to train animals for this task. All mice were first 
trained for at least 2 days in an hour-long RR 5 sessions, in which on average every fifth lever 
press was rewarded. Following this training, animals were subjected to the concurrent choice 
task, consisting of RR sessions, in which animals could press a lever to obtain a milk reward, in 
operant boxes that also contained 8-12 g freely accessible laboratory chow in a dish. Increasing 
ratios were used (RR5, RR10, RR20) with concurrent choice (i.e. freely available chow), and all 
mice underwent at least two sessions with each ratio. For the experiments in which mice were 
virally injected in the DMS, an RR 30 schedule of reinforcement was also used, and mice were 
also tested at least twice in RR 30 session without concurrent free chow available. The amount of 
food consumed by each mouse in each session was calculated by subtracting the weight of the 
food remaining after a session from the weight of the food pellet measured before the session. 
Outcome devaluation 
In this task, mice are tested to determine whether or not they are pressing the lever 
because they have formed a habit, or if they are still sensitive to the outcome. The reward is 
therefore devalued by allowing mice to have unlimited access to the reward for a specified time 
period prior to the trial. If mice are truly pressing the lever in order to obtain the reward, they 
should press the lever fewer times throughout the session if they have been exposed to the 
reward beforehand. Here, the valued reward was sweetened evaporated milk, and standard 
mouse chow served as the control. Mice were therefore pre-fed with the valued reward or a non-
valued reward before testing. The mice were then placed in an operant chamber with a lever 
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extended, but lever presses were not reinforced throughout the session. Because this non-
reinforced task should extinguish pressing behavior, mice were trained in RR 30 sessions for 1-2 
days in between devaluation testing days in order to maintain high press rates.  
On outcome devaluation testing days, mice were first pre-fed with either the valued 
reward (sweetened evaporated milk) for 30 min or laboratory chow – a control food which they 
had never been trained to associate as a reward for lever pressing – for 1 h. Mice were only given 
30 min of access to the valued reward in order to prevent complete satiation with milk, which 
might have resulted in complete loss of motivation to obtain the reward during the session. All 
mice were single-housed during pre-feeding. Immediately after pre-feeding mice were placed in 
an operant chamber with an extended lever for 15 minutes without ever receiving a reward. 
Testing occurred on two different days in a randomized design so that each mouse received pre-
feeding with milk or chow once. The number of lever presses made in each session was 
measured for assessment of outcome devaluation. 
Food preference 
 Assessment of food preference was always done at the end of all operant training and 
testing. On separate days, mice were subjected to two food preference sessions, in which they 
were individually placed in standard holding cages with access to different foods or water. In one 
session, mice had access to freely available evaporated milk and laboratory chow, and in the 
other session mice had access to freely available water and laboratory chow. The order of 
sessions was counterbalanced for each experimental group. Total consumption of milk, chow, 
and water was calculated for each mouse by measuring the weight of the food or the volume of 




Histology and immunohistochemistry 
For all histological analysis of brain tissue following behavioral experiments, mice were 
anesthetized with a mixture of ketamine and xylazine (100 mg/kg and 10mg/kg, respectively), 
administered by intraperitoneal injection, and were transcardially perfused, first with PBS and 
then with 4% paraformaldehyde. Following perfusion, brains were post-fixed in 4% 
paraformaldehyde for 24 hours, and then transferred to PBS. Brains were then sliced into 50-μm 
coronal sections using a vibratome and every section was collected. 
For confirmation of virally targeted regions, immunohistochemistry using fluorescence 
was performed on these free-floating sections by treating sections first with blocking buffer 
(0.5% bovine serum albumin, 5% horse serum, 0.2% Triton X-100), followed by the primary 
rabbit dsRed polyclonal antibody (1:250, Clontech, cat. 632496) and subsequently with goat 
anti-rabbit IgG (H+L) secondary antibody Alexa Fluor 568 conjugate (1:1000, Thermo Fisher 
Scientific, cat. A-11011). Sections were washed with 0.2% Triton X-100 in between incubation 
with antibodies and with 50 mM Tris-Cl pH 7.4 before mounting. Sections were mounted on 
glass slides and subsequently coverslipped for imaging with VectaShield containing DAPI 
(Vector Labs). Images were acquired at 2.5x magnification using a Hamamatsu camera attached 
to a Carl Zeiss epifluorescence microscope. Micrographs were processed using ImageJ software 
(National Institutes of Health). 
Data analysis and statistics 
All data collected in the current study were processed with Excel (Microsoft). Statistical 
analyses were done with either Excel or with Prism 5 (GraphPad). Most data sets were normally 
distributed and Student’s t test, repeated-measures ANOVAs, or two-way ANOVAs were done, 
with Bonferroni or Dunnett post hoc tests conducted when appropriate. Because the data set for 
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session duration in the progressive ratio task was not normally distributed, the Log-rank non-
parametric test was used to compare whether or not the independent variables significantly 
affected survival functions for session duration. 
 
RESULTS 
INCREASING EXCITABILITY OF DIRECT PATHWAY 
First, I chronically increased excitability of the direct pathway by expressing the trans-
dominant negative Kir2.1
AAA channel in dMSNs in the DMS. I used Drd1-Cre mice to selectively 
target the direct pathway. These animals were injected with the AAV2/1-Syn-DIO-Kir2.1AAA-
IRES-mCherry virus, characterized in Chapter 2, or the control virus AAV2-EF1α-DIO-mCherry 
into the DMS. The purpose of this experiment was to determine whether changes in chronic 
excitability of the direct pathway arising from the DMS might lead to specific changes in 
motivated behavior. After allowing the transgene to be expressed for several weeks, I tested 
these animals in a number of behavioral assays, the results of which are shown in Figure 14. This 
manipulation was carried out in two separate cohorts of mice, and most, but not all, behavior 
tests were conducted for both cohorts. In tests for which data from both cohorts were available, 
results were pooled to yield the plots presented in Figure 14. The number of subjects tested to 
generate each plot and statistics is reported. 
In this first experiment, I found that Drd1-Cre mice expressing Kir2.1
AAA in dMSNs in 
the DMS did not show differences in locomotor activity in an open field compared to control 
littermates (t(11) = 1.337, p = 0.2082; n = 20 mice per group) (Figure 14A). In addition, animals’ 
preferences for laboratory chow and evaporated milk were also assayed, and no differences in 
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food consumption or preference between groups were detected for any of the food pairs tested 
(F(1,18) = 0.00004571, p = 0.9947; n = 10 mice per group) (Figure 14B). 
These animals were then trained to press a lever to earn a food reward. Increasing FI schedules 
were used during training to shape mice to press a lever at high rates to continue earning 
rewards. In each FI session, for each trial, a pre-determined time interval (4, 8, 12, 16, or 24 s) 
after the lever extension had to elapse before a lever press resulted in the presentation of a 
reward. As shown in Figure 14C, mice expressing Kir2.1AAA in dMSNs in the DMS 
progressively increased their rate of responding with increasing FI schedules (F(4,38) = 247.0, p < 
0.0001; n = 20 mice per group). However, for each FI schedule, no difference in training 
performance was observed between mice expressing Kir2.1
AAA and those expressing a control 
gene in dMSNs in the DMS (F(1,38) = 0.08082, p = 0.7777; n = 20 mice per group) (Figure 14C). 
Once all animals were adequately trained, they were tested in a progressive ratio schedule 
of reinforcement, a test of motivation that measures how much effort an animal is willing to 
expend to obtain a food reward. I used a specific progressive ratio schedule in which the lever 
press requirement doubled with each successive reward and the session timed out if a mouse 
stopped responding for three minutes. Animals were tested in this schedule for multiple 
consecutive days, and the parameters used to compare performance between groups included the 
session duration, representing how long an animal continued to press a lever on average across 
all sessions, as well as total number of lever presses and lever press rate for each session. No 
significant differences were observed between mice expressing Kir2.1
AAA or a control gene in 
dMSNs in the DMS in the survival functions of their average session duration (Log-rank test: χ² 
= 1.907, p = 0.1763; n = 20 mice per group), or in the number of lever press responses they made 
in each session (F(1,38) = 1.456, p = 0.2350; n = 20 mice per group) (Figures 14D-E). Finally, in 
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all progressive ratio sessions, animals’ press rates were not different between groups (F(1,38) = 
0.0009894, p = 0.9751; n = 20 mice per group) (Figure 14F). 
Animals were also tested in a concurrent choice task, in which they were given the choice 
to press a lever to obtain a preferred food reward (evaporated milk) or to consume a less 
palatable food reward (laboratory chow) without expending any effort. In this assay, although I 
tested animals in different RR schedules, I only show the data from the highest RR schedule 
tested (RR 30). I found that chronically increasing excitability of dMSNs in the DMS did not 
affect how much animals were willing to press a lever to obtain a more palatable reward in an 
RR 30 schedule of reinforcement when given the option to freely consume a less palatable food 
(F(1,18) = 0.1271, p = 0.7256; n= 10 mice per group) (Figures 14G). Both groups showed 
decreased operant responding when a freely available food was introduced (chow availability: 
F(1,18) = 70.44, p < 0.001, group: F(1,18) = 0.4262, p = 0.5221; n = 10 mice per group), 
demonstrating that animals in both groups could modulate their behavior based on the available 
choices (Figure 14G). In sessions in which laboratory chow was freely available, the amount of 
chow consumed by each mouse was measured, and no difference was observed in chow 
consumption between mice with more excitable dMSNs in the DMS and control animals (F(1,18) 
= 0.5920, p = 0.4516; n = 10 mice per group) (Figure 14H). 
I further tested whether mice with increased excitability of the direct pathway in the DMS 
showed any behavioral difference to controls in how well they could encode the value of the  
reward. Since all animals were trained to press a lever to obtain evaporated milk as a food 
reward, I tested whether decreasing the value of that reward by pre-feeding animals with 




Figure 14: Effects of chronically increasing excitability of direct pathway in the DMS. A. Mice expressing 
Kir2.1AAA in dMSNs in the DMS have similar baseline locomotor activity compared to controls, as measured by 
distance traveled in an open field for 1 h (p = 0.2082; n = 20 mice per group). B. No differences in food preference 
between groups were detected for any of the food pairs tested (p = 0.9947; n = 10 mice per group). C. All mice 
progressively increased their rate of responding with increasing FI schedules (p = 0.7777; n = 20 mice per group). 
D-F. No differences were observed between groups in the progressive ratio schedule of reinforcement, as measured 
by (D) the survival functions for average session duration (p = 0.1763; n = 20 mice per group), (E) number of 
responses in each session (p = 0.2350; n = 20 mice per group), and (F) rate of lever pressing (p = 0.9751; n = 20 
mice per group). G. In the concurrent choice task, both groups showed decreased operant responding when a freely 
available food was introduced (chow availability: p < 0.001, group: p = 0.5221; n = 10 mice per group). G-H. There 
were also no performance differences between mice expressing Kir2.1AAA or a control virus in the concurrent choice 
task, as measured by (G) the total number of responses in concurrent choice sessions with RR 30 schedule of 
reinforcement (p = 0.7256; n= 10 mice per group), and (H) amount of chow consumed by mice in each group during 
these concurrent choice sessions (p = 0.4516; n = 10 mice per group). I. In an outcome devaluation test, mice in both 
groups showed similar decreased rates of pressing after pre-feeding with evaporated milk compared to a control 
condition in which mice were pre-fed chow, a food that had never been associated with lever pressing (pre-fed food: 




compared to a control condition in which mice were pre-fed chow, a food that had never been 
previously associated with lever pressing, mice in both groups showed similar decreased rates of 
pressing after pre-feeding with evaporated milk (pre-fed food: F(1,17) = 13.61, p = 0.0018, group: 
F(1,17) = 0.08970, p = 0.7682; n = 10 mice per group) (Figure 14I). This finding demonstrates that 
expressing Kir2.1AAA in dMSNs in the DMS does not impair animals’ sensitivity to outcome 
devaluation.  
 Given the negative results reported above, I attempted to determine whether it was 
possible to induce a behavioral phenotype in animals expressing Kir2.1
AAA in the direct pathway 
in the DMS. Since acute amphetamine leads to extracellular levels of dopamine that are higher 
than physiological levels (Kuczenski and Segal, 1997), I predicted that increased dopamine 
activation of D1Rs in more excitable dMSNs could further potentiate the direct pathway’s 
function to drive behavior. I therefore measured locomotion in freely behaving mice expressing 
Kir2.1
AAA or a control gene in dMSNs in the DMS before and after acute systemic treatment with 
Figure 15. Chronically increasing excitability of dMSNs in the DMS potentiates locomotor response 
to acute amphetamine. A. Open field locomotor activity of mice expressing Kir2.1AAA or a control gene 
in dMSNs in the DMS 90 min before and 90 min after treatment with amphetamine (2 mg/kg). B. 
Comparing locomotor activity for both groups 20 min before and 20 min after treatment with 
amphetamine showed that mice in both groups increased locomotion in response to amphetamine (p = 
0.0006), and mice expressing Kir2.1AAA had a potentiated response to the drug compared to controls (p = 
0.0437). A total of 10 mice expressing Kir2.1AAA and 10 mice expressing the mCherry control gene were 
assayed for this analysis. 
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amphetamine. As expected, mice in both groups showed increased locomotion after acute 
treatment with amphetamine (F(1,18) = 17.33, p = 0.0006; n = 10 mice per group) (Figure 15). 
And most importantly, mice expressing Kir2.1
AAA in dMSNs in the DMS exhibited a potentiated 
locomotor response to amphetamine treatment compared to control animals (F(1,18) = 4.705, p = 
0.0437; n = 10 mice per group) (Figure 15). Therefore, it is possible to induce a behavior read-
out for chronically increasing excitability in a selective population of striatal MSNs using the 
AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry virus despite negative findings in behavioral 
measures of baseline locomotion and motivation for food. 
 I also conducted a similar experiment involving a similar series of behavioral assays in a 
separate cohort of Drd1-Cre mice, but this time expression of Kir2.1
AAA was targeted to dMSNs 
in the NA core instead of the DMS. The purpose of this experiment was to test whether 
chronically increased excitability of dMSNs in the NA core would affect incentive motivation in 
mice. The results for this experiment are presented in Figure 16 which includes data from one 
single cohort of mice tested in all behavioral assays. 
 Similar to what was observed when excitability was increased in the DMS, expressing 
Kir2.1
AAA in dMSNs in the NA core also did not change animal’s baseline locomotor activity 
(t(22) = 0.1937, p = 0.8482; n = 9-10 mice per group) or animal’s food preferences (F(1,16) = 
0.0008703, p = 0.9768) (Figures 16A-B). Mice were then trained to press a lever to obtain a food 
reward and were trained in FI schedules with progressively longer intervals before testing in 
operant tasks of motivation. FI schedules with longer intervals led to higher number of lever 
press responses in both groups (F(4,15) = 140.5, p < 0.0001; n = 9 mice per group) (Figure 16C). 





Figure 16: Effects of chronically increasing excitability of direct pathway in the NA core. A. Mice 
expressing Kir2.1AAA in dMSNs in the NA core show similar baseline locomotor activity compared to 
controls, as measured by distance traveled in an open field for 1 h (p = 0.8482). B. No differences in food 
preference between groups were detected for any of the food pairs tested (p < 0.0001). C. No differences 
were observed between groups when animals were tested in FI 4 s through FI 16 s (p = 0.8308). At the 
longest FI interval, FI 24 s, mice with more excitable dMSNs in the NA core made significantly more 
lever presses in a session compared to the control group (p = 0.0486). D-F. No differences were observed 
between groups in the progressive ratio schedule of reinforcement, as measured by (D) the survival 
functions for average session duration (p = 0.5982), (E) number of responses in each session (p = 0.9587), 
and (F) rate of lever pressing (p = 0.7580). G-H. There were also no differences between performance in 
mice expressing Kir2.1AAA or a control virus in the concurrent choice task, as measured by (G) the total 
number of responses in concurrent choice sessions with RR 20 schedule of reinforcement (p = 0.8111), 
and (H) the amount of chow consumed by mice in each group during these concurrent choice sessions (p 
= 0.7535). A total of 9 mice expressing Kir2.1AAA and 9 mice expressing the mCherry control gene were 
assayed for this analysis.  
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through FI 16 s (F(1,15) = 0.04726, p = 0.8308; 9 mice per group), at the longest intervals, FI 24 s, 
mice with more excitable dMSNs in the NA core made significantly more lever presses in a 
session compared to the control group (F(1,15) = 4.608, p = 0.0486; n = 9 mice per group) (Figure 
16C). However, when animals were tested in tasks of motivation, including the progressive ratio 
and concurrent choice tasks, no behavioral differences in performance were observed between 
groups (Figures 16D-H). In the progressive ratio task, the survival functions for session duration 
were not different between groups (Log-rank test: χ² = 0.2777, p = 0.5982; n = 9 mice per group) 
(Figure 16D). Other parameters in this task, including total number of lever presses (F(1,16) = 
0.002762, p = 0.9587; n = 9 mice per group) and rate of responding (F(1,16) = 0.09826, p = 
0.7580; n = 9 mice per group) in each session were similarly not changed (Figures 16E-F). In the 
concurrent choice assay for this experiment, animals were given the choice to either press a lever 
to obtain a more palatable food reward at different RR schedules of reinforcement or to consume 
the freely available less palatable laboratory chow. Only data for the highest RR schedule tested 
(RR 20) is shown for this experiment. Mice expressing Kir2.1
AAA or a control gene in dMSNs in 
the NA core did not perform differently in this task, as measured by the total number of lever 
presses (F(1,16) = 0.05903, p = 0.8111; n = 9 mice per group) and amount of chow consumed 
(F(1,16) = 0.1021, p = 0.7535; n = 9 mice per group) in concurrent choice sessions (Figures 16G-
H). 
 
INCREASING EXCITABILITY OF INDIRECT PATHWAY 
I also carried out a parallel set of experiments using Drd2-Cre mice to manipulate 
excitability in iMSNs selectively in the DMS or NA core. As in the set of experiments described 
above, I injected mice with the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry viral vector or the  
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control virus AAV2-EF1α-DIO-mCherry into either the DMS or NA core. Mice were tested in 
the same behavioral paradigms as those done for experiments targeting dMSNs in Drd1-Cre 
mice. In addition to testing how MSN excitability affects motivation, these experiments were 
also intended to determine whether increasing density of bridging collaterals could also affect 
motivation because in Chapter 2 I showed that injecting the AAV2/1-Syn-DIO-Kir2.1AAA-
IRES-mCherry virus in the DMS of Drd2-Cre mice to increase excitability of iMSNs can induce 
growth of bridging collaterals (see Figure 9).  
Chronically increasing excitability of the indirect pathway by expressing Kir2.1
AAA 
selectively in iMSNs in the DMS did not lead to behavior effects in most assays tested. There 
were no differences in baseline locomotor activity (t(22) = 0.5121, p = 0.6137; n = 9-10 mice per 
group) or food preferences (F(1,17) = 0.07919, p = 0.7818; n = 9-10 mice per group) between 
groups (Figures 17A-B). Moreover, when animals of both groups were trained to press a lever to 
obtain a food reward, they showed a similar progressive increase in lever pressing with 
increasing FI schedule intervals (F(4,17) = 95.49, p < 0.0001; group: F(1,17) = 0.1091, p = 0.7452; n 
= 9-10 mice per group) (Figure 17C). In the progressive ratio task, mice expressing either 
Kir2.1
AAA or a control gene in iMSNs in the DMS continued to respond for a similar amount of 
time (Log-rank test: χ² = 0.01734, p = 0.8952; n = 9-10 mice per group) and made similar total 
number of lever presses (F(1,17) = 3.854, p = 0.0662; n = 9-10 mice per group) (Figures 17D-E). 
However, the rate of lever pressing was significantly different between groups, with mice 
injected with the Kir2.1AAA virus showing increased rates of responding compared to controls 
(F(1,17) = 10.45, p = 0.0049; n = 9-10 mice per group) (Figure17F). In the concurrent choice task, 




Figure 17: Effects of chronically increasing excitability of indirect pathway in the DMS. A. Mice 
expressing Kir2.1AAA in iMSNs in the DMS show similar baseline locomotor activity compared to 
controls, as measured by distance traveled in an open field for 1 h (p = 0.6137). B. No differences in food 
preference between groups were detected for any of the food pairs tested (p = 0.7818). C. All mice 
progressively increased their rate of responding with increasing FI schedules (p < 0.0001; group: p = 
0.7452). D-E. No differences were observed between groups for two parameters in the progressive ratio 
schedule of reinforcement, (D) the survival functions for average session duration (p = 0.8952) and (E) 
the number of responses in each session (p = 0.0662). F. The rate of lever pressing in the progressive ratio 
schedule was increased in mice expressing Kir2.1AAA compared to controls (p = 0.0049). G. In RR 30 
sessions without concurrent choice, a trend towards increased total number of lever presses for mice 
expressing Kir2.1AAA compared to controls was observed (p = 0.0546). Both groups showed decreased 
operant responding when a freely available food was introduced (chow availability: p < 0.0001). G-H. 
There were also no differences between mice expressing Kir2.1AAA or a control virus in the concurrent 
choice task, as measured by (G) the total number of responses in concurrent choice sessions with RR 30 
schedule (p = 0.1150), and (H) the amount of chow consumed by mice in each group during these 
concurrent choice sessions (p = 0.7592). I. In an outcome devaluation test, mice in both groups showed 
similar decreased rates of pressing after pre-feeding with evaporated milk compared to a control condition 
in which mice were pre-fed chow, a food that had never been previously associated with lever pressing 
(pre-fed food: p = 0.0003, group: p = 0.5916). A total of 10 mice expressing Kir2.1AAA and 9 mice 




in the RR 30 schedule of reinforcement at baseline (F(1,17) = 4.262, p = 0.0546; n = 9-10 mice per 
group). When animals were given the choice to either press a lever to obtain evaporated milk or  
freely eat laboratory chow, they reduced their number of responses compared to baseline (chow 
availability: F(1,17) = 27.94, p < 0.0001; n = 9-10 mice per group) (Figure 17G). However, on 
concurrent choice sessions, no differences were observed between groups in either total number 
of lever presses (F(1,17) = 2.759, p = 0.1150; n = 9-10 mice per group) or amount of food 
consumed (F(1,17) = 0.09700, p = 0.7592; n = 9-10 mice per group) (Figures 17G-H). In addition, 
animals in this cohort were subjected to an outcome devaluation test, and both groups were 
similarly sensitive to pre-feeding with evaporated milk (pre-fed food: F(1,16) = 20.90, p = 0.0003, 
group: F(1,16) = 0.2997, p = 0.5916), suggesting that chronically increasing excitability of the 
indirect pathway in the DMS does not affect how animals encode the value of a reward (Figure 
17I). 
 Finally, I also injected the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry virus into the 
NA core of Drd2-Cre mice in order to selectively increase excitability of the indirect pathway in 
that striatal region. Subsequent behavioral testing yielded the results presented in Figure 18. As 
can be seen in Figures 18A-B, baseline locomotor activity (t(22) = 0.1140, p = 0.9103; n = 8 mice 
per group) and food preferences (F(1,42) = 0.005533, p = 0.9411; n = 8 mice per group) were not 
changed between groups. Mice were also trained in operant tasks including FI schedules with 
progressively longer time intervals, and no differences between groups were observed for FI 
schedule with interval requirements between 4 and 16 s (F(3,14) = 0.1254, p = 0.7285; n = 8 mice 
per group) (Figure 18C). However, in striking contrast to what was observed in Drd1-Cre mice 
(see Figure 16C), Drd2-Cre mice expressing Kir2.1




Figure 18: Effects of chronically increasing excitability of iMSNs in the NA core. A. Mice expressing 
Kir2.1AAA in iMSNs in the NA core show similar baseline locomotor activity compared to controls, as 
measured by distance traveled in an open field for 1 h (p = 0.9103). B. No differences in food preference 
between groups were detected for any of the food pairs tested (p = 0.9411). C. No differences were 
observed between groups when animals were tested in FI 4 s through FI 16 s (p = 0.7285). At the longest 
interval, FI 24 s, mice with more excitable dMSNs in the NA core made significantly more lever presses 
in a session compared to the control group (p = 0.0346). D-F. No differences were observed between 
groups in the progressive ratio schedule of reinforcement, as measured by (D) the survival functions for 
average session duration (p = 0.4762), (E) number of responses in each session (p = 0.6822), and (F) rate 
of lever pressing (p = 0.4833). G-H. There were also no differences in performance between mice 
expressing Kir2.1AAA or a control virus in the concurrent choice task, as measured by (G) the total number 
of responses in concurrent choice sessions with RR 20 schedule of reinforcement (p = 0.7100), and (H) 
the amount of chow consumed by mice in each group during concurrent choice tasks (p = 0.1573). A total 





Figure 19: Kir2.1AAA was selectively expressed in targeted 
regions. Sample micrographs of coronal sections from mice 
injected with the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry 
virus used in each of the experiments in the current study. A. 
Drd1-Cre mice injected in the DMS. B. Drd1-Cre mice injected in 
the NA core. C. Drd2-Cre mice injected in the DMS. D. Drd2-Cre 
mice injected in the NA core. Scale bar: 1 mm. 
lever presses when compared to controls in the FI 24 s schedule (F(1,14) = 0.5480, p = 0.0346; n = 
8 mice per group) (Figure 18C). However, when animals were then tested in tasks of motivation, 
including the progressive ratio and the concurrent choice tasks, no differences in performance 
were observed between animals with chronically increased excitability of iMSNs in the NA core 
and controls (Figures 18D-H). The survival functions for average session duration were not 
statistically different between groups (Log-rank tests: χ² = 0.5076, p = 0.4762; n = 8 mice per 
group) (Figure 18D). And the total number of lever presses (F(1,14) = 0.1748, p = 0.6822; n = 8 
mice per groups) and rate of responding (F(1,14) = 0.5185, p = 0.4833; n = 8 mice per group) were 
also not different between groups expressing Kir2.1
AAA or a control gene in iMSNs in the NA 
core (Figures 18E-F). Finally, in the concurrent choice task, mice were given the option to either 
press a lever to obtain a more palatable reward (RR 20 schedule of reinforcement) or to consume 
a freely available less palatable 
reward. No differences were 
observed between groups in the 
number of lever presses made 
(F(1,14) = 0.1440, p = 0.7100; n = 8 
mice per group) or in the amount 
of food consumed (F(1,14) = 2.233, 
p = 0.1573; n = 8 mice per group) 
in this task (Figures 18G-H). 
For all experiments 
involving expression of Cre-
dependent Kir2.1
AAA by injecting 
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the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry virus in selective striatal sub-region of Drd1-
Cre and Drd2-Cre mice, histological confirmation of virus expression was done for all subjects. 
As shown in Figure 19, the stereotaxic coordinates and virus injection protocol used in this study 
were appropriate to selectively transfect neurons in either the DMS or NA core. 
 
DISCUSSION 
In summary, I conducted a series of experiments in which I selectively increased 
excitability of the direct or indirect pathway in specific striatal sub-regions that have been 
implicated in goal-directed behavior, namely the DMS and NA core. I found that this 
manipulation did not lead to significant changes in different behavioral assays, such as locomotor 
activity in an open field and tasks of motivation, including the progressive ratio and concurrent 
choice tasks. 
Even though I did not observe any clear effect on motivation after increasing excitability 
of striatal MSNs in a pathway-specific and region-specific manner, I did identify a few 
behavioral effects of this manipulation. One interesting finding was that among mice targeted in 
the NA core, expressing Kir2.1
AAA in dMSNs led to increased responding in an FI 24 s schedule, 
while expressing Kir2.1
AAA in iMSNs led to the exact opposite effect, with animals showing 
decreased responding in this same operant schedule. For this study, I decided to use FI schedules 
to train animals to press at high rates because this schedule has been previously used for the 
same purpose in other studies that investigated the effects of basal ganglia manipulations on 
incentive motivation (Drew et al., 2007, Trifilieff et al., 2013). However, it is known that mice 
can learn to time the interval and will scale their rate of responding to the FI schedule with 
repeated training on the same schedule (Taylor et al., 2007). In the current study, mice were not 
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subjected to the same FI schedule more than twice precisely to avoid this effect. Nevertheless, a 
specific effect in operant responding in the FI 24 s schedule, with no differences observed in all 
other behavioral assays in this study, suggest that excitability of dMSNs and iMSNs in the NA 
core may have a specific effect related to timing. Additional experiments with mice expressing 
Kir2.1
AAA selectively in dMSNs or iMSNs in the NA core could be done to test for a behavioral 
effect on a peak interval timing task (Taylor et al., 2007), potentially establishing a new link 
between NA function and timing in mice. 
One possibility for the lack of effect of increasing MSN excitability on motivation is that 
protein expression or function of the Kir2.1
AAA channel was not efficient in dMSNs and iMSNs. 
The data presented in Chapter 2 showing an effect of chronic excitability on bridging collaterals 
goes against this possibility, as the same virus, AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry, 
was used in both studies. Moreover, I also demonstrated potentiated amphetamine-induced 
locomotion in animals expressing Kir2.1
AAA in dMSNs in the DMS, consistent with what would 
be expected with increased function of the direct pathway. In addition, electrophysiological 
recordings done in the Kellendonk laboratory in iMSNs from Drd2-Cre mice injected with the 
AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry virus in the NA have shown that resting 
membrane in these neurons have a mean of -74.62 mV (95% C.I.: -79.25 to -69.99 mV), a value 
statistically higher than the mean of -79.62 mV (95% C.I.: -80.70 to -78.53 mV) observed in 
iMSNs in the NA in animals injected with a control virus. Together, these data indicate that Cre-
dependent expression of the Kir2.1
AAA channel using the AAV2/1-Syn-DIO-Kir2.1AAA-IRES-
mCherry virus leads to a physiological effect on excitability of striatal MSNs that can induce a 
behavioral phenotype under specific pharmacological conditions. Nevertheless, as discussed in 




AAA virus leads to a robust effect on neuronal excitability is still lacking. 
Despite this limitation, the negative results on motivation presented here suggest that chronically 
increasing excitability of dMSNs or iMSNs in a striatal sub-region-specific manner does not 
affect incentive motivation in mice.  
When testing animals in tasks of motivation, I did observe a significant effect on rate of 
responding when I manipulated excitability of iMSNs in the DMS. Similar manipulation to 
dMSNs in the DMS did not lead to differences in rate of responding in any of the motivation 
assays. Some measurable parameters of goal-directed behavior that characterize motivation can 
be isolated and interpreted individually. These parameters include latency to initiate behavior, 
vigor of behavior, and duration of behavior. In this study, mice expressing Kir2.1
AAA in the DMS 
were not different from controls in their latency to initiate lever pressing (data not shown) or in 
the amount of time it took for them to “give up” lever-pressing behavior as the ratio requirement 
to obtain a reward increased. Lever press rate, which can be considered a measure of action vigor 
in the progressive ratio task, was specifically increased in mice with increased excitability of 
iMSNs in the DMS. These results can appear counterintuitive because the indirect pathway is 
traditionally thought to inhibit behavior initiation, and here I increased excitability of the indirect 
pathway. However, consistent with the known role of the DMS on performance vigor (Wang et 
al., 2013), it is plausible that disturbing excitability of the indirect pathway may interfere with 
the function of that pathway in inhibiting behaviors, rendering the influence of the direct 
pathway on vigor unrestrained by the indirect pathway and, consequently, stronger compared to 
controls. In support of this interpretation, in a separate cohort of Drd2-Cre mice injected with the 
AAV2/1-Syn-DIO-Kir2.1AAA-IRES-mCherry virus in the DMS, albeit in a smaller region of 
the DMS (data not shown), the same specific increase in press rate in the progressive ratio task 
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was observed. To further explore these findings, the role of iMSNs in the DMS on restricting the 
vigor of goal-directed actions should be studied using different strategies to manipulate function 
of the indirect pathway, ideally with better temporal control, including optogenetic and 
chemogenetic approaches. 
As described in Chapter 2, increasing excitability of iMSNs in the DMS using the same 
genetic strategy used in the current study leads to growth of direct-pathway bridging collaterals 
into the GPe. My initial hypothesis was that increased collateral density may be responsible for 
the motivational deficit in D2R-OEdev mice. This one-to-one relationship does not hold true, as 
increasing the density of bridging collaterals by increasing excitability of iMSNs in the DMS 
was not sufficient to affect motivation in mice. It can be concluded, therefore, that plasticity 
involving the bridging collaterals likely does not mediate the reversible deficit in motivation 
observed in D2R-OEdev mice. Nevertheless, another strategy that could be used to confirm this 
conclusion would be to attempt to rescue the motivational deficit of D2R-OEdev mice by 
overexpressing the wild-type Kir2.1 protein in selective populations of striatal MSNs to decrease 
neuronal excitability. If the interpretation of the current data is correct, overexpression of the 
wild-type Kir2.1 channel would also not be sufficient to rescue the motivational deficit of D2R-
OEdev mice. For technical reasons, I was not able to carry out this experiment. Instead, I 
attempted to perform a similar pathway-specific manipulation using a designer receptor 
exclusively-activated by a designed drug (DREADD), which provided additional temporal 
control of neuronal function and, as described in Chapter 4, led to further insight on how basal 
ganglia circuits regulate motivated behavior. 
Another consideration for the data presented in this study is that, as I also showed in 
Chapter 2, behavioral training leads to plasticity involving the bridging collaterals, and the 
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density of these collaterals were never measured in either D2R-OEdev mice or mice expressing 
Kir2.1
AAA in the striatum after testing on operant tasks of motivation. It is conceivable that, in this 
study, expressing Kir2.1AAA in iMSNs in the DMS induced growth of bridging collaterals in 
mice but the daily operant training that preceded the actual behavioral assays for motivation may 
have led to retraction of collaterals, masking a potential effect of bridging collaterals on 
motivation.  
The results of this study were largely negative, although some specific behavioral 
phenotypes were identified that can be further explored. One of the aims of the study was to 
determine the role of basal ganglia sub-circuits on motivation for natural rewards, but it may be 
possible that the manipulation was too mild to induce behavioral effects in the absence of higher 
levels of extracellular dopamine in the striatum. The observation that Kir2.1
AAA expression in 
dMSNs in the DMS potentiated animals’ locomotor response to a psychostimulant supports this 
speculation. It might be possible that by producing a mild shift in the balance between the direct 
and indirect pathways, expression of Kir2.1
AAA in iMSNs might also lead to a behavioral effect 
on psychostimulant-induced locomotion. A reduced response to psychostimulant would be 
expected because Kir2.1
AAA expression in the indirect pathway would increase excitability of 
iMSNs, presumably counteracting the effect of dopamine to inhibit activity of iMSNs via D2Rs. 
Thus, to expand on some of the negative findings presented in this study, it would be interesting 
to test mice expressing Kir2.1
AAA in different striatal sub-circuits in similar behavioral assays 
after treatment with psychostimulants that increase extracellular levels of dopamine in the 
striatum, including amphetamine and cocaine. Moreover, it would also be informative to conduct 
the comprehensive set of manipulations and behavioral assays done in the current study using 
other strategies to selectively target function of striatal dMSNs and iMSNs. Some of such 
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selective strategies include the use of DREADDs and opsins, which can be selectively expressed 
in dMSNs and iMSNs and has been shown to affect behaviors regulated by the striatum (Kravitz 
et al., 2010, Ferguson et al., 2011, Kravitz et al., 2012). Other strategies that could be used to 
further study motivated behavior and have been previously shown to affect how dMSNs and 
iMSNs regulate behavior include inactivation of specific neuronal populations using neurotoxins 
(Durieux et al., 2009, Hikida et al., 2013) or selective deletion of DARPP32 in specific MSN 
populations (Bateup et al., 2010). Although these strategies have been used by researchers to 
probe specific aspects of basal ganglia function, comprehensive descriptions of how each of 
these strategies for disrupting basal ganglia function affect motivation when applied to specific 




INDIRECT PATHWAY FUNCTION AND MOTIVATION 
 
INTRODUCTION 
The findings presented in Chapter 3 demonstrate that downregulation of Kir2.1 function 
in MSNs is not sufficient to impair motivation in wild-type mice. Nevertheless, these findings do 
not discard the alternative that increased MSN excitability and activity may be necessary in 
D2R-OEdev mice for their motivational deficit. I therefore attempted to rescue the motivational 
deficit of D2R-OEdev mice by increasing function of the indirect pathway of the basal ganglia in 
these mice. For the current study, in addition to manipulating neuronal function chronically, as I 
did with Kir2.1
AAA expression in Drd1-Cre and Drd2-Cre animals in Chapter 2, I also 
manipulated indirect-pathway function acutely, with the aim to dissociate the acute effect on 
neuronal activity from the chronic plasticity effects that may alter the density of bridging 
collaterals. To address the question of whether the increase in excitability of iMSNs in D2R-
OEdev mice could explain the motivational deficit induced by striatal D2R upregulation, I used 
hM4D, a designer Gαi-coupled receptor exclusively-activated by the designer drug clozapine-N-
oxide (CNO) to selectively decrease function of the indirect pathway in D2R-OEdev and control 
mice. CNO can be used to activate hM4D receptors – and consequently activate intracellular Gαi 
signaling – both acutely and chronically to test if these manipulations in striatal iMSNs could be 
sufficient to rescue the motivational deficit of D2R-OEdev mice.  
For the acute manipulation, I first tested how activating Gαi-coupled signaling in the 
indirect pathway affected locomotion and motivation in D2R-OEdev and control mice. I further 
tested animals expressing hM4D in striatal iMSNs in a novel behavioral assay, the progressive 
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hold-down task, that attempts to dissociate the directional from the activational components of 
motivation. I found that activating Gαi-signaling in iMSNs boosts motivation in both D2R-OEdev 
and control mice by energizing behavior at the cost of goal-directed efficiency. Moreover, I also 
used the DREADD system to selectively activate Gαi signaling in iMSNs in either the DMS or 
NA core, and I found that both striatal sub-regions contribute to the acute effect on motivation of 
decreasing indirect-pathway function. 
In order to further characterize the acute behavioral effects and understand how activating 
Gαi-coupled signaling in MSNs affects striatal circuit function, I probed activity of iMSNs 
expressing hM4D after CNO treatment both in vitro and in vivo. First I tested whether I could 
measure a change in intrinsic excitability in iMSNs expressing hM4D in the absence and 
presence of CNO using slice electrophysiology. In addition, I used in vivo calcium imaging in 
freely-behaving animals to probe how neurons at different nodes in the indirect pathway respond 
to activation of hM4D receptors in iMSNs. I tested whether activating Gαi signaling could lead to 
a change in somatic MSN activity. Then I also tested how neuronal activity in the GPe, which 
receives monosynaptic inhibition from the indirect pathway, was affected by activation of hM4D 
receptors in iMSNs. I found that activating Gαi-signaling does not lead to a significant change in 
somatic MSN activity. In contrast, neurons in the GPe, which receive monosynaptic inhibition 
from the indirect pathway, show increased activity when striatal hM4D receptors are activated. 
Consistent with these findings, I found that excitability of iMSNs was not affected by hM4D 
activation at the somatic level, and recent work from the Kellendonk laboratory and others has 
demonstrated that activation of hM4D receptors in iMSNs can inhibit GABAergic synaptic 
transmission to the pallidum (Bock et al., 2013). My observations, therefore, suggest that acutely 
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inhibiting indirect-pathway output to the pallidum arising from the DMS and NA core are 
potential therapeutic strategies for energizing behavior and thereby enhance motivation. 
Previous work from the Kellendonk laboratory has shown that, similar to the effects of 
restoring MSN excitability in D2R-OEdev mice by overexpressing wild-type Kir2.1 channels 
(Cazorla et al., 2014), expressing hM4D receptors non-conditionally in the DMS of D2R-OEdev 
and treating these animals with CNO chronically is sufficient to retract bridging collaterals. To 
expand on these findings, I also investigated whether selectively decreasing iMSN function in 
D2R-OEdev and control littermates chronically using the DREADD system could affect 
motivation in these animals. To this end, I treated mice expressing hM4D in iMSNs in the DMS 
and NA core chronically with CNO before testing for changes in locomotor activity and 
motivation. In an attempt to dissociate the acute effects of the drug on neuronal activity from the 
potential chronic effects of the drug on circuit rewiring, animals were tested both while on 
chronic CNO treatment and after allowing the drug to clear for 48 h. Having found that 
chronically activating hM4D receptors in iMSNs does not lead to a measurable effect on 
motivation, I conducted additional experiments to show that the lack of behavioral response to 
the chronic manipulation may be due to receptor desensitization or to short-term circuit-level 
compensation to a chronic decrease in iMSN function. These findings have important 
implications for drug therapies that target GPCRs in the striatum, and the behavioral 
desensitization effect described in this study should be considered in predicting how chronic 





MATERIALS AND METHODS 
Animals 
All animal protocols used in the present study were approved by the Institutional Animal 
Care and Use Committees of Columbia University and New York State Psychiatric Institute. The 
generation of D2R-OEdev mice has been described previously (Kellendonk et al., 2006). TetO-
D2R mice have been backcrossed onto the C57BL/6J background and CaMKIIα-tTA mice 
backcrossed onto the 129SveVTac background. To generate D2R-OEdev mice, tetO-
D2R/C57BL6 mice were crossed to CaMKIIα-tTA/129SveVTac mice. Double transgenic mice 
express the transgenic D2R, and these animals were crossed to Drd2-Cre (ER44Gsat/Mmcd) 
mice, purchased from the Mutant Mice Resource & Research Centers, to obtain the transgenic 
D2R-OE/Drd2-Cre mice. For experiments that included D2R-OEdev animals, controls were 
littermates of D2R-OE/Drd2-Cre mice that were positive for the Cre transgene but negative for 
the TetO or tTa transgenes. For experiments that did not include D2R-OEdev mice, animals were 
Drd2-Cre backcrossed onto the C57BL/6J background. Both male and female adult mice at least 
8-weeks old were used in this study. Mice were housed under a 12:12-hour light:dark cycle in a 
temperature-controlled environment, and all behavioral testing was done during the light cycle. 
Food and water were available ad libitum except for experiments that required restriction. 
Animals were food-deprived when being trained or tested in operant behavioral tasks. During 
such training or testing each animal was restricted to 1.8 g of food per day, provided immediately 
after each operant session. For chronic CNO treatment, mice had ad libitum access to CNO-
treated water instead of regular drinking water. Animals were water-restricted for 16 h prior to 





For viral injection surgeries that did not involve lens implantation, including surgeries 
done for mice used for behavioral assays of motivation and for electrophysiology, mice were 
anesthetized with a mixture of ketamine and xylazine (100 mg/kg and 10 mg/kg) administered by 
intraperitoneal injection. Since viral injection surgeries that included lens implantation last 
longer than suitable for anesthesia with ketamine/xylazine, mice were anesthetized by inhalation 
with isoflurane (3.0% for induction, 1.0% for maintenance) mixed with oxygen (1 L/min) for 
such surgeries. For all surgeries, once anesthetized, animals were placed in a stereotaxic 
apparatus and body temperature was maintained at 37 ˚C with a heating pad. Surgical incisions 
to expose the cranium were made, and small cranial windows (<0.5 mm) were drilled at the 
appropriate sites. Virus was delivered at an average rate of 100 nL/min using glass pipettes (tip 
opening 10-15 µm). All stereotactic coordinates were measured relative to bregma. A total of 
0.4-0.5 µL volume was delivered into each site for all injections. For co-injection of two viruses 
in the case of AAV1-Syn-flexed-GCaMP6F and AAV5/hSyn-DIO-hM4D-mCherry delivered 
into the DMS for calcium imaging, equal volumes of each virus were mixed and loaded into the 
injection pipette. Unless otherwise indicated, two sites of injection were used for bilaterally 
targeting the DMS to allow diffusion of the virus to the entire region (site A: anterior-posterior 
(AP): +1.3 mm, medial-lateral (ML): ±1.4 mm, dorsal-ventral (DV): -3.3; site B: AP +0.9 mm, 
ML ±2.0 mm, DV -3.4 mm). The NA core was targeted bilaterally with one set of coordinates 
(AP: +1.7 mm, ML: ±1.2 mm, DV: 4.0 mm). For calcium imaging in the striatum, the DMS was 
targeted unilaterally using a single injection site (AP: +1.3 mm, ML: ±1.4 mm, DV: -3.3 mm). 
The GPe was targeted unilaterally for calcium imaging with virus injected in discrete pulses 
covering a 0.3-mm distance in the DV axis (AP: 0.0 mm, ML: +1.8 mm, DV: -3.9-4.1 mm). 
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For viral injections accompanied by lens implantation, a microlens composed of a pair of 
gradient refractive index lenses fused to a relay lens was used. A 2-mm cranial window was 
drilled over the intended implantation site, followed by removal of the dura and aspiration of 
portions around the edges of the craniotomy. Following unilateral injection of AAV1-Syn-
GCaMP6F into the GPe or co-injection of AAV1-Syn-flexed-GCaMP6F and AAV5/hSyn-DIO-
hM4D-mCherry into the DMS, as described above, the microlens was lowered into the same site 
used for viral injection with alternate retractions of 0.5 mm for every 1 mm ventral increment to 
allow penetrated tissue to properly settle around the lens. For implants into the DMS, 
microlenses measuring 0.6 mm in diameter and ~7.3mm in length were used, and for implants 
into the GPe, microlenses measuring 0.5 mm in diameter and ~8.4 mm in length were used 
(Inscopix). After implantation, the portion of the lens extending above the skull was fixed in 
place using dental cement and anchored by 3 screws attached to different plates on the skull. The 
lens was covered with a silicone elastomer to protect the imaging surface from external damage. 
The silicone elastomer was removed four weeks after surgery for attachment of a baseplate 
(Inscopix) to support the miniature microscope on each animal’s head. For this procedure, mice 
were once again anesthetized with isoflurane. The silicone mold was removed, and the miniature 
microscope (Inscopix) with a baseplate attached and the 475-nm LED turned on was positioned 
above the implanted lens and lowered with a micromanipulator until fluorescence could be 
detected. Once the microscope was positioned for imaging in an adequate focal plane, the 
magnetic baseplate was cemented around the lens adjoined to the dental cement previously 
placed at the time of surgery. The microscope was subsequently detached and a magnetic cover 





CNO was provided by the National Institutes of Health as part of the National Institutes 
of Mental Health Chemical Synthesis and Drug Supply Program. For behavioral experiments, 
CNO was always dissolved in sterile PBS on the same day it was used for treatment. For acute 
treatment, the drug was always prepared at 0.2 mg/mL and delivered at 2 mg/kg dose by 
intraperitoneal injections 30 minutes prior to a behavioral task, unless otherwise indicated. Saline 
injections for control condition consisted of 0.25 mL sterile PBS. For chronic treatment, CNO 
was dissolved in animals’ regular drinking water at a concentration of 0.25 mg/mL. Animals 
treated with CNO chronically had this CNO solution as their only source of drinking water for at 
least two weeks, to which they had access ad libitum. Except where otherwise indicated, CNO 
solution in the drinking water was freshly-prepared on the day prior to start of chronic treatment, 
and freshly-prepared solution was replenished as needed approximately every 2-4 days for the 
duration of chronic treatment. Vehicle chronic treatment consisted of regular mouse drinking 
water. For acute oral CNO administration, animals were allowed to freely consume CNO 
solution in drinking water at 0.25 mg/mL for 1 h before behavioral testing. Crossover designs for 
drug treatment were used for testing in all behavioral assays, unless otherwise indicated, with 
animals receiving CNO or saline/vehicle on alternate days of testing counterbalancing for 
variables such as genotype, virally-targeted brain region, and sex. CNO solutions used for 
electrophysiology experiments were first dissolved at 1 mM or 100 µM in artificial cerebrospinal 
fluid (ACSF, exact composition described in “In vitro electrophysiology” section) and stored at -
20 ˚C until the day of recording, at which time an aliquot was thawed and diluted 1:100 in 






Training and testing for the progressive ratio schedule of reinforcement were conducted 
similarly to the training and testing conducted for the study presented in Chapter 3, with a few 
differences detailed below. The first exception was that in the current study, mice were never 
subjected to FI schedules. Instead, in order to get animals pressing at high rates, they were 
trained in random interval (RI) schedules. In RI schedule training, the lever remained extended 
throughout the session but lever presses were not reinforced until after a random interval had 
elapsed. Between reinforcements, there was a variable ITI, defined by the RI schedule. All mice 
began on RI 3 s schedule, meaning that the first lever press occurring on average 3 s after start of 
a trial was reinforced. When a mouse earned at least 40 rewards in one session, the RI schedule 
was increased. The RI schedules used were 3 s, 10 s, 15 s, and 20 s. When all mice reached the 
criterion of 40 rewards in one session on the RI 20 s schedule, they began experimental testing 
on the progressive ratio schedule. Mice continued to be trained in RI 20 s sessions for 1-2 days in 
between each progressive ratio session in order to prevent lever pressing behavior from 
extinguishing with the low reinforcement rate characteristic of the progressive ratio schedule. 
Mice were subjected to 1-3 progressive ratio sessions for each condition, and measures for each 
condition were averaged. 
Progressive hold-down 
All mice tested in the progressive hold-down test were subjected to this task after being 
tested in the progressive ratio task. Specific training for the progressive hold-down test consisted 
of variable interval hold-down (VIH) schedules. Each session involved up to 40 trials and, at the 
beginning of each trial, the required hold duration was drawn randomly from a distribution with 
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a mean specified by the session. Each session ended when a mouse successfully completed 40 
trials or when 1 h elapsed. This hold requirement remained in place until the subject was 
reinforced for completing the trial. During the first session, the distribution of required hold 
durations had a mean of 0.5 s (VIH 0.5 s). When all mice in the cohort earned 40 rewards in one 
session, they were moved to the subsequent VIH schedule, following the sequence VIH 0.5 s, 1 
s, 2 s, 4 s, 6 s, 8 s, and 10 s. Animals only started being tested in the progressive hold-down test 
when all subjects in the cohort were able to complete all 40 trials in VIH 10 s. For the 
progressive ratio task, the first required hold duration was fixed at 3 s, and the requirement for 
subsequent hold durations was increased sequentially by a factor of 1.4. The sessions could last 
up to 2 h but ended early if the mouse did not press the lever for 10 minutes. The energizing 
component of motivation was assessed by the number of lever presses made and how long 
subjects continued to respond, while the goal-directed component was assessed by the number of 
rewards earned in a session and the proportion of rewarded presses. Mice were subjected to two 
progressive hold-down sessions for each condition, and measures for each condition were 
averaged. 
Outcome devaluation 
In this task, mice are tested to determine whether or not they are pressing the lever 
because they have formed a habit, or if they are still sensitive to the outcome. The reward is 
therefore devalued by allowing mice to have unlimited access to the reward for a specified time 
period prior to the trial. If mice are truly pressing the lever in order to obtain the reward, they 
should press the lever fewer times throughout the session if they have been exposed to the 
reward beforehand. Here, the valued reward was sweetened evaporated milk, and standard 
mouse chow served as the control. Mice were therefore pre-fed with the valued reward a non-
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valued reward before testing. The mice were then placed in an operant chamber with a lever 
extended, but lever presses were not reinforced throughout the session. Because this non-
reinforced task should extinguish pressing behavior, mice were trained in random ratio (RR) 
sessions for 2-3 days in between devaluation testing days in order to maintain high press rates. In 
an RR schedule there is a constant probability of reinforcement for each lever press. The specific 
schedule used, RR 20, required that the animal press the lever on average 20 times before 
receiving a reward.  
On outcome devaluation testing days, mice were first pre-fed with either the valued 
reward (sweetened evaporated milk) for 30 min or laboratory chow – a control food which they 
had never been trained to associate as a reward for lever pressing – for 1 h. Mice were only given 
30 min of access to the valued reward in order to prevent complete satiation with milk, which 
might have resulted in complete loss of motivation to obtain the reward during the session. All 
mice were single-housed during pre-feeding.  After 1 h passed from the start of pre-feeding, mice 
were treated with either CNO or saline. Thirty minutes after the injection, mice were placed in an 
operant chamber with an extended lever for 15 minutes without ever receiving a reward. Testing 
occurred on four different days in a randomized design so that each mouse received each 
experimental manipulation once (pre-feeding with milk or chow and injected with either an acute 
CNO or saline injection). The number of lever presses made in each session was measured for 
assessment of outcome devaluation. 
Open field 
For experiments that did not involve calcium imaging, exploration and reactivity to an 
open field was assessed in acrylic activity chambers (42 cm long × 42 cm wide × 38 cm high) 
equipped with infrared photobeams for motion detection (Kinder Scientific). Mice were placed 
109 
 
in the open field, and activity was automatically recorded for a specified amount of time (90 or 
120 min). The open field system was programmed to interrupt recording 20 or 30 min after the 
start, at which point mice were administered CNO or saline and placed back in the open field. 
Recording of locomotor activity resumed immediately after injections. 
For calcium imaging experiments, cellular activity and locomotor activity were 
simultaneously measured while animals moved freely in an open field. Before each imaging 
session, the miniature microscope was connected to the magnetic baseplate attached to each 
animal’s cranium and fixed in place by the baseplate screw set while the mouse was briefly 
anesthetized with isoflurane. Each animal was placed back into its home cage for 20 min to 
recover from anesthesia before drug injection or imaging. For imaging sessions, mice were place 
in acrylic activity chambers (42 cm long × 42 cm wide × 38 cm high) less than 1 min before 
optical recording with the miniature microscope was initiated. The Ethovision XT system 
(Noldus) was used to trigger both start and end of recording sessions using a TTL pulse 
converter. This software was also used to track each animal’s locomotor activity using a video 
camera placed over the open field area.  
Histology and immunohistochemistry 
For all histological analysis of brain tissue following behavioral experiments, mice were 
anesthetized with a mixture of ketamine and xylazine (100 mg/kg and 10mg/kg, respectively), 
delivered by intraperitoneal injection, and transcardially perfused, first with PBS and then with 
4% paraformaldehyde (PFA). Following perfusion, brains were post-fixed in 4% PFA for 24 
hours, and then transferred to PBS. Brains were then sliced into 50-μm sagittal or coronal 
sections using a vibratome and every section was collected. Immunohistochemistry using 
fluorescence was performed on these free-floating sections by treating sections first with 
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blocking buffer (0.5% bovine serum albumin, 5% horse serum, 0.2% Triton X-100), followed by 
overnight incubation with one or more primary antibody and subsequently with the appropriate 
secondary antibody conjugated to a fluorophore. The primary antibodies used included rabbit 
anti-DsRed (1:250, Clontech, cat. 632496), mouse anti-RFP (1:1000, Abcam, cat. AB65856), 
rabbit anti-Cre (1:2000 (Kellendonk et al., 1999)), and goat anti-ChAT (1:100, Millipore, cat. 
AB144P). Sections were washed with 0.2% Triton X-100 in between primary and secondary 
antibody incubations and with 50 mM Tris-Cl pH 7.4 before mounting. Sections were mounted 
on glass slides and subsequently coverslipped for imaging with VectaShield containing DAPI 
(Vector Labs). For confirmation of spread of viral infection in targeted structures, images were 
acquired at 2.5x magnification using a Hamamatsu camera attached to a Carl Zeiss 
epifluorescence microscope. For analysis of co-expression of fluorescent and immune-labelled 
proteins, images were acquired at 20x or 40x using a Nikon Ti Eclipse inverted microscope for 
scanning confocal microscopy. Micrographs were processed using ImageJ software (National 
Institutes of Health). 
In vitro electrophysiology 
Mice injected with AAV5/hSyn-DIO-hM4D-mCherry into the DMS, were sacrificed four 
weeks after surgery by rapid decapitation and brains were harvested into ice-cold, oxygenated 
ACSF containing 1.25 mM NaH2PO4, 2.5 KCl mM, 10 mM glucose, 26.2 mM NaHCO3, 126 
NaCl mM, 2 CaCl2 mM and 2 MgCl2 mM (pH 7.4, 300–310 mOsm). Coronal sections (300 µm 
thick) containing striatum were cut using a vibratome in ice-cold oxygenated ACSF and 
incubated at 32 °C for 30 min, followed by at least 30 min incubation at room temperature before 
recordings. Voltage- and current-clamp whole-cell recordings were performed using standard 
techniques (Cazorla et al., 2012). Electrode resistance was 3-6 MΩ when filled with internal 
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solution composed of 130 mM K+-gluconate, 5 mM NaCl, 10 mM HEPES, 0.5 mM EGTA, 2.0 
mM Mg+-ATP, and 0.3 mM Na+-GTP (pH 7.3, 280 mOsm). Cells expressing the hM4D receptor 
in the striatum were identified by mCherry fluorescence under epifluorescence microscopy. 
Measures of excitability were obtained by injecting 500-ms currents ranging from -150 to 350 
pA in 20 pA steps. The resting membrane potential was determined from this protocol as each 
patched cell’s potential with 0 pA current. Rheobase was determined as the minimal injected 
current that resulted in an action potential. Spike frequency was determined from the initial pair 
of action potentials as previously described (Cazorla et al., 2012). For each cell patched, 
measures of excitability were obtained 5 min after the cell was patched first with ACSF in the 
bath and then 15 min after maintaining ACSF in the bath solution or exchanging the bath 
solution to 1 µM CNO or 10 µM CNO diluted in ACSF. 
Data analysis and statistics 
All data collected in the current study were processed with Excel (Microsoft) or with 
custom scripts and functions written with MATLAB (Mathworks). Statistical analyses were done 
with either one of the latter software or with Prism 5 (GraphPad). All statistical tests were 2-
tailed and alpha level was set to 0.05. 
For operant tests of motivation, the behavioral measures used for analysis included the 
total number of lever presses and reinforcers earned in a session for the progressive ratio and 
progressive hold-down tests. For outcome devaluation tests, total number of lever presses made 
in a session was the parameter analyzed. To compare normally-distributed parameters, such as 
number of lever presses and reinforcers earned, under different conditions, repeated measures 
analysis of variance (ANOVA) tests were used to test for statistical significance. The log-rank 
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Mantel-Cox test, a nonparametric statistical test, was used to compare whether or not the 
independent variables significantly affected session durations. 
To analyze the effect of drug on locomotor activity in an open field, the sums of the total 
ambulatory distance from a time point 30 min after i.p. injection until the end of each session 
were obtained. These measures were tested for statistical significance using repeated measures 
ANOVA tests. 
Calcium imaging recordings acquired at 15-20 Hz were processed using Mosaic 
(Inscopix). First, movies were spatially down-sampled using a spatial binning factor of 4 to 
reduce the large file size and decrease processing time. To correct for brain movement, all 
frames in movie sequences acquired from the same mouse and same focal place were registered 
to one single frame. Multiple movies sequences registered to the same frame were then 
concatenated in time and a sub-region within the field of view in the concatenated movie was 
cropped in order to remove post-registration black borders. Using the mean z-projection image of 
the entire movie as reference (FO) to normalize fluorescence signals to the average fluorescence 
of the entire frame, a movie representing percent-change-over-baseline (ΔF/FO) was generated. 
The ΔF/FO movie was temporally binned by a factor of 4. Calcium transients from individual 
cells were isolated and identified with an automated cell-sorting algorithm that employs 
independent and principal component analyses of each ΔF/FO movie. The independent 
components identified by the algorithms were visually inspected for spatial configuration and 
temporal properties of calcium traces and those that appeared like calcium transients from 
individual cell bodies were used for further analysis. These raw calcium traces for each cell 
measured as z-scores over the entire time recorded were separated into 12-s time bins for 
statistical analysis. For individual cell analysis, the sums of calcium activity in 12-s bins 
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measured from each 5-min recording session done after treatment with either saline or CNO – or 
after two treatments with saline – were compared using one-factor ANOVA tests. Cells that 
displayed significant increases or decreases in activity in between sessions were identified and 
the proportions of significantly changed and unchanged cells were used in a chi-squared test to 
determine whether these proportions were expected by chance. Additional analyses were done 
for data obtained from calcium imaging in the striatum after thresholding the raw traces to obtain 
estimates of individual calcium events. The sums of these events (either counting each event as a 
single unit or summing the z-scores for each event) were obtained in 12-s bins. Since the latter 
data sets were not normally distributed, individual cell analyses were performed using the non-
parametric Wilcoxon rank sum test to identify cells that showed significantly decreased or 
increased calcium activity after treatment with either saline or CNO – or after two treatments 
with saline. Proportions of significantly changed and unchanged cells were compared using the 




ACUTE BEHAVIORAL EFFECTS OF DECREASING INDIRECT-PATHWAY FUNCTION 
The D2R-OEdev mouse overexpress D2Rs selectively in striatal MSNs and exhibit a 
deficit in motivation (Kellendonk et al., 2006, Drew et al., 2007). Since chronic upregulation of 
striatal D2Rs leads to increased excitability of MSNs (Cazorla et al., 2012), I questioned whether 
an increase in iMSN function in D2R-OEdev mice could explain the motivational deficit induced 
by developmental D2R upregulation in the striatum. I therefore expressed hM4D receptors in 
indirect-pathway MSNs of the DMS and NA core of Drd2-Cre/D2R-OEdev mice and Drd2-Cre 
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control littermates. The hM4D protein is a genetically modified Gαi-coupled receptor that can no 
longer be activated by endogenous ligands, but instead can be activated by CNO (Armbruster et 
al., 2007). Activation of hM4D in the indirect pathway of the rat has been shown to decrease 
excitability of MSNs (Ferguson et al., 2011). Thus, I attempted to use this chemogenetic 
approach to study how activating Gαi signaling, and presumably decreasing excitability and 
function, of the indirect pathway acutely would affect motivation D2R-OEdev and control mice. 
To study the behavioral consequences of acutely activating Gαi signaling in the indirect 
pathway of D2R-OEdev mice and control littermates, I selectively targeted iMSNs in the DMS 
and NA core, sub-regions of the striatum known to support motivated behavior (Corbit and 
Balleine, 2011, Hilario et al., 
2012, Burton et al., 2015). I 
injected Drd2-Cre mice with 
an AAV vector for Cre-
dependent expression of the 
hM4D receptor. The virus was 
delivered bilaterally to target 
either the medial striatum, 
encompassing both DMS and 
NA core (Figure 20B), or each 
of these striatal sub-regions 
separately (Figures 20C-D). 
The hM4D protein expressed 
virally is fused to the 
Figure 20: The Gαi-coupled designer receptor hM4D can be 
expressed selectively in specific striatal regions. A. Diagram of 
coronal section showing targeted injection sites in DMS and NA. B. 
Coronal section micrograph showing hM4D-mCherry expression in 
the DMS and NA core of Drd2-Cre mouse. Scale bar: 1 mm. C. 
Sagittal section micrograph showing hM4D-mCherry expression in 
the DMS, as well as immune-positive axon terminals present in the 
GPe and absent in the SNr. Scale bar: 1 mm. E. Sagittal section 
micrograph showing hM4D-mCherry expression in the NA core and 
axon terminals in the VP. Scale bar: 1 mm.  
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fluorophore mCherry, allowing for detection of the subcellular localization of the receptor by 
probing for mCherry. Expression of hM4D receptor in the injected sites was observed at the 
soma and dendrites of infected cells. In addition, hM4D expression was also observed in the 
neuropil and in regions where axons of iMSNs terminate: the GPe, in the case of animals 
injected in the DMS (Figure 20C), and the VP, in the case of animals injected in the NA core 
(Figure 20D). No fluorescence signal was observed in the output nuclei of the direct pathway, 
the SNr and GPi, in animals injected in the DMS (Figure 20C), evidencing that expression was 
restricted to iMSNs, as these neurons are known to only project to the GPe (Gerfen and 
Surmeier, 2011). 
I also quantified the selectivity of this expression system by immunohistochemistry. Co-
staining for hM4D and Cre revealed that 95% of hM4D-positive cells were also immune-positive 
for Cre, and the efficiency of transfection was also high, as 86% of Cre-positive cells within the 
constraints of the virally-infected region were immune-positive for hM4D (Figure 21A). 
Cholinergic interneurons that represent less than 2% of neurons in the striatum are also known to 
Figure 21: The Gαi-coupled designer receptor hM4D can be expressed selectively in iMSNs. A. 
Micrograph of immunostained striatal tissue from Drd2-Cre mouse expressing hM4D-mCherry (red) in 
neurons that also express Cre (green); 95% of mCherry-positive neurons are also Cre-positive and 86% of 
Cre-positive neurons in virally-targeted region are positive for hM4D-mCherry (n = 175 cells). Scale bar: 
50 µm. B. Micrograph of striatal tissue from Drd2-Cre mouse immunostained for hM4D-mCherry (red) 
and the marker for cholinergic neurons, ChAT; 5% of ChAT-positive neurons express hM4D-mCherry in 
virally-targeted region (n = 110 cells). Scale bar: 100 µm. 
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Figure 22: Motivational deficit of D2R-OEdev mice can be reproduced in animals expressing hM4D 
in iMSNs. At baseline without any drug treatment, D2R-OEdev expressing hM4D in iMSNs show 
impaired performance in the progressive ratio task of motivation compared to control animals, as 
measured by (A) the survival functions for session durations (p = 0.0121) and (B) the total number of 
reinforcers earned in a session (p = 0.0140). A total of 11 D2R-OEdev mice and 11 control mice were 
assayed for this analysis. 
express D2Rs (Dawson et al., 1990). I therefore quantified what proportion of these interneurons 
also expressed hM4D in our viral transfection system. I found that only 5% of neurons positive 
for choline acetyltransferase (ChAT), a marker for cholinergic interneurons, were also immune-
positive for hM4D in the virally-infected region (Figure 21B), in agreement with previous results 
using this BAC transgene Cre mouse line (Kravitz et al., 2010). Hence, I demonstrated that I can 
selectively and efficiently express hM4D receptors in the striatal indirect pathway and that these 
receptors localize to both somatic and axonal regions of MSNs. 
To test for the effect of hM4D receptor activation in the indirect pathway of mice 
chronically overexpressing striatal D2Rs, I trained Drd2-Cre/D2R-OEdev mice and Drd2-Cre 
control littermates expressing Cre-dependent hM4D in the DMS and NA core to press a lever to 
earn a food reward. Once all animals were adequately trained, they were tested in a progressive 
ratio schedule of reinforcement, a test of motivation that measures how much effort an animal is 
willing to expend to obtain a reward. I used a specific progressive ratio schedule in which the 
lever press requirement doubled with each successive reward.  
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I first tested whether I could measure the motivation deficit of D2R-OEdev mice in our 
experimental system. I confirmed the previously reported impairment in performance of D2R-
OEdev mice in the progressive ratio task, as D2R-OEdev stopped responding sooner than control 
littermates (Log-rank test: χ² = 4.235, p = 0.0121, n = 11 mice) and earned fewer rewards (t(20) = 
2.692, p = 0.0140; n = 11 mice) (Figure 22) (Drew et al., 2007).  
I then retested the animals after treatment with saline or CNO using a within-group 
Figure 23: Decreasing function of indirect pathway increases motivation in D2R-OEdev and control 
littermates. A-C. Both D2R-OEdev and control mice expressing hM4D in iMSNs in the DMS and NA core 
show enhanced performance in the progressive ratio test of motivation after treatment with CNO compared to 
saline, as measured by (A) survival functions for session duration (D2R-OEdev: p < 0.0001; control: p = 
0.0019), (B) total number of lever presses made (p < 0.001), and (C) total number of reinforcers earned (p < 
0.001). A-C. When comparing performance between genotypes after treatment with CNO in the progressive 
ratio test, (A) D2R-OEdev continued to respond in the task for shorter times (p < 0.0012), (B) made fewer total 
lever presses (p < 0.0101, Bonferroni post hoc test: p < 0.001) and (C) earned fewer reinforcers (p < 0.0119, 
Bonferroni post hoc test, p < 0.01) per session compared to control littermates. Analysis of animals’ press rate 
per ratio requirement show that subjects of either genotype did not exhibit a general increase in rate of 
pressing when treated with CNO compared to saline (D) (p = 0.1446). A total of 12 D2R-OEdev mice and 12 
control mice were assayed for this analysis. 
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design in which animals received treatment with saline or CNO on alternate days of testing. I 
found that D2R-OEdev mice continued to respond by pressing a lever for significantly longer 
times after treatment with CNO compared to treatment with saline (Log-rank test: χ² = 19.56, p < 
0.0001, Log-rank test; n = 12 mice) (Figure 23A). Control littermates also responded to CNO 
treatment by continuing to press the lever for longer times compared to the saline control 
condition (χ² = 9.671, p = 0.0019, Log-rank test; n = 12 mice) (Figure 23A). Both D2R-OEdev 
and control animals showed increased total number of lever presses in sessions after CNO 
treatment compared to saline treatment (F(1,22) = 69.21, p < 0.001; n = 12 mice per genotype) 
(Figure 23B). Consistent with these results, both D2R-OEdev and control mice also earned more 
reinforcers after treatment with CNO compared with saline (F(1,22) = 65.49, p < 0.001; n = 12 
mice per genotype) (Figure 23C). Moreover, although mice in both groups showed enhanced 
performance in the progressive ratio task after CNO treatment, this enhancement cannot be 
attributed to a general increased rate of pressing because, for each ratio requirement, mice in 
both groups showed unaltered press rates after treatment with CNO when compared with saline 
(F(1,44) = 1.894, p = 0.1446; n = 12 mice per genotype) (Figure 23D). However, while CNO 
robustly enhanced motivation in both groups, D2R-OEdev still displayed decreased performance 
in the task compared to control littermates after acute treatment with the drug, as measured by 
how long animals continued to respond in the task (χ² = 10.49, p < 0.0012, Log-rank test; n = 12 
per genotype) (Figure 23A), the number of lever presses made (F(1,22) = 7.912, p < 0.0101, 
Bonferroni post hoc test, p < 0.001, n = 12 per genotype) (Figure 23B), and the number of 
reinforcers earned (F(1,22) = 7.526, p < 0.0119, Bonferroni post hoc test, p < 0.01, n = 12 per 
genotype) (Figure 23C).  
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The indirect pathway of the basal ganglia has been strongly linked to regulation of motor 
behaviors (Lenz and Lobo, 2013) and optogenetic activation of MSNs expressing D2Rs inhibit 
motor activity, (Kravitz et al., 2010). Thus, I hypothesized that acutely activating hM4D 
receptors in iMSNs in the DMS and NA core would also energize motor behavior. To test this 
hypothesis, I tracked locomotion of D2R-OEdev and control littermates expressing hM4D in 
iMSNs before and after treatment with CNO or saline. I found that both D2R-OEdev and control 
littermates showed increased ambulation after treatment with CNO (F(1,22) = 32.36, p < 0.0001; 
12 mice per genotype), which peaked approximately 30 min after drug injection and remained 
elevated for the remainder of the testing session (Figure 24). There were, however, no 
differences between D2R-OEdev mice and control littermates in their locomotor response to CNO 
(F(1,22) = 1.388, p = 0.2513; 12 mice per genotype) (Figure 24). 
Figure 24: Decreasing function of indirect pathway increases locomotion in D2R-OEdev and control 
littermates. Plot of locomotion in open field across time showed that both D2R-OEdev and control mice 
increased ambulatory activity after treatment with CNO compared to saline (p < 0.0001). The increase in 
locomotion reached maximum level approximately 30 min after injection with CNO for mice of both 
genotypes. No difference was observed between D2R-OEdev and control littermates in their response to 





motivation is thought to consist 
of at least two components. Both 
changes in directional action 
selection, the goal-directed 
component, and changes in 
arousal, the activational 
component, can lead to changes 
in motivation measured by 
behavioral tasks such as the 
progressive ratio schedule of 
reinforcement (Salamone and 
Correa, 2002, Bailey et al., 
2015). Given that activating 
hM4D receptors in iMSNs leads 
to hyperactivity in the open field 
and enhanced performance in 
the progressive ratio task, I 
questioned whether this manipulation differentially affects the directional and activational 
components of motivation. To this end, I  tested these animals in the progressive hold-down task, 
which requires animals to hold-down a lever for progressively longer intervals of time to earn 
each subsequent reward (Bailey et al., 2015). During training, both D2R-OEdev and control mice 
Figure 25: Both D2R-OEdev mice and control littermates can 
learn to hold down a lever to obtain a food reward. Before 
testing in the progressive hold-down test, mice were trained to hold 
down a lever to obtain a food reward. Animals underwent daily 
VIH sessions in which the mean hold requirement increased 
progressively from 0.5 s to 10 s; each session ended when 40 trials 
were completed or when 1 h elapsed. On transitions to more 
difficult VIH schedules, mice tended to show decreased 
performance, requiring a greater number of lever presses to 
complete the trials, but efficiency improved with repeated training 
in the same schedule. Both D2R-OEdev and control mice showed 
similar progression of efficiency throughout training, measured by 
the number of lever presses made during a session for different VIH 
schedules (p = 0.1066). Mice of both genotypes were able to 
complete all 40 trials in the VIH 10 s schedule before being tested 
in the progressive hold-down test. A total of 12 D2R-OEdev mice 
and 12 control mice were assayed for this analysis. 
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showed similar learning curves (F(1,21) = 2.842, p = 0.1066, n = 12 mice per genotype) and were 
able to successfully learn to hold-down a lever to obtain a food reward (Figure 25). 
When tested on the progressive hold-down task after acute treatment with CNO or saline, 
both D2R-OEdev mice and control littermates responded to acute treatment with CNO by 
continuing to engage in the task for longer times (Log-rank tests: control: χ² = 12.02, p = 0.005; 
D2R-OEdev: χ² = 21.23, p < 0.0001, n = 12 mice per genotype) (Figure 26A). However, after 
acute treatment with CNO, mice of both genotypes also showed reduced efficiency at making 
longer presses, as confirmed by calculating the proportion of rewarded presses per hold 
requirement; this measure was decreased at hold requirements of 8.2 s and longer when mice 
were treated with CNO compared to saline (F(1,21) = 7.080, p = 0.0143; n = 12 mice per 
genotype) (Figure 26B). Consistent with reduced efficiency, both D2R-OEdev and control mice 
made more lever presses (F(1,21) = 44.82, p < 0.0001; n = 12 mice per genotype) (Figure 26C) and 
earned fewer rewards after treatment with CNO (F(1,21) = 31.92, p < 0.0001; n = 12 mice per 
genotype) (Figure 26D). Figure 26E shows representative histograms of press durations on 
different days of testing for one subject. While this mouse made progressively longer presses on 
saline treatment days, it made generally shorter presses and a greater number of presses on days 
when it was treated with CNO. These results demonstrate that activating Gαi signaling in iMSNs 
in the DMS and NA core leads to increased motivation by energizing behavioral performance at 





Figure 26: Decreasing function of indirect pathway energizes behavioral performance at the 
expense of goal-directed efficiency. A-D. D2R-OEdev and control littermates expressing hM4D in 
iMSNs show decreased efficiency in the progressive hold-down test after treatment with CNO compared 
to saline. A. Mice of both genotypes continued to respond for longer times on CNO compared to saline, 
as measured by survival functions for session durations (control: p = 0.005; D2R-OEdev: p < 0.0001). B. 
For each hold requirement, mice treated with CNO showed lower efficiency in responding compared to 
treatment with saline, as measured by the proportion of rewarded presses (p = 0.0143) C-D. Other 
behavioral parameters of the progressive hold-down task also demonstrate that both D2R-OEdev and 
control mice expressing hM4D in iMSNs were less efficient after treatment with CNO: (C) mice on CNO 
made a greater number of lever presses (p < 0.0001) and (D) earned fewer reinforcers (p < 0.0001) in a 
session compared to performance after treatment with saline. E. Histograms of press durations on 
different days of testing for one representative subject: while this mouse made progressively longer 
presses on saline treatment days, it made generally shorter presses and a greater number of presses on 




In the results presented above, all manipulations targeted both the DMS and NA core, 
medial regions of the striatum that have been specifically shown to support incentive motivation 
in instrumental tasks of reinforcement (Corbit and Balleine, 2011, Hilario et al., 2012, Burton et 
al., 2015). I therefore sought to determine the contribution of each of these regions to the effects 
on motivation of acutely decreasing function of the indirect pathway. I injected the Cre-
dependent hM4D virus in Drd2-Cre mice bilaterally in either the DMS or NA core and then 
trained and tested these animals in the progressive ratio task. I found that there was no difference 
in the response to CNO between mice expressing the hM4D receptor in the DMS or NA core. 
After treatment with CNO, both groups showed no significant differences in how long they 
Figure 27: Inhibiting the indirect pathway in either DMS or NA core leads to enhanced motivation. 
A-C. Mice expressing hM4D in iMSNs selectively in the DMS or NA show enhanced performance in the 
progressive ratio task of motivation after treatment with CNO compared to saline, as measured by (A) 
survival functions for session duration (DMS and NA: p = 0.0183), (B) total number of lever presses 
made (p = 0.0014), and (C) total number of reinforcers earned (p = 0.0003) in a session. There were also 
no differences in the relative responses to CNO between animals expressing hM4D in iMSNs in the DMS 
and those expressing hM4D in the NA core, as measured by (A) survival functions for session duration (p 
= 0.7547), (B) total number of lever presses made (p = 0.7723), and (C) total number of reinforcers 
earned (p = 0.8038). D-E. Plot of animals’ press rate per ratio requirement show that CNO treatment did 
not lead to increased rate of pressing in animals expressing hM4D in either (D) the DMS (p = 0.9422) or 
(E) the NA core (p = 0.7126). A total of 8 mice expressing hM4D in iMSNs in the DMS and 9 mice 
expressing hM4D in iMSNs in the NA core were used for this analysis. 
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continued to engage in the task (Log-rank test: χ² = 0.09760, p = 0.7547, n = 8-9 mice per site) 
(Figure 27A), the total number of lever presses they made (F(1,15) = 0.08685, p = 0.7723 n = 8-9 
mice per site) (Figure 27B), or the total number reinforcers they earned (F(1,15) = 0.1355, p = 
0.8038; n = 8-9 mice per site) (Figure 27C). Moreover, as observed for mice expressing hM4D in 
both DMS and NA core, the response to CNO in mice expressing hM4D separately in each 
striatal sub-region cannot be attributed to higher rates of pressing: for each ratio requirement 
reached by all animals in the study, mice in each group showed similar rates of lever pressing 
after treatment with CNO or saline (DMS: F(1,14) = 0.005455, p = 0.9422, n = 8 mice; NA core: 
F(1,16) = 0.1406, p = 0.7126, n = 9 mice) (Figures 27D-E). 
A comparison of the responses to CNO treatment across experiments, including Drd2-
Cre animals expressing hM4D in both DMS and NA core or in each region separately are 
presented in Figure 28. It is clear that decreasing function of iMSNs in either region separately 
led to smaller effects than those of manipulation to both regions combined, as measured by 
parameters such as session duration (F(2,25) = 7.496, p = 0.0028, Dunnett post hoc tests: DMS: p < 
Figure 28: Inhibiting the indirect pathway in both DMS and NA core has larger effect on 
motivation than separate inhibition of either DMS or NA core. When comparing results across 
experiments (i.e. the effect of response to CNO when expressing hM4D in both the DMS and NA core 
compared to expressing hM4D in each of these sub-regions selectively), it can be seen that the response 
to CNO when hM4D was expressed in both NA and DMS was greater than when hM4D was expressed 
selective in either striatal sub-region, as measured by (A) session duration (p = 0.0028, Dunnett post hoc 
tests: DMS: p < 0.05, NA core: p < 0.001), (B) number of lever presses (p = 0.0155, Dunnett post hoc 
tests: DMS: p < 0.05, NA core: p < 0.05), and (C) number of reinforcers earned (p = 0.0187; Dunnett post 
hoc tests: NA core: p < 0.05). ). A total of 11 mice expressing hM4D in iMSNs in both the DMS and NA 
core, 8 mice expressing hM4D in iMSNs only in the DMS, and 9 mice expressing hM4D in iMSNs only 
in the NA core were used for this analysis. 
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0.05, NA core: p < 0.001; n = 8-11 mice per site) (Figure 28A), lever presses (F(2,25) = 4.950, p = 
0.0155, Dunnett post hoc tests: DMS: p < 0.05, NA core: p < 0.05; n = 8-11 mice per site) 
(Figure 28B), and number of reinforcers earned (F(2,25) = 4.683, p = 0.0187; Dunnett post hoc 
tests: NA core: p < 0.05; n = 8-11 mice per site) (Figure 28C).  
I also investigated the contributions of the DMS and NA core to the locomotor effect of 
acutely decreasing function of the indirect pathway. As shown in Figure 29, I tracked locomotor 
Figure 29: Mice expressing hM4D receptors in iMSNs in either DMS or NA core respond to 
acute CNO treatment with increased locomotion. A. Plot of locomotor activity in 5-min time bins 
of mice expressing hM4D in the DMS before and after receiving acute treatment with either saline or 
CNO. Animals displayed increased locomotion after treatment with CNO but not with saline (p = 
0.0141). The effect peaked approximately 30 min after injection and persisted through the remainder 
of the testing session B. Plot of locomotor activity in 5-min time bins of mice expressing hM4D in the 
NA core before and after receiving acute treatment with either saline or CNO. Animals displayed 
increased locomotion after treatment with CNO but not with saline (p = 0.0102). The effect peaked 
approximately 30 min after injection and persisted through the remainder of the testing session. C. 
Mice expressing hM4D in iMSNs in either the DMS or NA core responded to acute CNO treatment 
with increased ambulatory activity compared to baseline before drug administration (p = 0.0002). 
There was no difference in the relative response to CNO between animals expressing hM4D in the 
DMS compared to those expressing hM4D in the NA core (p = 0.6162).  A total of 8 mice expressing 




Figure 30: Activating hM4D receptors in iMSNs in the DMS or 
NA core does not affect sensitivity to reward value. In a test of 
outcome devaluation, compared to a control condition in which 
mice were pre-fed chow, a food that had never been previously 
associated with lever pressing, mice in all groups showed similar 
decreased rates of pressing after pre-feeding with evaporated milk 
and treatment with CNO or saline (pre-feeding: p < 0.0001; striatal 
sub-region: p = 0.0790). A total of 8 mice expressing hM4D in 
iMSNs in the DMS and 9 mice expressing hM4D in iMSNs in the 
NA core were used for this analysis. 
activity of Drd2-Cre mice expressing hM4D in either the DMS or NA core before and after 
treatment with CNO or saline. The kinetics of the effects CNO on locomotion with this sub-
region-selective manipulation appeared to be similar to that observed in mice expressing the 
hM4D receptor in both striatal sub-regions (Figures 29A-B, compare to Figure 24). Moreover, I 
observed that animals in both groups displayed increased ambulatory activity after treatment 
with CNO (F(1,15) = 22.96, p = 0.0002; n = 8-9 mice per site) (Figure 29C). There was no 
difference in the relative effects on CNO for mice expressing the hM4D receptor in the DMS 
compared to the NA core (F(1,15) = 0.6162, p = 0.6162; n = 8-9 mice per site) (Figure 29C). 
I then tested whether 
after activating Gαi signaling in 
the striatal indirect pathway 
mice are still sensitive to the 
value of a reward or whether 
this manipulation causes 
animals to become habit-driven. 
Since all animals expressing 
hM4D in the DMS or NA core 
were trained to press a lever to 
obtain evaporated milk as a 
food reward, I tested whether 
decreasing the value of the 
reward by pre-feeding animals 
with evaporated milk would 
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decrease their rate of operant responding in extinction trials. Specifically, I was interested in 
determining if CNO treatment could affect the animals’ ability to encode the value of the reward. 
I found that, compared to a control condition in which mice were pre-fed chow, a food that had 
never been previously associated with lever pressing, mice in all groups showed similar 
decreased lever pressing after pre-feeding with evaporated milk and treatment with CNO or 
saline (pre-feeding: F(3,1) = 23.95, p < 0.0001; striatal sub-region: F(3,1) = 2.392, p = 0.0790; n = 
8-9 mice per site) (Figure 30). This finding suggests that activating Gαi signaling in iMSNs in the 
DMS or NA core does not affect how animals encode the value of the reward. It further suggests 
that these mice are still sensitive to changes in the value of the reward and do not become habit-
driven after treatment with CNO. 
 
ELECTROPHYSIOLOGICAL EFFECTS ON EXCITABILITY 
We then investigated how acute hM4D activation affects neuronal function of the indirect 
pathway. Gαi-coupled GPCRs have been shown to activate a family of inwardly-rectifying 
potassium, the GIRK channels, to evoke inhibitory currents in many cells types (Luscher and 
Slesinger, 2010). In neurons with high levels of GIRK channels, such as the thalamus, it has been 
previously observed in the Kellendonk laboratory that the resting membrane potential of neurons 
expressing hM4D decreases by approximately 7 mV when 1 µM CNO is applied to the bath 
(Parnaudeau et al., 2013). In the striatum, one study in rats found that bath application of CNO to 
acute slices similarly reduced resting membrane potential as well as the spike frequency of 
hM4D-positive iMSNs (Ferguson et al., 2011). To determine whether hM4D activation also 
affects iMSN excitability in the mouse, I patched iMSNs expressing the hM4D receptor in acute 
slices and measured intrinsic excitability properties of these neurons before and after applying 
CNO to the bath. I found no effect of 1 µM or 10 µM CNO on the current-voltage relationship (1 
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µM: F(1,8) = 0.0092, p = 0.9258, n = 6 cells; 10 µM: F(1,14)  = 0.001789, p = 0.9669, n = 8 cells), 
spike frequency (1 µM: F(1,10) = 0.4561, p = 0.5148, n = 6 cells; 10 µM: F(1,14) = 0.006540; p = 
0.9367, n = 8 cells), resting membrane potential (1 µM: t(8) = 0.5527, p = 0.5956, n = 6 cells; 10 
µM: t(12) = 0.5307, p = 0.6053, n = 8 cells), or rheobase (1 µM: t(5) = 1.400, p = 0.2204, n = 6 
cells; 10 µM: t(7) = 0.4213, p = 0.6852, n = 8 cells) in the neurons recorded (Figures 31-32).  
These findings suggest that Gαi signaling in iMSNs does not change intrinsic excitability 
Figure 31: Membrane excitability properties at the soma of iMSNs expressing hM4D are not 
changed in vitro by treatment with CNO (part 1). A-C. Sample traces of voltage response of patched 
cells to injection of 280 pA current in regular ACSF and after incubation for 15 min with (A) regular 
ACSF, (B) 1 µM CNO, or (C) 10 µM CNO. D-F. Current-voltage curves of all cells patched in regular 
ACSF and after incubation for 15 min with (D) regular ACSF, (E) 1 µM CNO, or (F) 10 µM CNO. No 
differences were observed between curves obtained before and after incubation with (D) regular ACSF (p 
= 0.7387), (E) 1 µM CNO (p = 0.9258), or (F) 10 µM CNO (p = 0.9669).  G-I. Input-output curves of all 
cells patched in regular ACSF and after incubation for 15 min with regular (G) ACSF, (H) 1 µM CNO, or 
(I) 10 µM CNO. No differences were observed between curves obtained before and after incubation with 
(G) regular ACSF (p = 0.2981), (H) 1 µM CNO (p = 0.5148), or (I) 10 µM CNO (p = 0.9367). A total of 
25 hM4D-positive cells from 16 mice were patched (6-11 cells from 6-8 mice per drug condition) to 
calculate all statistics reported above. 
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measured at the cellular soma. Instead, Bock et al. have used slice physiology to show that 
stimulation of iMSNs exposed to CNO leads to decreased amplitude of inhibitory post-synaptic 
currents in pallidal neurons (Bock et al., 2013), a finding that has been recently replicated in the 
Kellendonk laboratory. 
 
SOMATIC EFFECTS ON NEURONAL ACTIVITY IN THE INTACT ORGANISM 
I then used in vivo calcium imaging to probe how neurons at different nodes in the 
indirect pathway respond to activation of hM4D. I first co-expressed the hM4D receptor and the 
calcium sensor GCaMP6f in a small region of the DMS of Drd2-Cre mice. The selectivity of this 
manipulation is presented in Figure 33. Using immunohistochemistry, I confirmed that 
Figure 32: Membrane excitability properties at the soma of iMSNs expressing hM4D are not 
changed in vitro by treatment with CNO (part 2). A-C. Resting membrane potential for all cells 
patched in regular ACSF or after incubation for 15 min with (A) regular ACSF, (B) 1 µM CNO, or (C) 10 
µM CNO. No differences were observed for the resting membrane potential of cells measured before and 
after incubation with (A) regular ACSF (p = 0.7380), (B) 1 µM CNO (p = 0.5956), or (C) 10 µM CNO 
(p = 0.6053). M-O. Rheobase calculated for all cells patched in regular ACSF or after incubation for 15 
min with (D) regular ACSF, (E) 1 µM CNO, or (F) 10 µM CNO. No differences were observed between 
rheobase calculated before and after incubation with (D) regular ACSF (p = 0.1038), (E) 1 µM CNO (p = 
0.2204), or (F) 10 µM CNO (p = 0.6852). A total of 25 hM4D-positive cells from 16 mice were patched 
(6-11 cells from 6-8 mice per drug condition) to calculate all statistics reported above. 
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GCaMP6f was only expressed 
in cells immune-positive for 
Cre, and 88% of Cre-positive 
cells in the region of viral 
infection expressed GCaMP6f 
(Figure 33B). Moreover, at 
the center of the virus 
injection site, 86% of cells 
positive for GCaMP6f were 
also immune-positive for 
hM4D (Figure 33C).  
By implanting a 
microlens into the region 
expressing hM4D and 
GCaMP6f, I was able to 
visualize and measure activity of iMSNs before and after activation of Gαi signaling with CNO. 
To compare activity across conditions, each experiment consisted of two sessions on two 
consecutive days in which each animal was allowed to behave freely while I imaged somatic 
activity of the same neurons after treatment with CNO on one day and treatment with saline on a 
different day (SAL/CNO; n = 339 cells from 4 animals). As a control, I also ran experiments in 
which I tested animals after treatment with saline on both days (SAL/SAL; n = 231 cells from 4 
animals). 
Figure 33: The Gαi-coupled designer receptor hM4D and the 
calcium sensor GCaMP can be co-expressed in iMSNs in the 
DMS. A. Diagram of coronal section showing region in the DMS 
virally targeted for in vivo calcium imaging of iMSNs expressing the 
hM4D receptor. A microlens was implanted over the same virally-
targeted region in the DMS for imaging using a miniature microscope. 
B. Representative micrograph of brain section showing GCaMP6f 
fluorescence signal (green) and immunohistochemistry signal for Cre 
recombinase (green). GCaMP6f was only expressed in cells immune-
positive for Cre, and 88% of Cre-positive cells in the region of viral 
infection expressed GCaMP6f (n = 96 cells). Scale bar: 50 µm. C. 
Representative micrograph of brain section showing co-localization of 
GCaMP6f (green) and hM4D (red) detected by immuno-staining for 
mCherry. At the center of virally-targeted site, 86% of cells positive 
for GCaMP6f were also immune-positive for hM4D (n = 120 cells). 
Scale bar: 50 µm. 
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One clear finding in these set of experiments was that activity in iMSNs is closely linked 
to locomotor activity, and positive significant correlations with similar slopes were observed 
between ambulatory distance and calcium activity for the same cells over discrete time intervals 
after treatment with CNO or saline (SAL: Pearson r = 0.5001, p < 0.0001, slope = 0.09681; 
CNO: Pearson r = 0.2395, p = 0.0164, slope = 0.04930; SAL vs. CNO: F(1,196) = 3.25681, p = 
0.07266) (Figure 34A). Figure 34B show an example heat map of calcium traces for one mouse 
with superimposed trace for locomotor activity. Traces for locomotor activity and total calcium 
activity for the entire population of neurons recorded during a 2-min interval illustrate the 
correlation between population-level iMSN activity and locomotion (Figure 34C). Heat maps 
and traces of locomotor activity and population calcium activity for SAL/CNO experiments in all 
mice are shown in Figure 35, and reveal that, although there is a clear relationship between 
population calcium activity and locomotion, distance traveled by the mouse cannot account for 
calcium activity at all time points during imaging. Nevertheless, I also found significant positive  
Figure 34: Somatic calcium activity of iMSNs in the DMS is correlated with motor activity in 
freely-behaving mice. A. Scatter plots and regression lines for calcium activity and locomotor activity in 
12-s time bins of all mice tested after treatment with CNO or saline. Significant correlations were 
observed for data collected after treatment with CNO (Pearson r = 0.2395, p = 0.0164) or saline (Pearson 
r = 0.2395, p = 0.0164). B. Representative heat map of calcium traces from 90 cells binned in time for one 
mouse imaged after treatment with saline (time bins 1-25) or CNO (time bins 26-50). The animal’s 
relative locomotor activity measured in the same time bins during the recording is also plotted. The 
yellow rectangle indicates the time interval in the recording used to generate the plot in C. C. Plot of 
relative locomotor activity and sum of calcium transients from 90 cells during the time interval indicated 




Figure 35: Heat maps and traces of motor activity and calcium activity 
for all SAL/CNO experiments imaging iMSNs in DMS. Left. Heat map of 
calcium traces from all cells imaged in SAL/CNO experiments for each 
mouse. Data is binned in time for each mouse imaged after treatment on day 
1 (time bins 1-25) and after treatment on day 2 (time bins 26-50), with saline 
or CNO treatment as indicated. Each animal’s relative locomotor activity 
measured in the same time bins during the recording is also plotted. Right. 
Plot of relative locomotor activity and sum of calcium transients from all 
cells imaged in SAL/CNO experiments for each mouse, illustrating the 
relationship between activity of the population of iMSNs imaged and the 




correlations between calcium activity and locomotor activity for each individual recording 
session (Figures 36). 
I then proceeded to analyze raw calcium traces to test for an effect of CNO compared to 
saline. Figure 37A shows sample calcium traces for ten neurons imaged in one SAL/CNO  
experiment, revealing that MSNs display characteristic long periods of little activity with 
 
Figure 36: Correlation between iMSN calcium activity and motor activity was observed 
in all mice tested. Scatter plots and regression lines for calcium activity and locomotor 
activity in 12-s time bins for each mouse used for calcium imaging in the striatum tested after 
treatment with CNO or saline. Significant correlations or correlation trends between 
locomotion and calcium activity were observed for all mice (mouse 1, SAL: Pearson r = 
0.3476, p = 0.0887, CNO: Pearson r = 0.5891, p = 0.0019; mouse 2, SAL: Pearson r = 0.6190, 
p = 0.0010, CNO: Pearson r = 0.07936, p = 0.7061; mouse 3, SAL: Pearson r = 0.3923, p = 
0.0524, CNO: Pearson r = 0.4553, p = 0.0222; mouse 4, SAL: Pearson r = 0.7356, p < 0.0001, 





Figure 37: Activating hM4D receptors in iMSNs does not decrease MSN calcium activity at the somatic 
level. A. Representative calcium traces for twenty isolated indirect-pathway MSNs imaged in a freely-
behaving mouse after treatment with saline or CNO. B Plot of percentage of cells that showed a significant 
decrease or increase in activity when comparing sessions after treatment with CNO to sessions after treatment 
with saline (SAL/CNO condition), and as a control, when comparing paired sessions done after treatment with 
saline (SAL/SAL condition). No difference was observed in the proportion of neurons that showed significant 
decrease or increase in activity across conditions (p = 0.9741). C. Pie chart showing percentage of neurons 
that significantly increase (3.83%), decrease (5.01%), or did not change (91.16%) activity in SAL/CNO 
experiments. D. Pie chart showing percentage of neurons that significantly increase (4.33%), decrease 
(4.33%), or did not change (91.33%) activity in SAL/SAL experiments. A total of 339 cells for the SAL/CNO 
condition and 231 cells for the SAL/SAL condition from 4 different animals were used to calculate all 
statistics reported above. E-F. Histograms of scaled calcium activity for all cells imaged in (E) SAL-SAL 
experiments, revealing no change in activity in the second session compared to the first session (t(231) = 1.134, 
p = 0.2579, n = 231), and (F) SAL-CNO experiments, showing no effect of CNO treatment compared to 
saline treatment (t(338) = 0.4202, p = 0.6746, n = 339). 
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Figure 38: Locomotor activity and variability of calcium transients were not affected by CNO in 
mice co-expressing hM4D and GCaMP6f in iMSNs unilaterally in small region of DMS. A. 
Locomotor activity of all subjects were comparable during striatal calcium imaging sessions after 
treatment with saline or CNO, as measured by distance traveled in an open field during recording sessions 
for each mouse. There was no significant difference in locomotor activity across drug conditions (p = 
0.7685). B. Average variability (standard deviations from the mean) of calcium activity for each mouse in 
12-s bins, recorded after treatment with saline or CNO. There was no significant difference in the 
variability of calcium activity across drug conditions (p = 0.0673). 
occasional short-lived large events thought to represent transient burst activity. Calculation of the 
proportion of cells imaged that showed a significant change in activity with CNO treatment 
compared to saline treatment revealed that 5.01% of cells decreased activity, while 3.83% 
increased activity (Figure 37B). I performed similar comparisons for control experiments in 
which the same animals received injections of saline on two recording sessions, and I found that 
4.33% of the cells recorded significantly decreased or increased activity across sessions (Figure 
37B). For the SAL/CNO and SAL/SAL experiments, the percentage of cells that increased 
activity, decreased activity, or remained unchanged are shown in Figures 37C-D. Analysis of the 
proportion of cells showing decreased or increased activity across experiments revealed that 
there were no differences between these proportions in SAL/CNO and SAL/SAL experiments (χ² 
= 0.05247, p = 0.9741) (Figure 37B-D). In addition, histograms for average activity of all iMSNs 
imaged in SAL-SAL and SAL-CNO experiments are shown in Figure 37E-F, confirming the lack of 
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effect on cellular activity in response to CNO. Moreover, since calcium activity was strongly 
associated with locomotor activity, I verified that total locomotor activity was not different 
between sessions when animals were treated with saline or CNO (F(1,3) = 2.253, p = 0.7685) 
(Figure 38A). The variability in calcium activity across cells for each mouse were also not 
different between recordings after treatment with saline or CNO (t(3) = 2.810; p = 0.0673) (Figure 
38B). 
Additionally, I also tested for an effect of CNO on the proportion of cells that showed a 
significant decrease or increase in activity after normalizing the calcium activity to each animal’s 
locomotor activity, and again, no differences were observed (χ² = 3.252, p = 0.1968). Finally, I 
detected individual calcium events of recorded MSNs for all experiments and performed similar 
statistical analysis. Compared to analysis with the raw calcium traces, using the event data, I was 
able to detect similar correlations between calcium activity and behavior, and I did not identify 
an effect of CNO treatment on the activity of the cells recorded (Figure 39). Thus, in line with 
the observation that activation of Gαi signaling does not alter intrinsic excitability properties of 
striatal iMSNs measured at the cellular soma in vitro, measures of somatic neuronal activity of 






Figure 39: Analysis of event calcium imaging data yields similar findings as analysis of raw calcium 
transients. A-B. Scatter plots and regression lines for calcium activity and locomotor activity in 12-s time 
bins of all mice tested after treatment with CNO or saline (A) using single-event data set and weighing for 
size of calcium events or (B) using single-event data set considering each event as a single unit. 
Significant correlations with similar slopes were observed for data collected after treatment with CNO or 
saline using either type of analysis, weighing size of events (SAL: Pearson r = 0.3427, p = 0.0005 slope = 
0.01326; CNO: Pearson r = 0.4609, p < 0.0001, slope = 0.01536; SAL vs. CNO: p = 0.6579) (A) and 
considering all events as single units (SAL: Pearson r = 0.3867, p < 0.0001, slope = 0.003165; CNO: 
Pearson r = 0.2929, p = 0.0031, slope = 0.002017; SAL vs. CNO: p = 0.258) C-D. Plots of percentage of 
cells that showed a significant decrease or increase in activity when comparing sessions after treatment 
with CNO to sessions after treatment with saline; and, as a control, when comparing paired sessions done 
after treatment with saline. The data was analyzed using either (C) the single event data set and weighing 
for size of calcium events, or (D) using the single event data set considering each event as a single unit. 
No difference was observed in the proportion of neurons that showed significant decrease or increase in 
activity across conditions with either type of analysis, weighing size of events (p = 0.6387) (C) or 
considering all events as single units (p = 0.5580) (D). A total of 339 cells for the SAL/CNO condition 





EFFECT ON NEURONAL ACTIVITY OF PALLIDAL NEURONS 
Previous work has shown that activating hM4D receptors in iMSNs in the NA core in 
vitro inhibits inhibitory post-synaptic currents (IPSCs) amplitude in the ventral pallidum after 
optogenetic stimulation of the indirect pathway (Bock et al., 2013). I hypothesized that this 
manipulation in the DMS should also lead to a disinhibition of the GPe in vivo. To address this 
question, I injected a non-conditional GCaMP6f virus in the GPe and Cre-dependent hM4D virus 
in the DMS of Drd2-Cre mice and further implanted a microlens in the GPe (Figures 40A-CD). I 
then imaged activity of cells in the GPe in freely-behaving animals after two treatments with 
CNO or saline. Figure 40D shows sample calcium traces for ten neurons imaged in one SAL-
CNO experiment, illustrating the activity of individual GPe neurons after treatment with saline 
and CNO. Similar analysis as that performed for neurons imaged in the DMS were performed for 
neurons imaged in the GPe. As a control, when animals were imaged in two sequential sessions 
after treatment with saline, only 2.40% of cells increased activity and 3.85% decreased activity 
(SAL-SAL, 211 cells from 3 animals) (Figure 40E). Most remarkably, however, I observed a 
significant increase in calcium activity in the GPe after treatment with CNO compared to saline, 
with 10.05% of cells imaged showing an increase in activity, while only 0.48% showed a 
decrease in activity (SAL/CNO, 209 cells from 3 animals) (Figure 40F). Analysis of these 
proportions demonstrated that the frequency of cells showing increased activity after CNO 
treatment was greater than expected by chance (χ² = 8.889, p = 0.0117). In addition, histograms 
for average activity of all GPe cells imaged in SAL-SAL and SAL-CNO experiments are shown 






Figure 40: Activating hM4D receptors in striatal iMSNs leads to increased neuronal activity in GPe. 
A. Diagram of sagittal section showing region in the DMS and GPe virally targeted for in vivo calcium 
imaging of GPe cells expressing GCaMP6f and iMSNs in the DMS expressing hM4D. A microlens was 
implanted into the GPe for imaging using a miniature microscope. The yellow arrowheads indicate the 
approximate AP level of the sections in the micrographs shown in C and D. B. Micrograph of representative 
coronal section through dorsal striatum (at the level of most anterior yellow arrowhead in A) immune-
stained for mCherry showing region in DMS expressing hM4D. Scale bar: 1 um. C. Micrograph of 
representative coronal section posterior to section shown in C (most posterior yellow arrowhead in A) 
showing expression of GCaMP6f in GPe. Scale bar: 1 um. D. Representative calcium traces for ten isolated 
GPe neurons imaged in a freely-behaving mouse after treatment with saline or CNO.  E-F. Histograms of 
scaled calcium activity for all cells imaged in (E) SAL-SAL experiments, revealing a small decrease in 
activity in the second session compared to the first session (t(210) = 2.308, p = 0.0220, n = 211), and (F) SAL-
CNO experiments, showing a robust increase in activity after CNO treatment compared to saline treatment 
(t(208) = 6.857, p < 0.0001, n = 209). Insets: Plots of percentage of cells that showed a significant decrease or 
increase in activity when (E, inset) comparing control paired sessions done after treatment with saline 
(SAL-SAL condition, 3.37% significantly increased, 3.79% significantly decreased), and (F, inset) 
comparing sessions done after treatment with saline to sessions after treatment with CNO (SAL-CNO 
condition, 10.05% significantly increased, 0.48% significantly decreased). A significant increase in the 
proportion of cells that showed increased activity can be attributed to CNO treatment when comparing 
proportions across conditions (p = 0.0117). A total of 211 cells for the SAL-CNO condition and 209 cells 




Figure 41: Increased GPe activity after treatment with CNO was observed in all mice imaged. 
Histograms of scaled calcium activity for all cells imaged for each mouse in (left) SAL-SAL experiments 
(mouse 1: t(102) = 0.2217, p = 0.8250, n = 103 cells; mouse 2: t(39) = 1.329, p = 0.1917, n = 40 cells; and 
mouse 3: t(68) = 2.577, p = 0.0121, n = 69 cells) and (right) SAL-CNO experiments  (mouse 1: t(97) = 
4.803, p < 0.0001, n = 98; mouse 2: t(49) = 3.755, p = 0.0005, n = 50; and mouse 3: t(60) = 3.225, p = 
0.0020, n = 61).  
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Detailed statistical analysis comparing these histograms are reported for all cells pooled in 
Figure 40 and for each individual mouse in Figure 41, confirming a significant increase in GPe 
cell activity in response to CNO. Hence, while activating Gαi signaling in iMSNs did not elicit a 
robust change in the cells’ intrinsic excitability or activity at the somatic level, the circuit-level 
effect of this manipulation could be readily observed in vivo as a disinhibition of neuronal 
activity in the GPe. 
 
CHRONIC EFFECTS OF DECREASING INDIRECT PATHWAY FUNCTION 
In addition to investigating the effect on acute activation of Gαi signaling in iMSNs in 
selective striatal sub-regions on motivated behavior, membrane excitability, and calcium activity, 
I also investigated the behavioral effects of chronically increasing indirect-pathway function by 
continuous activation of hM4D receptors in the iMSNs in the DMS and NA core. I found that, in 
Drd2-Cre mice expressing the hM4D receptor in both the DMS and NA core, motivated 
behavior was not affected by chronic treatment with CNO in the drinking water for two weeks. 
Chronic CNO treatment did not affect performance of D2R-OEdev mice or control littermates in 
the progressive ratio schedule of reinforcement, as measured by comparing the survival functions 
of average session duration for each group (Log-rank test: control: χ² = 0.2393, p = 0.6247, n = 6 
mice per treatment; D2R-OEdev: χ² = 3.690, p = 0.2969, n = 6 mice per treatment) (Figure 42A), 
or the total number of lever presses for each group (F(1,20) = 1.671, p = 0.2108, n = 6 mice per 
genotype and treatment) (Figure 42B). Moreover, 48 h after chronic treatment with CNO or 
vehicle ended, mice were again tested in the progressive ratio schedule. Once again, no 
differences in performance were detected that could be attributed to previous chronic drug 
treatment with CNO, as measured by survival functions of average session duration (Log-rank 
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test: control: χ² = 0.4089, p = 0.5225, n = 5 mice per treatment; D2R-OEdev: χ² = 1.933, p = 
0.5864, n = 6 mice per treatment) (Figure 42), and total number of lever presses (F(1,19) = 1.867, p 
= 0.2719, n = 5-6 mice per genotype and treatment) (Figure 42D). 
 These negative results led to the question of whether chronic CNO treatment in the 
drinking water was effective in producing CNO levels in the brain that was sufficient to induce 
Figure 42: Chronically activating Gαi signaling in iMSNs in both the DMS and NA core does 
not affect motivation in D2R-OEdev or control littermates. A. No differences were observed in 
the survival function for average session duration in the progressive ratio schedule for D2R-OEdev 
and control mice being treated with CNO or vehicle for at least 2 weeks (control: p = 0.6247; D2R-
OEdev: p = 0.2969). B. The number of lever presses made in a progressive ratio session was also not 
changed in D2R-OEdev and control mice being treated with CNO or vehicle for at least 2 weeks (p = 
0.2108). C. No differences were observed in the survival function for average session duration for 
D2R-OEdev and control mice tested in the progressive ratio schedule 48 h after ending chronic 
treatment with CNO or vehicle (control: p = 0.5225; D2R-OEdev: p = 0.5864). D. The total number 
of lever presses was also not affected by drug treatment in D2R-OEdev and control mice tested in the 
progressive ratio schedule 48 h after ending chronic treatment with CNO or vehicle (p = 0.2719). A 
total of 12 D2R-OEdev mice expressing hM4D in iMSNs in the DMS and NA core (6 mice treated 
with chronic CNO and 6 mice treated with chronic vehicle) and 12 control mice expressing hM4D 
in iMSNs in the DMS and NA core (6 mice treated with chronic CNO and 6 mice treated with 
chronic vehicle) were used for this analysis. A crossover design was not used for this experiment; 
each subject was subjected to only one chronic treatment (CNO or vehicle). 
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any behavior effect in mice. Alternatively, CNO solution in the drinking water maintained at 
room temperature for several days may have been unstable and may have become ineffective 
throughout the two-week treatment period. To get at these questions, one month after conducting 
the last motivation assay in D2R-OEdev and controls expressing hM4D in iMSNs in the DMS and 
NA core, I attempted to induce acute oral consumption of CNO by water-depriving animals for 
16 h and subsequently allowing them to drink CNO-treated water for 1 h before assaying 
locomotion in an open field. Each animal was subjected to three total sessions, including control 
sessions, on different days, counterbalancing the order of sessions for genotype and treatment 
group. In one session animals were given untreated water before testing, in another session 
animals were given freshly-prepared CNO-treated water (fresh CNO) before testing, and in yet 
Figure 43: Oral consumption of CNO induces a behavior response in mice. Distance 
traveled in an open field for 1 h immediately after water-deprived D2R-OEdev or control mice 
expressing hM4D in striatal iMSNs were allowed to freely consume water, freshly-prepared 
CNO, or a CNO solution prepared 1 month prior and stored at room temperature. This acute 
oral consumption of fresh CNO or old CNO led to comparable increases in locomotion in both 
D2R-OEdev and control mice p = 0.0001; Bonferroni post hoc tests: water vs. fresh CNO: 
control: p < 0.01, D2R-OEdev: p < 0.05; water vs. old CNO: control: p < 0.05, D2R-OEdev: p < 
0.01; fresh CNO vs. old CNO: control: p > 0.05, D2R-OEdev: p > 0.05). A total of 12 D2R-




another session animals were given CNO-treated water that had been prepared one month prior 
and stored at room temperature (old CNO). CNO-treated water (fresh CNO and old CNO) 
contained CNO at the same concentration used for chronic treatment in the experiments 
described above. I found that, compared to the baseline condition in which animals were given 
plain water, acute oral consumption of fresh CNO or old CNO led to comparable increases in 
locomotion in both D2R-OEdev and control mice (F(2,22) = 11.42, p = 0.0001, n = 12 mice per 
group; Bonferroni post hoc tests: water vs. fresh CNO: Control: p < 0.01, D2R-OEdev: p < 0.05; 
water vs. old CNO: Control: p < 0.05, D2R-OEdev: p < 0.01; fresh CNO vs. old CNO: Control: p 
> 0.05, D2R-OEdev: p > 0.05) (Figure 43). Thus, oral consumption of CNO can induce a behavior 
response in mice, and CNO solution appears to be stable at room temperature since a one-month 
old solution was just as effective as a fresh solution in inducing hyperlocomotion in mice 
expressing hM4D in striatal iMSNs. 
To expand on these findings, I further investigated the lack of response on motivation of 
chronically decreasing function of iMSNs specifically in the DMS or the NA core. In addition, I 
also further tested whether or not mice are able to respond to an acute injection of CNO while 
being chronically administered CNO for two weeks. First, I found that similarly to mice 
expressing the hM4D receptor in iMSNs in both the DMS and NA core, mice expressing the 
receptor in iMSNs of either region separately did not respond to chronic treatment with CNO in 
the drinking water. While mice were on CNO, no difference in performance was observed in the 
progressive ratio task, as measured by the survival functions for average session duration (Log-
rank test: DMS: χ² = 0.02327, p = 0.8788, n = 8 mice; NA core: χ² = 0.02327, p = 0.8788, n = 9 
mice) (Figure 44A), and total number of lever presses (F(1,15) = 1.062, p = 0.3192, n = 8-9 mice 
per site) (Figure 44B). Likewise, there was no effect of previous CNO treatment on performance 
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in the progressive ratio task when animals were tested 48 h after ending chronic treatment. This 
lack of effect was determined from the survival functions for average session duration (Log-rank 
test: DMS: χ² = 0.1018, p = 0.7496, n = 8 mice; NA core: χ² = 0.2851, p = 0.5934, n = 9 mice) 
Figure 44: Chronically activating Gαi signaling in iMSNs in either the DMS or NA core does 
not affect motivation in mice. A. No differences were observed in the survival function for 
average session duration in the progressive ratio schedule for mice expressing hM4D in the DMS 
or NA core being treated with CNO or vehicle for at least 2 weeks (DMS: p = 0.8788; NA core: p 
= 0.8788). B. The number of lever presses made in a progressive ratio session was also not changed 
in mice expressing hM4D in the DMS or NA core being treated with CNO or vehicle for at least 2 
weeks (p = 0.3192). C. No differences were observed in the survival function for average session 
for mice expressing hM4D in the DMS or NA core tested in the progressive ratio schedule 48 h 
after ending chronic treatment with CNO or vehicle (DMS: p = 0.7496; NA core: p = 0.5934) D. 
The total number of lever presses was also not affected by drug treatment in mice expressing 
hM4D in the DMS or NA core tested in the progressive ratio schedule 48 h after ending chronic 
treatment with CNO or vehicle (p = 0.8347). A total of 8 mice expressing hM4D in iMSNs in the 
DMS and 9 mice expressing hM4D in iMSNs in the NA core were used for this analysis. 
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(Figure 44C), and total number of lever presses (F(1,15) = 0.9435, p = 0.8347, n = 8-9 mice per 
site) (Figure 44D). 
The lack of response to chronic treatment with CNO in mice expressing hM4D in iMSNs 
in either the DMS or NA core was expected given that, in a different cohort, mice expressing 
hM4D in iMSNs in both DMS and NA core also did not response to chronic CNO.  In the cohort 
of mice targeted specifically in the DMS or NA core, I also tested whether animals on chronic 
CNO treatment for at least two weeks could exhibit a behavioral response to an acute 
intraperitoneal administration of CNO in tests of motivation and locomotion. In the progressive 
ratio schedule, I found that, while animals expressing hM4D in either DMS or NA core on 
chronic treatment with vehicle responded to acute CNO treatment with increased total number of 
lever presses (F(1,15) = 8.785, p = 0.0097, n = 8-9 mice per site), animals on chronic treatment 
with CNO did not exhibit an acute response to the drug (F(1,15) = 1.108, p = 0.3092, n = 8-9 mice 
per site) (Figure 45A). Session duration times of mice expressing hM4D in the DMS were 
compared with those of mice expressing hM4D in the NA core and there was no difference in 
performance between these groups while animals were on chronic vehicle and treated acutely 
with CNO (Log-rank test, χ² = 0.7529, p = 0.3855, n = 8-9 mice per site). Likewise, there was no 
difference in performance between mice expressing hM4D in the DMS or NA core on chronic 
CNO after acute treatment with CNO (Log-rank test: χ² = 0.5967, p = 0.4512, n = 8-9 mice per 
site). Therefore, the data were pooled for mice expressing hM4D in the DMS or NA core, and a 
significant difference was observed in average session duration when mice were being treated 




Figure 45: Mice expressing hM4D in iMSNs in either DMS or NA core being chronically treated with 
CNO no longer respond to acute CNO treatment, but response is recovered 48 h after ending chronic 
treatment. A. The number of lever presses made in a progressive ratio session was increased after acute CNO 
treatment in mice chronically treated with vehicle (p = 0.0097) but not in mice chronically treated with CNO 
(p = 0.3092). B. For session duration in the progressive ratio schedule, pooling data for mice expressing 
hM4D in the DMS and NA core revealed a significant difference in session duration when mice were being 
treated with chronic CNO and acutely administered CNO compared to when mice were being treated with 
chronic vehicle and acutely administered CNO (p = 0.0143). C. After discontinuing chronic treatment with 
CNO or saline, mice were re-tested 48 h later and all groups responded to acute CNO with increase total 
number of lever presses (previous chronic vehicle: p = 0.0007; previous chronic vehicle: p < 0.0001). D. 
Discontinuing chronic treatment with CNO or vehicle was sufficient to re-elicit a response to acute CNO in 
mice measured by session duration (previous chronic vehicle: p = 0.0039; previous chronic CNO: p = 0.0143). 
A total of 8 mice expressing hM4D in iMSNs in the DMS and 9 mice expressing hM4D in iMSNs in the NA 
core were used for this analysis. 
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received chronic vehicle and were treated with an acute administration of CNO  
(Log-rank test: χ² = 6.000, p = 0.0143, n = 17 mice) (Figure 45B). Thus, a response to acute 
CNO in the progressive ratio task could no longer be elicited when animals were being 
chronically treated with CNO for two weeks (Figures 45A-B). 
I also tested whether or not mice are able to once again display a response to an acute 
injection of CNO after ending chronic CNO treatment. This experiment tested the hypothesis that 
hM4D receptors may become permanently desensitized after a long period of continued 
activation with CNO. Mice that had been treated with chronic CNO for two weeks were taken 
off chronic CNO treatment for 48 hours and were subsequently treated with an acute 
administration of CNO or saline to test whether or not they had recovered their sensitivity to this 
drug. After being taken off chronic treatment, mice expressing hM4D in either DMS or NA core 
and previously treated with either CNO or vehicle demonstrated a significant increase in lever 
presses in response to acute CNO (previous chronic vehicle: F(1,15) = 17.89, p = 0.0007; previous 
chronic vehicle: F(1,15) = 33.30, p < 0.0001; n = 8-9 mice per site) (Figure 45C). No significant 
differences were observed between mice expressing hM4D receptors in the DMS or the NA core 
in average session duration when the performance of mice in both groups were compared 48 h 
after discontinuing treatment with chronic vehicle (Log-rank test: χ² = 0.3035, p = 0.5817, n = 8-
9 per site). Similarly, there were no differences for average session duration when performance 
in the two groups was compared 48 h after discontinuing treatment with chronic CNO (Log-rank 
test: Log-rank test: χ² = 0.3035, p = 0.5817, n = 8-9 per site). Thus, the data for average session 
duration after ending chronic treatment were pooled to show that discontinuing chronic treatment 
with CNO or vehicle was sufficient to re-elicit a response to acute CNO in mice (previous 
chronic vehicle: Log-rank test: χ² = 8.335, p = 0.0039; previous chronic CNO: Log-rank test: χ² = 
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6.000, p = 0.0143; n = 17 mice) (Figure 45D). Finally, I also tested mice expressing hM4D in 
iMSNs in the DMS and NA core for baseline locomotor activity in an open field in response to 
an acute intraperitoneal injection of CNO while they were on chronic treatment with CNO or 
vehicle in their drinking water for two weeks, as well as after discontinuing chronic treatment for 
48 h. Remarkably, the results for tests of locomotor activity closely paralleled those obtained for 
measures of motivation.  For analysis of locomotion data, the distance traveled per min as a 
percent of baseline before acute treatment was used for comparison between groups. While mice 
Figure 46: Mice expressing hM4D in iMSNs in either DMS or NA core being chronically treated with 
CNO do not display locomotor response to acute CNO treatment. A. While mice were still on chronic 
treatment, animals on chronic vehicle showed a locomotor response to an acute administration of CNO (p < 
0.0001; Bonferroni post hoc tests, DMS: p < 0.001, NA: p < 0.001), and animals on chronic CNO did not 
respond to acute CNO (p = 0.1873; n = 8-9 mice per site). B-C. Plots of distance traveled in an open field by 
mice expressing hM4D in iMSNs in (B) the DMS or (C) the NA core on chronic treatment with CNO or vehicle 
for 2 weeks. Data is shown in 5-min bins 20 min before and 70 min after acute injection with CNO or saline. A 
total of 8 mice expressing hM4D in iMSNs in the DMS and 9 mice expressing hM4D in iMSNs in the NA core 
were used for this analysis. 
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were still on chronic treatment, animals expressing hM4D in iMSNs in either the DMS or the 
NA core on chronic vehicle showed a locomotor response to an acute administration of CNO 
(F(1,15) = 45.16, p < 0.0001; Bonferroni post hoc tests, DMS: p < 0.001, NA: < 0.001; n = 8-9 
mice per mice) (Figure 46). In contrast, animals on chronic CNO did display a locomotor 
response to an acute administration of CNO (F(1,15) = 1.909, p = 0.1873; n = 8-9 mice per site) 
(Figure 46). Similar to what was observed for assays of motivation, after discontinuing chronic 
treatment for 48 h, an acute CNO administration was sufficient to re-elicit a locomotor response 
Figure 47: Mice expressing hM4D in iMSNs in either DMS or NA core recover locomotor response 
to acute CNO treatment after being taken off chronic CNO treatment for 48 h. A. After being taken 
off 2-week chronic treatment with CNO or vehicle, animals that had been on chronic vehicle showed a 
locomotor response to an acute administration of CNO (p < 0.0001; Bonferroni post hoc tests, DMS: p < 
0.01, NA: < 0.001). A locomotor response was also elicited in animals that were previously treated with 
chronic CNO (p = 0.0001; Bonferroni post hoc tests, DMS: p < 0.01, NA: < 0.01). B-C. Plots of distance 
traveled in an open field by mice expressing hM4D in iMSNs in (B) the DMS or (C) the NA core 48 h 
after discontinuing chronic treatment with CNO or vehicle. Data is shown in 5-min bins 20 min before 
and 70 min after acute injection with CNO or saline. Data is shown in 5-min bins 20 min before and 70 
min after acute injection with CNO or saline. A total of 8 mice expressing hM4D in iMSNs in the DMS 
and 9 mice expressing hM4D in iMSNs in the NA core were used for this analysis. 
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in both groups. Mice previously treated with chronic vehicle responded to acute CNO as before 
(F(1,15) = 39.06, p < 0.0001; Bonferroni post hoc tests, DMS: p < 0.01, NA: < 0.001) (Figure 47). 
And a locomotor response could also be elicited in animals that had been previously treated with 




The original aim of this study was to determine whether the motivational deficit of D2R-
OEdev mice, induced by upregulation of D2Rs in the striatum, could be reversed by acutely 
activating Gαi-coupled signaling in the indirect pathway in these animals. I found that this 
manipulation increased motivation in D2R-OEdev mice but also in control littermates. This effect 
was due to energized behavioral performance, which, however, came at the cost of goal-directed 
efficiency. Moreover, selective manipulation of iMSNs in either the DMS or NA core showed 
that both striatal regions contribute to this effect on motivation. Further investigation aimed at 
understanding how activating Gαi-coupled signaling affects striatal circuit function revealed that 
that activating Gαi signaling did not lead to a significant change in somatic iMSN activity in vivo 
or to a change in neuronal excitability in vitro. In contrast, the GPe, which receives 
monosynaptic inhibition from the indirect pathway, showed disinhibited activity when Gαi-
signaling was activated in striatal MSNs. 
In testing my initial hypothesis that MSN excitability might underlie the motivational 
deficit of D2R-OEdev mice, I found that decreasing function of the indirect pathway by acutely 
activating the hM4D receptor in striatal iMSNs boosts motivation in mice, as both D2R-OEdev 
and control mice showed increased performance in the progressive ratio schedule of 
reinforcement after treatment with CNO. Since both genotypes improved performance, it is 
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unclear whether hM4D activation rescued the underlying neuronal mechanism that caused the 
motivational deficit of D2R-OEdev mice or whether it enhanced motivation by an independent 
mechanism. Nevertheless, since I reversed the motivational deficit, I propose that inhibiting 
function of the indirect pathway by activating Gαi signaling in iMSNs may represent a more 
general strategy to ameliorate deficits in motivation. 
Using the progressive hold-down task, I demonstrated that inhibiting function of the 
indirect pathway energizes behavior, which however came at the cost of goal-directed efficiency. 
In this task of motivation, maximal efficiency requires animals to suppress hyperactive behavior 
in order to successfully maintain a lever held down until a reward is obtained. Both D2R-OEdev 
and control mice on CNO made more responses and continued to respond for longer times in the 
task, but they earned fewer rewards. These observations suggest that inhibition of the indirect 
pathway in the NA core and DMS enhances motivation by regulating the arousal and readiness 
to initiate behaviors rather than specifically affecting processes related to the optimal selection of 
specific behaviors, such as positively affecting the value of the reward. Ideally, a manipulation 
that enhances motivation would enhance performance in both the progressive ratio and 
progressive hold-down tasks so that the best results with regard to positive outcome would be 
achieved independently of external conditions (Bailey et al., 2015). Thus, therapeutic strategies 
aimed at manipulating the indirect pathway to treat abnormal motivation should take into 
consideration the risks of enhancing motivation while impairing goal-directed efficiency.  
I also addressed the question of whether the DMS and NA core contributed differently to 
the enhancement in motivation observed in the progressive ratio task after inhibition of iMSNs. 
Previous studies have placed emphasis on the NA core as playing a key role in goal-directed 
behavior by regulating how animals allocate effort to achieve specific outcomes based on the 
153 
 
rewarding value of those outcomes (Nowend et al., 2001, Mai et al., 2012). However, the role the 
DMS in the performance of goal-directed actions based on action-outcome associations has also 
been clearly established (Yin et al., 2005, Shiflett et al., 2010, Hilario et al., 2012). The 
progressive ratio task is a task of goal-directed behavior that measures how much effort a subject 
is willing to expend to obtain a reward. Acutely decreasing function of the indirect pathway 
selectively in either the NA core or DMS led to similar increased performance in this task, 
without affecting outcome devaluation, suggesting that both striatal regions can regulate goal-
directed behavior by modulating indirect-pathway output. Nevertheless, more refined behavioral 
assays of instrumental performance, such as tasks that measure sensitivity to response 
contingencies or effort/value relationships, after inhibiting the function of the indirect pathway in 
the DMS or NA core may potentially reveal specific dissociations between these two striatal sub-
regions. 
Using in vitro electrophysiology and in vivo calcium imaging, I found that hM4D 
activation in iMSNs disinhibits activity of downstream pallidal neurons without changes in 
somatic excitability or iMSN activity. Given the well-established effect of Gαi signaling on 
neuronal excitability via GIRK channels (Luscher and Slesinger, 2010), it was surprising that I 
did not observe changes in excitability in striatal MSNs expressing the hM4D receptor after 
CNO treatment. However, MSNs only express low levels of GIRK channels (Karschin et al., 
1996). Consistent with low GIRK levels, D2R-dependent outward currents that are characteristic 
of GIRKs cannot be readily measured somatically in MSNs unless GIRK channels are artificially 
overexpressed (Marcott et al., 2014). Furthermore, slice physiology experiments using D2R 
agonists generally report little or no change in MSN resting membrane potential, and, instead, 
D2R activation alters membrane conductances thought to affect synaptic integration and lead to 
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decreased synaptic output (Hernandez-Lopez et al., 2000, Sun et al., 2000, Cepeda et al., 2001, 
Salgado et al., 2005, Perez et al., 2006, Gerfen and Surmeier, 2011, Tritsch and Sabatini, 2012).  
Of note, using the exact same methodology used in the present study, the Kellendonk laboratory 
previously showed that CNO reliably hyperpolarizes thalamic neurons expressing hM4D 
(Parnaudeau et al., 2013). In contrast to the excitability measurements reported in the current 
study, one study has shown an effect of hM4D receptor activation on excitability of iMSN; 
however, this study was performed in rats while I used mice (Ferguson et al., 2011).  
In line with unaltered excitability, I found no effect of hM4D activation on calcium 
activity of iMSNs measured somatically in freely behaving mice. In all conditions tested, 
calcium activity of iMSNs in the DMS was correlated with the animal’s locomotor activity. The 
experimental design I used controlled for a potential effect of this correlation on my ability to 
detect an effect of CNO on somatic calcium activity. I co-expressed hM4D and GCaMP6f 
unilaterally in a small region of the DMS in an effort to image the cells being manipulated 
without broadly affecting basal ganglia output and behavior. I was indeed able to image animals 
across sessions in which they displayed comparable levels of locomotor activity after treatment 
with CNO or saline. Moreover, in my analysis, I tested for the effect of CNO treatment on the 
correlation between activity of iMSNs and locomotion, and I also conducted statistical analysis 
after normalizing calcium activity to locomotor activity. In all cases, I found no effect of CNO 
treatment on somatic calcium activity of iMSNs expressing hM4D. A change in calcium activity 
in these neurons would be expected if hM4D activation led to increased firing of action 
potentials generated near the soma. However, intracellular changes in free calcium resulting from 
changes in spike activity and synaptic input can be compartmentalized in the neuron (Yasuda et 
al., 2004). Axons of iMSNs project out of the striatum to the adjacent pallidum, and changes in 
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firing activity specifically localized to these presynaptic terminals would not be detectible using 
our imaging system in the striatum. 
In contrast to unaltered activity in the indirect pathway, I found that CNO enhanced 
activity in the GPe. This observation suggests that hM4D receptors in the presynaptic axon 
terminals of iMSNs may mediate the effect of CNO on pallidal activity. In support of this 
hypothesis, I found that (a) virally expressed hM4D was transported to the terminals and (b) 
electron microscopy has revealed that the Giα heterotrimeric subunit can be found in axon 
terminals in the GPe, consistent with the distribution characteristic of projections from iMSNs 
(Aronin and DiFiglia, 1992). More importantly, previous work from the Kellendonk laboratory 
and others using slice physiology have shown that optogenetic stimulation of presynaptic 
terminals of iMSNs expressing hM4D leads to decreased light-evoked IPSCs in VP neurons in 
the presence of CNO compared to control conditions (Bock et al., 2013). 
In dopaminergic neurons, the Kv1.2 and other voltage-gated potassium channels have 
been shown to mediate inhibition of axonal dopamine release in a G-protein dependent manner 
upon activation of D2Rs (Martel et al., 2011). RT-PCR analysis has shown that Kv1 family 
channels, including Kv1.2, are also expressed in striatal MSNs (Shen et al., 2004). Future work 
on the mechanism proposed here should probe for specific channels, including Kv1 family 
channels, which may mediate the presynaptic effect of activating Gαi signaling in iMSNs. 
Previous work has also shown that MSNs can laterally inhibit activity of neighboring 
MSNs, and inhibition of iMSNs onto other iMSNs has been established in the striatum (Tunstall 
et al., 2002, Taverna et al., 2008, Tecuapetla et al., 2009, Kohnomi et al., 2012). By expressing 
hM4D in the indirect pathway, I therefore expected to observe decreased inhibition after CNO 
treatment not only of the GPe but also of neighboring iMSNs. As a consequence, some neurons 
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of the indirect pathway would be expected to show enhanced firing and activity upon treatment 
with CNO. I may not have observed the effect of lateral inhibition using in vivo calcium imaging 
because of biological or technical reasons. One biological reason could be that hM4D activation 
may have led to decreased activity at the soma that was compensated for by decreased lateral 
inhibition. If this were the case, I nevertheless would have expected that variability of calcium 
transients would increase after hM4D activation. Another reason could be that hM4D does not 
mediate local inhibition to other iMSNs. And a technical reason could be that calcium imaging 
did not capture all aspects of neuronal activity. Compared to other types of neurons, MSNs are 
hyperpolarized at rest and require excitatory inputs from cortex and thalamus to fire action 
potentials (Wilson and Kawaguchi, 1996). Consistent with this idea, I found that activity of 
MSNs measured at the soma was highly correlated with animals’ engagement in voluntary 
actions, as has been previously described (Cui et al., 2013). However, the calcium imaging 
system I used to measure striatal activity may have predominantly measured burst activity, and 
sparser individual spikes were likely below detection threshold, as they were difficult to 
distinguish from signal noise in the recording conditions I used. In fact, when detecting 
individual calcium events as single units, I found that the average firing rate of iMSNs in freely 
behaving animals was about 0.03 Hz, while in vivo electrophysiology studies report firing rates 
closer to 1 Hz (Kim et al., 2014). Since I did not record activity of iMSNs using 
electrophysiology and calcium imaging in parallel, I cannot reliably infer how many action 
potentials a single calcium transient represents. As a result, I may have not have captured all 
activity in the striatal neurons imaged in vivo, potentially masking some of the more subtle 
effects of CNO treatment. In addition, since I co-expressed hM4D together with GCaMP6f using 
two viruses in vivo, calcium imaging may have been inefficient if areas were imaged that did not 
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have high co-localization of transfected proteins. Although histology revealed that the majority 
of the targeted region had high co-localization of GCaMP6f and hM4D, some regions in the 
periphery of the virally-targeted site were observed where transfection of each virus appeared to 
be segregated in striatal cells. Since I could not identify the cells that were imaged in vivo using 
post hoc histological methods, I cannot confirm that all striatal cells imaged in the current study 
expressed hM4D. 
In addition to the acute manipulations, animals were also chronically treated with CNO in 
order to characterize what happens when function of iMSNs is continuously suppressed. The 
finding in the current study that the chronic manipulation had no effect on motivation or 
locomotion raised several alternative interpretations. Some of these alternatives could be ruled 
out in this study. For instance, I showed that acute oral consumption of CNO (as was done for 
chronic administration of this drug) can induce behavioral effects on locomotion, demonstrating 
that this route of administration is effective. However, given that the exact concentration of CNO 
is the blood or brain was not determined, it is difficult to compare the relative effectiveness of 
oral an intraperitoneal administration of CNO. I was also able to rule out the possibility that the 
CNO solution used in the drinking water is unstable for two weeks at room temperature. I 
showed that the acute effect of oral CNO was similar regardless of whether I used freshly 
prepared solution or a one-month old solution stored at room temperature. 
One alternative explanation for the lack of behavioral response after chronic CNO 
treatment is that the mutated Gαi-protein coupled hM4D receptor could become desensitized 
during chronic CNO administration. To address this question, I administered an acute 
intraperitoneal injection of CNO or saline to mice expressing hM4D in iMSNs while they were 
chronically consuming CNO. The persistent lack of behavioral response to an acute CNO 
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injection supports the hypothesis that a compensatory mechanism takes place that fully occludes 
the effect on motivation and locomotion mediated by hM4D receptor activation. However, this 
observation is consistent with both desensitization at the receptor level and circuit-level re-wiring 
as a consequence of continuous activation of Gαi signaling. 
In order to test whether or not hM4D receptors were permanently suppressed after 
chronic CNO administration, I re-tested mice in the progressive ratio task 48 hours after 
discontinuing chronic treatment with CNO. These mice once again received acute intraperitoneal 
injections of either CNO or saline, and the results indicate that the response to CNO was fully 
recovered within this timeframe. These findings suggest that hM4D receptors are not 
permanently altered after being chronically activated by CNO. However, these results do not 
exclude the possibility that circuit-level rewiring may still mediate this behavioral desensitization 
effect. The fast recovery of the response suggests that structural anatomical rewiring may not be 
required, but circuit-level synaptic plasticity is known to occur in shorter timescales (Caroni et 
al., 2014). One likely possibility given the known regulatory pathways of GPCR activity 
(Gainetdinov et al., 2004) is that the hM4D receptor becomes internalized after chronic 
stimulation. All of these possibilities, therefore, represent new research avenues for advancing 
the findings presented in this study on the chronic effects of activating Gαi signaling in iMSNs. 
In conclusion, the present study shows that acute activation of Gαi signaling in indirect-
pathway striatal neurons enhances motivation in mice, although at the cost of goal-directed 
efficiency. It further demonstrates that neurons in both the DMS and NA core mediate this effect, 
consistent with both striatal sub-regions playing a role in performance of motivated behavior. In 
addition, the observation that activation of Gαi signaling in the striatal indirect pathway leads to 
disinhibition of activity in the GPe without affecting intrinsic excitability of iMSNs suggests that 
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Gαi signaling may be specifically exerting its effects at presynaptic terminals. And finally, this 
study also characterizes a behavioral desensitization effect of continuous activation of Gαi-
coupled receptors in striatal iMSNs. Future work investigating the proposed mechanisms of 
action for the effects reported here, including Gαi signaling in presynaptic terminals of iMSNs 
and desensitization after continuous activation, should provide insight on basal ganglia function 
and guide the development of new treatments for neuropsychiatric disorders caused by basal 








SUMMARY AND IMPLICATIONS OF MAIN FINDINGS  
 The first study presented in this dissertation investigated the bridging collaterals and their 
relevance for basal ganglia function, including behavior and potentially neuropsychiatric 
disorders. First, I demonstrated that the bridging collaterals form synaptic contacts in the GPe. 
Then I generated a viral construct to study the neural and behavioral effects of chronically 
increasing excitability of dMSNs and iMSNs. Using this construct, I showed that chronically 
increasing excitability of the indirect pathway, but not the direct pathway, of the basal ganglia is 
sufficient to induce growth of bridging collaterals. Furthermore, I also showed that chronic 
pharmacologic blockade of D2Rs can rescue an abnormal behavioral phenotype associated with 
the bridging collaterals. I also showed that, in addition to genetic and pharmacologic 
interventions, changes in anatomical connectivity in the basal ganglia involving the bridging 
collaterals can also be induced by behavioral intervention, as motor training was sufficient to 
retract bridging collaterals and to rescue an abnormal behavioral phenotype associated with 
increased density of these collaterals.  
In the second study presented in this dissertation, I used the viral construct I created as 
part of the first study to selectively increase excitability of the direct or indirect pathway in 
specific sub-regions of the basal ganglia. Even though these manipulations did not lead to clear 
effects on motivated behavior, the results of this study identified specific behavioral findings that 
contribute to the field of research on basal ganglia function and behavior.  
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Finally, in the third study of this dissertation, I conducted a series of experiments using a 
chemogenetic approach to alter the function of the indirect pathway both acutely and chronically, 
revealing a number of novel findings about basal ganglia function and cell signaling in MSNs. I 
found that acutely activating Gαi-coupled signaling in the indirect pathway increases motivation 
by energizing behavioral performance, which, however, comes at the cost of goal-directed 
efficiency. Furthermore, I also demonstrated both in vitro and in vivo that activating Gαi 
signaling does not lead to a significant change in somatic excitability or activity in MSNs. 
Instead, I show that the effect of activating a Gαi-coupled receptor in MSNs can be measured 
downstream as disinhibition of the GPe. In addition, I also provide compelling behavioral results 
showing that chronically decreasing function of the indirect pathway using a chemogenetic 
approach may not be effective in increasing motivation because it induces compensatory 
desensitization.  
Even though these three studies had their own specific aims, I argue that the findings are 
not independent from each other. The main commonality between the studies is that all of them 
provide useful insight on how MSN excitability is related to neuronal activity and behavior. In 
Chapter 2, I learned that increasing excitability of MSNs can presumably induce compensatory 
changes in basal ganglia connectivity through a network effect. In Chapter 3, I found that using 
the same manipulation to change MSN excitability does not lead to robust behavioral effects on 
incentive motivation for natural rewards, but instead suggests a potential role for the NA core on 
timing and implicates the balance of direct and indirect pathway on action vigor. Finally, in 
Chapter 4, I attempted to affect neuronal excitability of iMSNs by activating Gαi signaling, but 
instead, I found that this manipulation produces a robust effect on motivated behavior but not by 
changing MSN excitability at the cell soma and likely via effects on presynaptic axon terminals. 
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First, although the bridging collaterals have been linked to excitability, my results do not 
establish an association between these collaterals and motivation in developmentally normal 
animals, However, it may still be possible that in models of disease states, such as the behavioral 
endophenotypes of schizophrenia modeled by overexpression of D2Rs in the striatum, basal 
ganglia connectivity may be abnormal. Thus, testing whether rescuing Kir2.1 function in D2R-
OEdev, both globally in all types of MSNs and selectively in dMSNs and iMSNs, may be 
worthwhile to determine whether impaired motivation in an animal model of schizophrenia 
endophenotypes is linked to bridging collaterals. Second, the results from all three studies beg 
the question of whether activating Gαi signaling in iMSNs, which does not affect somatic 
excitability in these neurons can still affect the bridging collaterals. One experiment done in the 
Kellendonk laboratory showed that non-conditionally expressing the hM4D receptor in the DMS 
to decrease neuronal excitability with chronic CNO treatment is sufficient to retract bridging 
collaterals in D2R-OEdev mice without affecting density of collaterals in control animals. It is not 
known, however, whether chronically activating hM4D receptors selectively in the iMSNs of 
D2R-OEdev mice is also sufficient to retract bridging collaterals. Such experiment can be done, 
but they would require breeding animals with four mutant alleles, D2R-OEdev mice (CaMKIIa-
tTa+/TetO-D2R+) that are also positive for Drd1-GFP, and Drd2-Cre. If this experiment reveals 
that bridging collaterals of D2R-OEdev mice can be retracted by chronically activating Gαi 
signaling in iMSNs in the DMS, it would suggest that collaterals were retracted in some of the 
experiments with chronic CNO treatment presented in Chapter 4. Since chronic CNO treatment 
in that study did not affect motivation in D2R-OEdev mice, this potential finding would further 
dissociate the bridging collaterals from motivation. On the other hand, if bridging collaterals are 
not retracted by chronically activating Gαi signaling in the indirect pathway in the DMS of D2R-
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OEdev mice, then the implication would be that affecting neuronal function via Gαi signaling may 
be fundamentally different from affecting neuronal excitability by regulating Kir2.1 function. In 
the case of Gαi signaling, it may be the case that globally targeting dMSNs and iMSNs, and not 
only iMSNs, in the striatum may be required to induce connectivity changes via the bridging 
collaterals. These potential results would still leave open the alternative that the bridging 
collaterals may be involved in the motivation deficit of D2R-OEdev mice. Thus, although the 
studies I conducted for this dissertation answer many questions about MSN excitability and 
motivation in an animal model of negative symptoms of schizophrenia, some questions remain 
open and should be further investigated. 
Another common ground among the studies, and especially between the studies presented 
in Chapters 2 and 4, is the relevance of the findings for therapies for neuropsychiatric disorders. 
Both pharmacological and behavior therapies for many psychiatric disorders require patients to 
either take a drug continuously, with effects being optimal after weeks of treatment, or, likewise, 
engage in behavior or talk therapy for weeks to months to achieve beneficial outcomes. In 
Chapter 2, I show that behavioral training for three weeks can induce changes in connectivity in 
the basal ganglia, leading to the same anatomical changes that may underlie the mechanism via 
which chronic haloperidol treatment exerts its beneficial effects in schizophrenia (Cazorla et al., 
2014). This finding opens a broad avenue for research on the mechanisms of behavioral therapy 
for schizophrenia, particularly for psychosis which cannot be modelled in rodents but is relieved 
by haloperidol and other D2R antagonists. In support of this proposal, recent studies have shown 
that cognitive behavioral therapy can be effective in treating psychosis in schizophrenia (Leff et 
al., 2013, Mehl et al., 2015). Moreover, in Chapter 4 I show that long-term, continuous 
pharmacological activation of a Gαi-coupled receptor induces desensitization to the beneficial 
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effects of the drug on motivated behavior. These findings should be taken into consideration 
when developing therapies for neuropsychiatric disorders since treatments traditionally require 
continuous use of drugs. These results may even help explain why drugs that target GPCRs, 
including antipsychotic mediations for schizophrenia, may not affect motivation when taken 
chronically by patients. Moreover, also relevant for therapy, in Chapter 4 I found that 
pharmacologically targeting Gαi signaling in the indirect pathway of the basal ganglia can be 
effective acutely to boost motivation, but this effect comes at the cost of goal-directed efficiency. 
The dissociability between the directional and activational components of motivation can, 
therefore, be determined experimentally and should be considered when designing strategies for 
treating disorders of abnormal motivation. Hence, some of the findings presented across different 
studies in this dissertation have important implications for development of therapies for 
neuropsychiatric disorders. 
Finally, the findings in Chapters 2 and 4 report two new types of plasticity in the basal 
ganglia that should be further explored by neuroscientists. One form of plasticity involves 
growth and retraction of the bridging collaterals that can be induced by neurophysiological and 
pharmacological manipulations directed at the indirect pathway of the basal ganglia. This form 
of plasticity has been linked to behavior in D2R-OEdev mice both in the artificial setting in which 
activity in the direct pathway is driven with optogenetics and in the more natural setting in which 
animals undergo motor learning. Both of these links are, however, largely correlational. The 
second form of plasticity involves the behavioral desensitization effect induced by chronic 
activation of a Gαi-coupled receptor expressed in iMSNs. It is not immediately clear whether 
these two forms of plasticity are related. As discussed above, it would be important to determine 
whether chronically activating hM4D in the indirect pathway can affect the density of bridging 
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collaterals. Moreover, although I characterize many aspects of the behavioral desensitization 
induced by chronic activation of Gαi signaling in iMSNs, including the findings that it occurs in 
both the DMS and NA core and can be reversed within 48 h of discontinuing drug treatment, the 
mechanism for this phenomenon remains unknown. The data I report in Chapter 4 is consistent 
with either a cell autonomous effect, such as receptor internalization, or with a fast network 
effect involving compensatory circuit changes, possibly similar to that described for the bridging 
collaterals, but that occur at a much faster timescale. Thus, to expand on the findings involving 
plasticity presented in different studies in this dissertation, it would be interesting to test whether 
a causal link between bridging collaterals and behavior can be established and to further 
investigate the biochemical, physiological, and anatomical mechanisms that may underlie 
behavioral desensitization to chronic activation of Gαi signaling in MSNs. 
 
FUTURE DIRECTIONS 
In this final section, I will explicitly lay out some of the broader research avenues I have 
opened with the findings presented in this dissertation. These future directions pertain to a 
number of sub-fields of neuroscience and to efforts to understand how basal ganglia circuits (a) 
regulate normal behavior, (b) can be disrupted in neuropsychiatric disorders, (c) can undergo 
plasticity with learning, and (d) can compensate to perturbations during both development and 
adulthood. In addition, my findings also open avenues for more mechanistic studies of G protein 
function in MSNs. 
In Chapter 2, I contributed to previous work done in the Kellendonk laboratory to show 
that plasticity involving the bridging collaterals is not regulated in a cell autonomous manner, but 
instead is mediated by a network mechanism. In light of these findings and knowledge about the 
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anatomy and connectivity in the basal ganglia, it is plausible that activity-dependent induction 
and retraction of the bridging collaterals may be controlled by regulated secretion of factors that 
guide, repel, or induce axonal growth. For instance, it is possible to conceive a scenario where 
increased activity of iMSNs targeting the GPe leads to secretion of an axon guidance molecule 
by cells in the GPe that selectively induces growth or releases inhibition for growth of dMSN 
axon collaterals into the GPe. Some studies have described activity-dependent synaptic plasticity 
mechanisms that regulate basal ganglia connectivity in development (Ding et al., 2012, 
Kozorovitskiy et al., 2012), but much less is known about similar phenomena in adulthood. 
Thus, strategies for screening axon guidance molecules for their effect on inducing growth or 
retraction of bridging collaterals should be developed in order to characterize the biochemical 
mechanisms that may underlie some of the behavioral findings I presented in this dissertation. 
In light of the many parallels I drew between the bridging collaterals and schizophrenia, 
another potential continuation of my findings would be to determine whether structural elements 
homologous to the bridging collaterals exist in humans and are associated with neuropsychiatric 
disease states. Brain imaging techniques may not have the resolution to image axon collaterals or 
activity related to function of these collaterals. But collaborations with neuropathologists who 
may have access to postmortem tissue of patients who suffered from schizophrenia can be 
promising.  It has been shown, for example, that D2R-OEdev mice have decreased protein 
expression of the Kir2.1 channel (Cazorla et al., 2012). Decreased Kir2.1 protein expression may 
also be detectable in striatal tissue from patients with schizophrenia and would provide a clear 
translational link between bridging collaterals and schizophrenia. Thus, approaches to study the 
associations between the findings presented here on bridging collaterals and symptoms in 
patients with schizophrenia could be fruitful and would require interdisciplinary collaborations. 
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In addition to this translational potential, further work on the bridging collaterals can also 
aim to optimize methods to selectively target the collaterals. If selective methods are developed 
to decrease and increase function of the bridging collaterals, it would be possible to determine 
causal relationships between their function and specific behaviors. So far, the evidence linking 
the bridging collaterals to behavior is correlational, and it may be possible that the collaterals 
themselves do not directly regulate behavior. Identifying an axon guidance molecule that can 
drive or inhibit collateral growth, as discussed above, could be useful in this approach. 
Moreover, as alluded to in Chapter 2, genetic tools could also be used for this purpose, but they 
present some challenges because both passing fibers that target basal ganglia output nuclei and 
bridging collaterals of the direct pathway are present in the GPe and the current optogenetic and 
chemo genetic tools currently available do not allow for targeting one of these types of axons 
selectively. Efforts to overcome such challenges, therefore, should be employed to establish 
causal links for some of the correlational findings presented in this dissertation. 
Another logical next step to expand on my findings related to Gαi-coupled signaling in 
MSNs is to characterize the compensatory mechanisms that mediate behavioral desensitization to 
chronic activation of hM4D receptors in iMSNs. Given that GPCRs are known to become 
internalized with repeated activation in many cell types (Doherty and McMahon, 2009), one 
strategy to test if internalization underlies desensitization to repeated activation of hM4D would 
be to perform electron microscopy imaging on immune-labeled hM4D receptors in animals 
expressing hM4D in iMSNs after chronic treatment with CNO.  
Finally, the findings presented in Chapter 4 are consistent with the expression of hM4D 
receptor in presynaptic axon terminals driving the effect of CNO on motivation and GPe 
disinhibition. As discussed in that chapter, the effect of Gαi signaling on motivation may be 
168 
 
mediated both through iMSN collateral disinhibition of dMSNs and/or through iMSN 
disinhibition of the GPe. The tools used in the current study do not allow for selectively studying 
these presynanptic terminal-specific effects. Recently, a chemogenetic tool has been developed 
to selectively express DREADDs in presynaptic terminals (Stachniak et al., 2014). These new 
tools could be used to activate only presynaptic Giα signaling in iMSNs in experiments designed 
to answer whether this mechanism can account for the effects presented in Chapter 4. It would 
also be interesting to investigate how activating hM4D receptors in iMSNs might affect lateral 
inhibition via iMSN-to-dMSN synapses using in vivo calcium imaging. Given that the vast 
majority of neurons in the striatum are either dMSNs or iMSNs, expressing D1Rs or D2Rs, 
respectively, using Drd2-Cre animals and co-injecting two viruses that lead to hM4D expression 
in Cre-positive neurons and GCaMP6f expression in Cre-negative neurons would provide a 
system in which hM4D is expressed in iMSNs and GCaMP6f is expressed in dMSNs, allowing 
activity of the direct pathway to be imaged while decreasing function of the indirect pathway 
with CNO treatment. Researchers have been able to successfully generate such “Cre-off” viral 
constructs that can be used together with the more traditional “Cre-on” constructs in the striatum 
to concomitantly express different genes in dMSNs and iMSNs (Saunders et al., 2012). If the 
hypothesis that hM4D acts on presynaptic sites to decrease axon terminal excitability or decrease 
neurotransmitter release is true, I would expect that, similar to the disinhibition of GPe activity 
reported in this study, CNO treatment in mice expressing hM4D in iMSNs would also lead to 
disinhibition of dMSNs in the striatum. Thus, developing new genetic tools for selectively 
targeting and imaging neuronal activity would be useful to advance my research and the field’s 
understanding of how basal ganglia output can be regulated. 
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Overall, therefore, the original research I present in this dissertation demonstrates that 
changes in connectivity in the basal ganglia can be induced by activity-dependent processes 
including behavioral training. I also show that selectively increasing excitability of specific 
pathways in the basal ganglia does not affect motivation for natural rewards. I further 
demonstrate that activating Gαi signaling in iMSNs does not affect excitability at the cell soma 
but leads to disinhibition of the GPe presumably by activing presynaptic axon terminals. And 
finally, I show that activating Gαi signaling acutely in the striatal indirect pathway can enhance 
motivation at the cost of goal directed efficiency and the same manipulation done chronically 
induces behavioral desensitization. I hope that these findings can contribute to neuroscience by 
providing a more complete understanding of how basal ganglia circuitry control motivated 
behavior and to neuropsychiatry by providing insight that can help guide therapeutic strategies 
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